carbamates has been researched along with Hepatitis C in 338 studies
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "gov: NCT02786537) was the first comparative effectiveness study to directly compare ledipasvir/sofosbuvir (LDV/SOF) and elbasvir/grazoprevir (EBR/GZR) for the treatment of chronic hepatitis C virus (HCV)." | 9.51 | Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. ( Dong, M; Evon, DM; Lok, AS; Michael, L; Nelson, DR; Peter, J; Reeve, BB; Stewart, PW, 2022) |
| " Accordingly, we evaluated the efficacy of 8 weeks fixed-dose combination of grazoprevir-elbasvir in treatment-naïve patients, with non-severe fibrosis." | 9.34 | Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. ( Abergel, A; Andant, N; Asselah, T; Bailly, F; Buchard, B; Chanteranne, B; Di Martino, V; Dodel, M; Faure, F; Fouchard-Hubert, I; Gournay, J; Lamblin, G; Larrey, D; Loustaud-Ratti, V; Mallat, A; Muti, L; Pereira, B; Pol, S; Reymond, M; Samuel, D; Teilhet, C; Tran, A, 2020) |
| "The Daclatasvir and Sofosbuvir combination therapy (SOF/DCV) has shown efficacy in patients with chronic hepatitis C in clinical trials." | 9.27 | Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. ( El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A, 2018) |
| "In phase 3 trials and real-world settings, smaller proportions of patients with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have a sustained virologic response 12 weeks after treatment (SVR12) with the combination of sofosbuvir and velpatasvir than in patients without cirrhosis." | 9.27 | Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. ( Andrade, RJ; Brainard, DM; Buti, M; Calleja, JL; Camus, G; Carrión, JA; Casado, M; Esteban, R; Forns, X; Lens, S; McNabb, B; Morano Amado, LE; Morillas, RM; Pascasio Acevedo, JM; Pineda, JA; Riveiro-Barciela, M; Rivero, A; Rodríguez, M; Stamm, LM; Subramanian, GM; Turnes, J; Zhang, G, 2018) |
| "Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients." | 9.24 | TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. ( Adeyemi, O; Bhatti, L; Hu, YB; Khatri, A; King, JR; Lalezari, J; Ruane, P; Saag, M; Shulman, NS; Trinh, R; Viani, RM; Wyles, D, 2017) |
| "Daclatasvir combined with asunaprevir is the first all-oral, ribavirin-free treatment of hepatitis C virus genotype 1b infection in Japan." | 9.22 | Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients. ( Chayama, K; Fujiyama, S; Hu, W; Hughes, E; Ishikawa, H; Ito, T; Itoh, Y; Karino, Y; Kawakami, Y; Kumada, H; Linaberry, M; McPhee, F; Suzuki, F; Suzuki, Y; Tamura, E; Toyota, J; Ueki, T, 2016) |
| "We performed a phase 2 trial of the efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection." | 9.22 | Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections. ( Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Schwabe, C; Stamm, LM; Stedman, CA; Svarovskaia, E; Yang, Y, 2016) |
| "Abstract Our objective was to evaluate the liver toxicity of antiretroviral regimens including fosamprenavir plus ritonavir (FPV/r) 1400/100 mg once daily (QD) in HIV/hepatitis C virus (HCV)-coinfected patients." | 9.15 | Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients. ( Delgado-Fernández, M; García-Figueras, C; López-Cortés, LF; Macías, J; Márquez-Solero, M; Martínez-Pérez, MA; Mata, R; Merchante, N; Merino, D; Omar, M; Pasquau, J; Pineda, JA; Ríos-Villegas, MJ; Rivero, A, 2011) |
| "The NS5A replication complex inhibitor, BMS-790052, inhibits hepatitis C virus (HCV) replication with picomolar potency in preclinical assays." | 9.15 | Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. ( Bifano, M; Fridell, RA; Gao, M; Huang, X; Kienzle, B; Nettles, RE; Nower, P; O'Boyle, DR; Qiu, D; Roberts, S; Sun, JH; Valera, L; Wang, C, 2011) |
| "To review the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C virus (HCV) infection." | 8.98 | Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. ( Chahine, EB; Childs-Kean, LM; Kelley, D, 2018) |
| "The direct-acting antiviral regimen of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r)±dasabuvir (DSV)±ribavirin (RBV) demonstrated high rates of sustained viral response at post-treatment week 12 (SVR12) in clinical trials for treatment of hepatitis C virus (HCV) genotypes (GT) 1 and 4." | 8.95 | Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. ( Bao, Y; Calleja, JL; Craxí, A; Dieterich, D; Flisiak, R; Martinez, M; Pangerl, A; Roberts, SK; Wedemeyer, H; Zhang, Z; Zuckerman, E, 2017) |
| "To review the pharmacology, efficacy, and safety of sofosbuvir/velpatasvir in the treatment of patients with hepatitis C virus (HCV) infection." | 8.95 | Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C. ( Chahine, EB; Hemstreet, BA; Sucher, AJ, 2017) |
| "The fixed-dose combination therapy of sofosbuvir (SOF) plus velpatasvir (VEL) is the first pangenotypic, direct-acting antiviral (DAA), single-treatment regimen (STR) for the treatment of hepatitis C virus (HCV) infection to be commercialized." | 8.95 | Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. ( Brieva, T; Rivero, A; Rivero-Juarez, A, 2017) |
| "Ombitasvir (ABT-267) is a potent inhibitor of the hepatitis C virus protein NS5A, has favorable pharmacokinetic characteristics and is active in the picomolar range against genotype 1 - 6." | 8.90 | Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. ( Stirnimann, G, 2014) |
| "Ombitasvir + paritaprevir combined with ritonavir and dasabuvir ± ribavirin is an effective treatment for patients infected with genotype 1 hepatitis C who have coagulation disorders." | 8.12 | Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders. ( Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S, 2022) |
| "Grazoprevir/elbasvir and glecaprevir/pibrentasvir (G/P) are the two preferred treatment options for patients with chronic hepatitis C virus (HCV) infection and a glomerular filtration rate (GFR) <30 mL/min." | 8.12 | Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). ( Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S, 2022) |
| "BACKGROUND The aim of this study was to evaluate the efficacy and safety of Sofosbuvir/Velpatasvir prophylaxis in hepatitis C virus (HCV)-negative recipients who received a transplant kidney from HCV-infected donors." | 8.02 | Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors. ( Chen, R; Li, D; Yuan, X; Zhang, M, 2021) |
| "Report the real-world experience of the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in chronic hepatitis C virus (HCV) infected patients who have previously experienced a direct-acting antiviral (DAA) containing regimen." | 8.02 | Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. ( Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B, 2021) |
| "In clinical trials, hepatitis C virus (HCV) salvage treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) achieved an SVR12 rate of >95% in NS5A-experienced participants." | 8.02 | Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. ( Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A, 2021) |
| "Clinic records were searched to identify treatment-naïve, noncirrhotic adults with acute hepatitis C (HCV viremia and a ≥10-fold elevation of serum alanine aminotransferase activity) and eGFR <30 mL/min, who had been treated with a sofosbuvir-based regimen." | 8.02 | Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. ( Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Rai, P; Rungta, S; Tiwari, P; Verma, A, 2021) |
| "In this randomised trial, 188 people with recently acquired hepatitis C infection were randomly assigned to treatment using either a short 6-week course (93 people) or standard 12-week course (95 people) of the hepatitis C treatment sofosbuvir/velpatasvir." | 8.02 | Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. ( Applegate, TL; Bhagani, S; Bruneau, J; Dore, GJ; Feld, JJ; Gane, E; Grebely, J; Hellard, M; Ingiliz, P; Kim, A; Marks, P; Martinello, M; Matthews, GV; Nelson, M; Petoumenos, K; Rauch, A; Rockstroh, J; Shaw, D; Thurnheer, C; Van der Valk, M, 2021) |
| "Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited." | 8.02 | Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. ( Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, KJ; Huang, YJ; Hwang, JJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Wu, JH; Yang, SS, 2021) |
| "Twelve weeks sofosbuvir/velpatasvir (SOF/VEL) is a highly effective pan-genotypic regimen for hepatitis C." | 7.96 | Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. ( Barclay, ST; Boyle, A; Datta, S; Heydtmann, M; Marra, F; Peters, E; Priest, M; Ritchie, T, 2020) |
| "The combination of pegylated-interferon and ribavirin (PegIFN+RBV) is currently the gold standard in treating chronic hepatitis C virus (HCV) patients in Malaysia and is reimbursed by the Malaysian authorities." | 7.96 | Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia. ( Abu Hassan, MR; Gonzalez, YS; Ong, SC; Shafie, AA; Virabhak, S, 2020) |
| "Many of the treatment regimens available for hepatitis C include sofosbuvir." | 7.96 | The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. ( Afshar, B; Agah, S; Amiriani, T; Fattahi Abdizadeh, M; Fattahi, MR; Hormati, A; Khoshnia, M; Latifnia, M; Majd Jabbari, S; Maleki, I; Malekzadeh, R; Malekzadeh, Z; Mansour-Ghanaei, F; Merat, D; Merat, S; Minakari, M; Moini, M; Mokhtare, M; Poustchi, H; Roozbeh, F; Sharifi, AH; Shayesteh, AA; Shayesteh, E; Sofian, M; Sohrabi, M; Somi, MH, 2020) |
| "Sofosbuvir/velpatasvir±ribavirin (SOF/VEL±RBV) and glecaprevir/pibrentasvir (GLE/PIB) are the drug combinations of choice for treating individuals with genotype 3 hepatitis C virus (G3-HCV) infection." | 7.96 | Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. ( Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P, 2020) |
| "Safe and efficacious pan-genotypic direct-acting antiviral (DAA) regimens, such as sofosbuvir and daclatasvir (SOF + DCV), facilitate simplified models of care for hepatitis C virus (HCV)." | 7.96 | High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia. ( Balkan, S; Brucker, C; Chhit, D; Dousset, JP; Hang, V; Iwamoto, M; Jolivet, P; Kien, A; Le Paih, M; Ly, S; Marquardt, T; O'Keefe, D; Sann, K; Zhang, M, 2020) |
| "Sofosbuvir plus daclatasvir with or without ribavirin has demonstrated a high efficacy and an acceptable safety profile in clinical trials of patients infected with genotype 2 hepatitis Cvirus (HCV); however, there are currently no real-world data available for this regimen." | 7.96 | Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. ( Bronowicki, JP; Carrat, F; Chazouillères, O; Chevaliez, S; de Lédinghen, V; Dorival, C; Fontaine, H; Larrey, D; Lusivika-Nzinga, C; Marcellin, P; Metivier, S; Pawlotsky, JM; Pol, S; Samuel, D; Tran, A; Zoulim, F, 2020) |
| "Sofosbuvir/velpatasvir (SOF/VEL) is expected to be highly effective, even in patients with decompensated liver cirrhosis." | 7.96 | Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir. ( Kakizaki, S; Kizawa, K; Kosone, T; Marubashi, K; Sato, K; Shimizu, M; Takagi, H; Takakusagi, S; Uraoka, T; Yokoyama, Y, 2020) |
| "This prospective study was conducted on a real word cohort of 1562 treatment naïve chronic hepatitis C (CHC) Egyptian patients, who received 12-weeks therapy with sofosbuvir (SOF) plus daclatasvir (DCV) ± ribavirin (RBV)." | 7.96 | Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. ( Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH, 2020) |
| "The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease." | 7.91 | Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection. ( Akarca, US; Danış, N; Ersöz, G; Günşar, F; Karasu, Z; Özkahya, M; Toz, H; Turan, İ; Ünal, N; Yılmaz, M, 2019) |
| "Hepatitis C virus was successfully eradicated in renal transplant recipients who received a combination of sofosbuvir plus ribavirin or sofosbuvir, daclatasvir, and ribavirin." | 7.91 | Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan. ( Aziz, T; Hanif, FM; Lail, G; Luck, NH; Mandhwani, R, 2019) |
| "Data regarding the efficacy and safety of paritaprevir/ritonavir, ombitasvir plus dasabuvir (PrOD) for East Asian non-cirrhotic hepatitis C virus genotype 1b (HCV GT1b) patients receiving hemodialysis were limited." | 7.91 | Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. ( Chen, CY; Chen, DS; Chen, PJ; Cheng, PN; Chiu, YC; Fang, YJ; Hsieh, TY; Kao, JH; Lin, CL; Liu, CH; Liu, CJ; Peng, CY; Shih, YL; Su, TH; Yang, HC; Yang, SS, 2019) |
| "This study evaluates the safety and efficacy of direct-acting antivirals (DAAs) including sofosbuvir, ledipasvir and daclatasvir in patients with hepatitis C viraemia who were on maintenance haemodialysis." | 7.88 | Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. ( Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R, 2018) |
| "Treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin (OPrD ± RBV), was the first interferon-free direct-acting antiviral for hepatitis C virus (HCV) introduced to Israel's national basket of health services in February 2015." | 7.88 | Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider. ( Chodick, G; Koren, G; Mehta, D; Pinsky, B; Samp, JC; Shalev, V; Weil, C, 2018) |
| " Food and Drug Administration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) fixed-dose combination (FDC), an interferon-free, complete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: • genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing a nonstructural protein 5A (NS5A) inhibitor; and • genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor." | 7.88 | Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. ( Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K, 2018) |
| "Hepatitis C virus could be eliminated in all patients after liver transplant with 12-week sofosbuvir/daclatasvir therapy." | 7.88 | A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population. ( Eurich, D; Globke, B; Pratschke, J; Schott, E; Teegen, EM, 2018) |
| "Twelve weeks of the pangenotypic direct-acting antiviral (DAA) combination sofosbuvir/velpatasvir (SOF/VEL) was highly efficient in patients with hepatitis C virus (HCV) genotype 3 (GT3) infection in the ASTRAL-3 approval study." | 7.88 | High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. ( Baumgarten, A; Boesecke, C; Busch, HW; Christensen, S; Daeumer, M; Hueppe, D; Ingiliz, P; Luebke, N; Lutz, T; Mauss, S; Rockstroh, JK; Sarrazin, C; Schewe, K; Schulze Zur Wiesch, J; Simon, KG; Timm, J; Vermehren, J; von Felden, J, 2018) |
| "Sofosbuvir (SOF) and daclatasvir (DCS) are novel, recently developed direct acting antiviral agents characterized by potent anti-hepatitis C virus action." | 7.88 | Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. ( Abo-Zeid, MN; Atia, NN; El-Gizawy, SM; El-Shaboury, SR, 2018) |
| "The aim of the current study was to characterize the population pharmacokinetics of a triple direct-acting antiviral (DAA) regimen (3D) (ombitasvir, paritaprevir-ritonavir and dasabuvir) and adjunctive ribavirin, and estimate covariate effects in a broad spectrum of subjects with hepatitis C virus (HCV) genotype 1 infection." | 7.85 | Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. ( Awni, WM; Dutta, S; Eckert, D; Khatri, A; Menon, RM; Mensing, S; Podsadecki, TJ; Polepally, AR; Sharma, S, 2017) |
| "Grazoprevir is a potent pan-genotype and macrocyclic inhibitor of hepatitis C virus (HCV) NS3/4A protease and was developed for treating chronic HCV infection." | 7.85 | Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a. ( Asante-Appiah, E; Black, S; Chase, R; Curry, S; Guo, Z; Hu, Y; Ingravallo, P; McMonagle, P, 2017) |
| "To compare the efficacy and tolerability of daclatasvir and sofosbuvir (DCV + SOF) versus SOF and ribavirin (SOF + R) and versus peginterferon-alfa plus ribavirin (A/R) in patients infected with hepatitis C genotype 3." | 7.83 | Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. ( Kalsekar, A; Kelley, C; Kim, S; Mu, F; Noviello, S; Signorovitch, J; Song, J; Swallow, E; Yuan, Y, 2016) |
| "We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC)." | 7.83 | Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. ( Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N, 2016) |
| "During a phase 3 study evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV." | 7.83 | Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir. ( Chodavarapu, K; McNally, J; Moreno, C; Schreiber, J; Svarovskaia, E, 2016) |
| "We investigated the real-world effectiveness of sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in treatment of different subgroups of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, or 4." | 7.83 | Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. ( Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI, 2016) |
| " A 49-year-old female developed a severe recurrent HCV genotype 1b infection 4 months after transplantation with severe cholestasis on biopsy, an HCV RNA level of 10,000,000 IU/mL, an alkaline phosphatase level of 1525 IU/mL, and a total bilirubin level of 8." | 7.78 | Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. ( Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA, 2012) |
| "The aim of this study was to compare amprenavir pharmacokinetics in HIV/hepatitis C virus (HCV)-co-infected cirrhotic patients receiving non-boosted fosamprenavir 700 mg twice daily with HCV/HIV-co-infected non-cirrhotic subjects and HIV-mono-infected subjects receiving fosamprenavir/ritonavir 700/100 mg twice daily." | 7.75 | Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. ( Bonora, S; Carosi, G; de Requena, DG; Gatti, F; Loregian, A; Matti, A; Nasta, P; Pagni, S; Palù, G; Parisi, SG; Prestini, K; Puoti, M, 2009) |
| "Direct-acting antivirals effectively treat chronic hepatitis C virus (HCV) infection but there is a paucity of data on their efficacy for acute HCV, when immediate treatment could prevent onward transmission." | 6.90 | Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. ( Ammerlaan, HSM; Arends, JE; Bierman, WF; Boerekamps, A; Claassen, MAA; De Weggheleire, A; den Hollander, J; Dofferhoff, ASM; Florence, E; Hullegie, SJ; Kootstra, GJ; Lauw, FN; Leyten, EM; Popping, S; Posthouwer, D; Rijnders, BJA; Schinkel, J; Soetekouw, R; van de Vijver, DACM; van den Berk, GE; van Kasteren, ME, 2019) |
| " However, evening atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recommended in combination with the 3D regimen." | 6.82 | Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. ( Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H, 2016) |
| " The success of these dosing recommendations was evaluated by analyzing pharmacokinetic data from liver transplant recipients in the CORAL-I study." | 6.82 | Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ( Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016) |
| " Patients in the control group (n = 66) received a combination of boceprevir and PR, dosed in accordance with boceprevir's US product circular." | 6.79 | The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. ( Bacon, BR; Baruch, Y; Bruno, S; Caro, L; Cooreman, MP; Dutko, FJ; Fandozzi, C; Gilbert, CL; Gress, J; Howe, AY; Hwang, P; Manns, MP; Marcellin, P; Mobashery, N; Robertson, MN; Shaw, PM; Shibolet, O; Vierling, JM; Wahl, J, 2014) |
| "Population and selective clonal sequencing were performed at baseline and at virologic failure in the 4 MK-5172 dosing arms." | 6.79 | Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. ( Barnard, RJ; Black, S; Caro, L; Curry, S; DiNubile, MJ; Gilbert, C; Howe, AY; Hwang, PM; Liu, R; Ludmerer, SW; Mobashery, N; Newhard, W; Nickle, D, 2014) |
| "Treatment for hepatitis C has escalated rapidly since the advent of direct-acting antivirals." | 6.61 | Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients. ( Kottilil, S; Mathur, P; Wilson, E, 2019) |
| "Although the combination with PrOD significantly affects the pharmacokinetics of CsA, it is effective and safe with regular monitoring of the CsA blood concentrations and appropriate CsA dose adjustment." | 5.72 | Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. ( Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022) |
| " Demographic information, HCV viral load (VL), profiles of lipid and sugar, and adverse events were recorded and reviewed." | 5.72 | Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C. ( Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD, 2022) |
| " Retrospective analysis of the fractions of patients that achieved sustained virological response (SVR) was performed, and the incidence of adverse events was noted." | 5.62 | Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study. ( Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ, 2021) |
| " There were no adverse events related to the use of Sof-Vel, with no major fluctuations in cyclosporine levels." | 5.62 | Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation. ( Bhakuni, P; Chakrabarti, S; Gupta, M; Jaiswal, SR; Soni, M; Thatai, A, 2021) |
| "gov: NCT02786537) was the first comparative effectiveness study to directly compare ledipasvir/sofosbuvir (LDV/SOF) and elbasvir/grazoprevir (EBR/GZR) for the treatment of chronic hepatitis C virus (HCV)." | 5.51 | Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. ( Dong, M; Evon, DM; Lok, AS; Michael, L; Nelson, DR; Peter, J; Reeve, BB; Stewart, PW, 2022) |
| " The primary safety endpoint was treatment withdrawal rates secondary to severe adverse events." | 5.51 | Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. ( Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I, 2019) |
| " Clinical and laboratory adverse events (AEs) were recorded from baseline to FU12." | 5.46 | Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. ( Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M, 2017) |
| " The aim of this study was to compare the efficacy and safety of PrOD-based therapy in hepatitis C genotype 1 patients with and without cirrhosis, and to explore pre-treatment factors predictive of sustained viral response (SVR) and serious adverse events (SAEs) on treatment." | 5.46 | Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. ( Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017) |
| " After a median follow-up period of 26 months (interquartile range, 20-30 mo), no patients had a serious adverse event or relapse of vasculitis." | 5.46 | Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. ( Alric, L; Bouyer, AS; Cacoub, P; Comarmond, C; de Saint Martin, L; Ferfar, Y; Hezode, C; Musset, L; Pol, S; Poynard, T; Resche Rigon, M; Saadoun, D; Si Ahmed, SN, 2017) |
| " No discontinuations were attributed to treatment-related adverse events." | 5.43 | 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. ( Ackerman, P; Bhore, R; Luetkemeyer, AF; McDonald, C; Noviello, S; Ramgopal, M, 2016) |
| "DCV was dosed at week 4 and at week 8 of treatment, and RBV at week 8." | 5.43 | Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin. ( Andreis, S; Basso, M; Cattelan, AM; Cavinato, S; Dal Bello, F; Loregian, A; Messa, L; Nannetti, G; Palù, G; Parisi, SG; Scaggiante, R, 2016) |
| " Accordingly, we evaluated the efficacy of 8 weeks fixed-dose combination of grazoprevir-elbasvir in treatment-naïve patients, with non-severe fibrosis." | 5.34 | Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. ( Abergel, A; Andant, N; Asselah, T; Bailly, F; Buchard, B; Chanteranne, B; Di Martino, V; Dodel, M; Faure, F; Fouchard-Hubert, I; Gournay, J; Lamblin, G; Larrey, D; Loustaud-Ratti, V; Mallat, A; Muti, L; Pereira, B; Pol, S; Reymond, M; Samuel, D; Teilhet, C; Tran, A, 2020) |
| " Macrocyclic beta-strand scaffolds were designed that allowed the discovery of potent, highly selective, and orally bioavailable compounds." | 5.32 | The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic. ( Tsantrizos, YS, 2004) |
| "Elbasvir/grazoprevir is a once-daily fixed-dose combination therapy for the treatment of chronic HCV infection, including HCV/HIV coinfection." | 5.30 | Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir. ( Butterton, JR; Caro, L; Fandozzi, C; Feng, HP; Fraser, I; Guo, Z; Huang, X; Iwamoto, M; Jumes, P; Ma, J; Mangin, E; Marshall, WL; Panebianco, D; Ross, LL; Talaty, J; Yeh, WW, 2019) |
| "The selection of viral strains with resistance-associated substitutions at hepatitis C virus (HCV) NS5A and NS5B genes is considered one of the limiting factors for achieving sustained virologic response (SVR) to combination of direct-acting antivirals daclatasvir (DCV) and sofosbuvir (SOF)." | 5.30 | Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes. ( Brandão-Mello, CE; Costa, VD; de Souza Rodrigues, LLLX; do Amaral Mello, FC; Dos Santos Silva, PGC; Lampe, E; Nunes, EP, 2019) |
| "The Daclatasvir and Sofosbuvir combination therapy (SOF/DCV) has shown efficacy in patients with chronic hepatitis C in clinical trials." | 5.27 | Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. ( El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A, 2018) |
| "Some individuals with hepatitis C virus infection treated with direct-acting antivirals require ribavirin to maximize sustained virological response rates." | 5.27 | Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. ( Bernstein, DE; Feld, JJ; Ferenci, P; Larsen, L; Tatsch, F; Vlierberghe, HV; Younes, Z, 2018) |
| "In phase 3 trials and real-world settings, smaller proportions of patients with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have a sustained virologic response 12 weeks after treatment (SVR12) with the combination of sofosbuvir and velpatasvir than in patients without cirrhosis." | 5.27 | Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. ( Andrade, RJ; Brainard, DM; Buti, M; Calleja, JL; Camus, G; Carrión, JA; Casado, M; Esteban, R; Forns, X; Lens, S; McNabb, B; Morano Amado, LE; Morillas, RM; Pascasio Acevedo, JM; Pineda, JA; Riveiro-Barciela, M; Rivero, A; Rodríguez, M; Stamm, LM; Subramanian, GM; Turnes, J; Zhang, G, 2018) |
| "Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients." | 5.24 | TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. ( Adeyemi, O; Bhatti, L; Hu, YB; Khatri, A; King, JR; Lalezari, J; Ruane, P; Saag, M; Shulman, NS; Trinh, R; Viani, RM; Wyles, D, 2017) |
| "To evaluate the efficacy and safety of pegylated interferon-lambda-1a (Lambda)/ribavirin (RBV)/daclatasvir (DCV) for treatment of patients coinfected with chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV)." | 5.24 | Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. ( Conway, B; Lazzarin, A; Luetkemeyer, A; Molina, JM; Nelson, M; Portsmouth, S; Romanova, S; Rubio, R; Srinivasan, S; Xu, D, 2017) |
| "Daclatasvir combined with asunaprevir is the first all-oral, ribavirin-free treatment of hepatitis C virus genotype 1b infection in Japan." | 5.22 | Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients. ( Chayama, K; Fujiyama, S; Hu, W; Hughes, E; Ishikawa, H; Ito, T; Itoh, Y; Karino, Y; Kawakami, Y; Kumada, H; Linaberry, M; McPhee, F; Suzuki, F; Suzuki, Y; Tamura, E; Toyota, J; Ueki, T, 2016) |
| "The new pan-genotypic regimen [sofosbuvir (SOF) and velpatasvir (VEL)] for hepatitis C virus (HCV) has been associated with high efficacy." | 5.22 | Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. ( Agarwal, K; Feld, J; Henry, L; Hezode, C; Hunt, S; Jacobson, I; Nader, F; Stepanova, M; Younossi, ZM; Zeuzem, S, 2016) |
| "We performed a phase 2 trial of the efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection." | 5.22 | Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections. ( Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Schwabe, C; Stamm, LM; Stedman, CA; Svarovskaia, E; Yang, Y, 2016) |
| "ABT-450, ombitasvir, and dasabuvir are direct-acting antiviral agents (DAAs) that have been developed for combination treatment of chronic hepatitis C virus (HCV) infection." | 5.20 | Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. ( Awni, W; Badri, P; Bernstein, B; Coakley, E; Cohen, D; Ding, B; Dutta, S; Menon, R; Podsadecki, T, 2015) |
| "The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and ribavirin has shown efficacy in patients with hepatitis C virus (HCV) genotype 1b infection-the most prevalent subgenotype worldwide." | 5.19 | ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. ( Andreone, P; Bernstein, B; Colombo, MG; Enejosa, JV; Ferenci, P; Horsmans, Y; Hu, YB; Koksal, I; Maieron, A; Müllhaupt, B; Podsadecki, T; Reesink, HW; Rodrigues, L; Weiland, O, 2014) |
| "Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg-IFN) and ribavirin (RBV) have limited therapeutic options." | 5.16 | Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. ( Chayama, K; Hughes, E; Ikeda, K; Ishikawa, H; Karino, Y; Kumada, H; McPhee, F; Takahashi, S; Toyota, J; Watanabe, H, 2012) |
| "Abstract Our objective was to evaluate the liver toxicity of antiretroviral regimens including fosamprenavir plus ritonavir (FPV/r) 1400/100 mg once daily (QD) in HIV/hepatitis C virus (HCV)-coinfected patients." | 5.15 | Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients. ( Delgado-Fernández, M; García-Figueras, C; López-Cortés, LF; Macías, J; Márquez-Solero, M; Martínez-Pérez, MA; Mata, R; Merchante, N; Merino, D; Omar, M; Pasquau, J; Pineda, JA; Ríos-Villegas, MJ; Rivero, A, 2011) |
| "The NS5A replication complex inhibitor, BMS-790052, inhibits hepatitis C virus (HCV) replication with picomolar potency in preclinical assays." | 5.15 | Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. ( Bifano, M; Fridell, RA; Gao, M; Huang, X; Kienzle, B; Nettles, RE; Nower, P; O'Boyle, DR; Qiu, D; Roberts, S; Sun, JH; Valera, L; Wang, C, 2011) |
| "To review the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C virus (HCV) infection." | 4.98 | Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. ( Chahine, EB; Childs-Kean, LM; Kelley, D, 2018) |
| "The direct-acting antiviral regimen of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r)±dasabuvir (DSV)±ribavirin (RBV) demonstrated high rates of sustained viral response at post-treatment week 12 (SVR12) in clinical trials for treatment of hepatitis C virus (HCV) genotypes (GT) 1 and 4." | 4.95 | Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. ( Bao, Y; Calleja, JL; Craxí, A; Dieterich, D; Flisiak, R; Martinez, M; Pangerl, A; Roberts, SK; Wedemeyer, H; Zhang, Z; Zuckerman, E, 2017) |
| "To review the pharmacology, efficacy, and safety of sofosbuvir/velpatasvir in the treatment of patients with hepatitis C virus (HCV) infection." | 4.95 | Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C. ( Chahine, EB; Hemstreet, BA; Sucher, AJ, 2017) |
| "Peginterferon/ribavirin has been the standard-of-care for chronic hepatitis C virus (HCV) infections: 48 weeks for genotype 1 or 4 (HCV-1/4) and 24 weeks for HCV-2/3." | 4.95 | Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. ( Yu, ML, 2017) |
| "The fixed-dose combination therapy of sofosbuvir (SOF) plus velpatasvir (VEL) is the first pangenotypic, direct-acting antiviral (DAA), single-treatment regimen (STR) for the treatment of hepatitis C virus (HCV) infection to be commercialized." | 4.95 | Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. ( Brieva, T; Rivero, A; Rivero-Juarez, A, 2017) |
| "AbbVie's 3 direct-acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir, and dasabuvir with and without ribavirin is approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection." | 4.95 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse. ( King, JR; Menon, RM, 2017) |
| "A literature search through EMBASE and PubMed was conducted (January 1966 to August 2015) using the terms BMS-790052, daclatasvir, and hepatitis C." | 4.93 | Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection. ( Mohammad, RA; Regal, RE; Smith, MA, 2016) |
| "Second wave direct acting antivirals such as sofosbuvir, simeprevir and daclatasvir can be combined with pegylated interferon alpha and ribavirin (PEG-IFN/RBV) as triple therapy in patients with hepatitis C virus (HCV) infection." | 4.91 | How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals. ( Serfaty, L, 2015) |
| "Daclatasvir (Daklinza) plus sofosbuvir (Sovaldi) is the first all-oral, interferon- and ribavirin-free drug regimen for treatment of hepatitis C virus genotype 3 infection." | 4.91 | Daclatasvir (Daklinza) for HCV genotype 3 infection. ( , 2015) |
| "The treatment of hepatitis C virus (HCV) infection with pegylated interferon (PEG-IFN) alfa and ribavirin (800 mg daily) (RBV) is the standard of care (SOC) for hepatitis C virus genotype 3-infection leading to a sustained virological response (SVR) in around 65% of patients." | 4.90 | Treatment of hepatitis C virus genotype 3-infection. ( Corouge, M; Pol, S; Vallet-Pichard, A, 2014) |
| "Ombitasvir (ABT-267) is a potent inhibitor of the hepatitis C virus protein NS5A, has favorable pharmacokinetic characteristics and is active in the picomolar range against genotype 1 - 6." | 4.90 | Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. ( Stirnimann, G, 2014) |
| "Ombitasvir + paritaprevir combined with ritonavir and dasabuvir ± ribavirin is an effective treatment for patients infected with genotype 1 hepatitis C who have coagulation disorders." | 4.12 | Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders. ( Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S, 2022) |
| "Owing to the advent of pangenotypic direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) treatment, utilization of HCV-infected deceased donor kidneys with simplified genotyping/subtyping-free sofosbuvir/velpatasvir (SOF/VEL) treatment strategy is now becoming a promising strategy for expanding the organ donor pool." | 4.12 | Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China. ( Dai, H; Fang, C; Guo, Y; Hu, S; Lan, G; Liu, Q; Nie, M; Peng, F; Peng, L; Tan, L; Xie, X; Zhang, H; Zhong, M, 2022) |
| "Grazoprevir/elbasvir and glecaprevir/pibrentasvir (G/P) are the two preferred treatment options for patients with chronic hepatitis C virus (HCV) infection and a glomerular filtration rate (GFR) <30 mL/min." | 4.12 | Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). ( Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S, 2022) |
| "BACKGROUND The aim of this study was to evaluate the efficacy and safety of Sofosbuvir/Velpatasvir prophylaxis in hepatitis C virus (HCV)-negative recipients who received a transplant kidney from HCV-infected donors." | 4.02 | Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors. ( Chen, R; Li, D; Yuan, X; Zhang, M, 2021) |
| "Report the real-world experience of the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in chronic hepatitis C virus (HCV) infected patients who have previously experienced a direct-acting antiviral (DAA) containing regimen." | 4.02 | Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus. ( Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B, 2021) |
| "In clinical trials, hepatitis C virus (HCV) salvage treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) achieved an SVR12 rate of >95% in NS5A-experienced participants." | 4.02 | Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. ( Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A, 2021) |
| "Clinic records were searched to identify treatment-naïve, noncirrhotic adults with acute hepatitis C (HCV viremia and a ≥10-fold elevation of serum alanine aminotransferase activity) and eGFR <30 mL/min, who had been treated with a sofosbuvir-based regimen." | 4.02 | Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. ( Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Rai, P; Rungta, S; Tiwari, P; Verma, A, 2021) |
| "In this randomised trial, 188 people with recently acquired hepatitis C infection were randomly assigned to treatment using either a short 6-week course (93 people) or standard 12-week course (95 people) of the hepatitis C treatment sofosbuvir/velpatasvir." | 4.02 | Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. ( Applegate, TL; Bhagani, S; Bruneau, J; Dore, GJ; Feld, JJ; Gane, E; Grebely, J; Hellard, M; Ingiliz, P; Kim, A; Marks, P; Martinello, M; Matthews, GV; Nelson, M; Petoumenos, K; Rauch, A; Rockstroh, J; Shaw, D; Thurnheer, C; Van der Valk, M, 2021) |
| "Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited." | 4.02 | Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. ( Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, KJ; Huang, YJ; Hwang, JJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Wu, JH; Yang, SS, 2021) |
| "Twelve weeks sofosbuvir/velpatasvir (SOF/VEL) is a highly effective pan-genotypic regimen for hepatitis C." | 3.96 | Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. ( Barclay, ST; Boyle, A; Datta, S; Heydtmann, M; Marra, F; Peters, E; Priest, M; Ritchie, T, 2020) |
| "Since 2017 treatment-naïve patients infected with genotype 1b of hepatitis C virus and minimal or moderate fibrosis can be treated with Ombitasvir/Paritaprevir/ritonavir + Dasabuvir (OPrD) for 8 weeks according to updated Summary of Product Characteristics." | 3.96 | Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. ( Baka-Ćwierz, B; Belica-Wdowik, T; Białkowska, J; Buczyńska, I; Citko, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Garlicki, A; Halota, W; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D, 2020) |
| "The combination of pegylated-interferon and ribavirin (PegIFN+RBV) is currently the gold standard in treating chronic hepatitis C virus (HCV) patients in Malaysia and is reimbursed by the Malaysian authorities." | 3.96 | Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia. ( Abu Hassan, MR; Gonzalez, YS; Ong, SC; Shafie, AA; Virabhak, S, 2020) |
| "Many of the treatment regimens available for hepatitis C include sofosbuvir." | 3.96 | The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. ( Afshar, B; Agah, S; Amiriani, T; Fattahi Abdizadeh, M; Fattahi, MR; Hormati, A; Khoshnia, M; Latifnia, M; Majd Jabbari, S; Maleki, I; Malekzadeh, R; Malekzadeh, Z; Mansour-Ghanaei, F; Merat, D; Merat, S; Minakari, M; Moini, M; Mokhtare, M; Poustchi, H; Roozbeh, F; Sharifi, AH; Shayesteh, AA; Shayesteh, E; Sofian, M; Sohrabi, M; Somi, MH, 2020) |
| "In this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir-velpatasvir (400/100 mg)." | 3.96 | Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study. ( Guyader, D; Jézéquel, C; Lalanne, S; Lemaitre, F; Mercerolle, M; Pronier, C; Tron, C; Verdier, MC, 2020) |
| "Sofosbuvir/velpatasvir±ribavirin (SOF/VEL±RBV) and glecaprevir/pibrentasvir (GLE/PIB) are the drug combinations of choice for treating individuals with genotype 3 hepatitis C virus (G3-HCV) infection." | 3.96 | Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. ( Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P, 2020) |
| "Safe and efficacious pan-genotypic direct-acting antiviral (DAA) regimens, such as sofosbuvir and daclatasvir (SOF + DCV), facilitate simplified models of care for hepatitis C virus (HCV)." | 3.96 | High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia. ( Balkan, S; Brucker, C; Chhit, D; Dousset, JP; Hang, V; Iwamoto, M; Jolivet, P; Kien, A; Le Paih, M; Ly, S; Marquardt, T; O'Keefe, D; Sann, K; Zhang, M, 2020) |
| "Sofosbuvir plus daclatasvir with or without ribavirin has demonstrated a high efficacy and an acceptable safety profile in clinical trials of patients infected with genotype 2 hepatitis Cvirus (HCV); however, there are currently no real-world data available for this regimen." | 3.96 | Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. ( Bronowicki, JP; Carrat, F; Chazouillères, O; Chevaliez, S; de Lédinghen, V; Dorival, C; Fontaine, H; Larrey, D; Lusivika-Nzinga, C; Marcellin, P; Metivier, S; Pawlotsky, JM; Pol, S; Samuel, D; Tran, A; Zoulim, F, 2020) |
| "Sofosbuvir/velpatasvir (SOF/VEL) is expected to be highly effective, even in patients with decompensated liver cirrhosis." | 3.96 | Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir. ( Kakizaki, S; Kizawa, K; Kosone, T; Marubashi, K; Sato, K; Shimizu, M; Takagi, H; Takakusagi, S; Uraoka, T; Yokoyama, Y, 2020) |
| "This prospective study was conducted on a real word cohort of 1562 treatment naïve chronic hepatitis C (CHC) Egyptian patients, who received 12-weeks therapy with sofosbuvir (SOF) plus daclatasvir (DCV) ± ribavirin (RBV)." | 3.96 | Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. ( Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH, 2020) |
| "The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease." | 3.91 | Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection. ( Akarca, US; Danış, N; Ersöz, G; Günşar, F; Karasu, Z; Özkahya, M; Toz, H; Turan, İ; Ünal, N; Yılmaz, M, 2019) |
| "In this prospective single-arm study, 18 TM adolescents with Chronic Hepatitis C received sofosbuvir based generic DAAs." | 3.91 | Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major. ( Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S, 2019) |
| "Hepatitis C virus was successfully eradicated in renal transplant recipients who received a combination of sofosbuvir plus ribavirin or sofosbuvir, daclatasvir, and ribavirin." | 3.91 | Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan. ( Aziz, T; Hanif, FM; Lail, G; Luck, NH; Mandhwani, R, 2019) |
| "Data regarding the efficacy and safety of paritaprevir/ritonavir, ombitasvir plus dasabuvir (PrOD) for East Asian non-cirrhotic hepatitis C virus genotype 1b (HCV GT1b) patients receiving hemodialysis were limited." | 3.91 | Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. ( Chen, CY; Chen, DS; Chen, PJ; Cheng, PN; Chiu, YC; Fang, YJ; Hsieh, TY; Kao, JH; Lin, CL; Liu, CH; Liu, CJ; Peng, CY; Shih, YL; Su, TH; Yang, HC; Yang, SS, 2019) |
| "Our study demonstrated that liver transplant patients with a recurrence of hepatitis C who are initiating ribavirin combined with a sofosbuvir-daclatasvir direct-acting antiviral regimen may be at risk of lower tacrolimus concentrations because of probable ribavirin-induced anaemia and higher fibrosis score, although there are no effects on cyclosporine levels." | 3.91 | Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. ( Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM, 2019) |
| "This study evaluates the safety and efficacy of direct-acting antivirals (DAAs) including sofosbuvir, ledipasvir and daclatasvir in patients with hepatitis C viraemia who were on maintenance haemodialysis." | 3.88 | Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. ( Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R, 2018) |
| "Treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin (OPrD ± RBV), was the first interferon-free direct-acting antiviral for hepatitis C virus (HCV) introduced to Israel's national basket of health services in February 2015." | 3.88 | Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider. ( Chodick, G; Koren, G; Mehta, D; Pinsky, B; Samp, JC; Shalev, V; Weil, C, 2018) |
| " Food and Drug Administration (FDA) approved sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) fixed-dose combination (FDC), an interferon-free, complete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: • genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing a nonstructural protein 5A (NS5A) inhibitor; and • genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor." | 3.88 | Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation. ( Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K, 2018) |
| "Subgenomic hepatitis C virus (HCV) replicons for genotype (GT) 1b, 2b, 3a, and 4a were treated with the mammalian target of rapamycin (mTOR) inhibitors everolimus and sirolimus or with the calcineurin inhibitors (CNIs) cyclosporine or tacrolimus, either alone or in combination with selected DAAs." | 3.88 | The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype. ( Frey, A; Gerken, G; Herzer, K; Piras-Straub, K; Timm, J; Walker, A, 2018) |
| "Hepatitis C virus could be eliminated in all patients after liver transplant with 12-week sofosbuvir/daclatasvir therapy." | 3.88 | A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population. ( Eurich, D; Globke, B; Pratschke, J; Schott, E; Teegen, EM, 2018) |
| "Twelve weeks of the pangenotypic direct-acting antiviral (DAA) combination sofosbuvir/velpatasvir (SOF/VEL) was highly efficient in patients with hepatitis C virus (HCV) genotype 3 (GT3) infection in the ASTRAL-3 approval study." | 3.88 | High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. ( Baumgarten, A; Boesecke, C; Busch, HW; Christensen, S; Daeumer, M; Hueppe, D; Ingiliz, P; Luebke, N; Lutz, T; Mauss, S; Rockstroh, JK; Sarrazin, C; Schewe, K; Schulze Zur Wiesch, J; Simon, KG; Timm, J; Vermehren, J; von Felden, J, 2018) |
| "Sofosbuvir (SOF) and daclatasvir (DCS) are novel, recently developed direct acting antiviral agents characterized by potent anti-hepatitis C virus action." | 3.88 | Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. ( Abo-Zeid, MN; Atia, NN; El-Gizawy, SM; El-Shaboury, SR, 2018) |
| "In this issue, Alric and colleagues demonstrate through real-world experience that grazoprevir-elbasvir is safe and effective for treating hepatitis C in advanced kidney disease patients with higher comorbidity burdens." | 3.88 | Treating hepatitis C infection in patients with advanced CKD in the real world: time to refocus on what our real treatment goals should be. ( Bloom, RD; Potluri, VS, 2018) |
| " One of them had increase in serum creatinine after 16 weeks of treatment with sofosbuvir and daclatasvir, with acute interstitial nephritis on kidney biopsy; his renal function improved on stopping the drugs." | 3.85 | Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients. ( Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Prasad, N; Rai, P; Sharma, RK, 2017) |
| "The aim of the current study was to characterize the population pharmacokinetics of a triple direct-acting antiviral (DAA) regimen (3D) (ombitasvir, paritaprevir-ritonavir and dasabuvir) and adjunctive ribavirin, and estimate covariate effects in a broad spectrum of subjects with hepatitis C virus (HCV) genotype 1 infection." | 3.85 | Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. ( Awni, WM; Dutta, S; Eckert, D; Khatri, A; Menon, RM; Mensing, S; Podsadecki, TJ; Polepally, AR; Sharma, S, 2017) |
| "Grazoprevir is a potent pan-genotype and macrocyclic inhibitor of hepatitis C virus (HCV) NS3/4A protease and was developed for treating chronic HCV infection." | 3.85 | Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a. ( Asante-Appiah, E; Black, S; Chase, R; Curry, S; Guo, Z; Hu, Y; Ingravallo, P; McMonagle, P, 2017) |
| "To compare the efficacy and tolerability of daclatasvir and sofosbuvir (DCV + SOF) versus SOF and ribavirin (SOF + R) and versus peginterferon-alfa plus ribavirin (A/R) in patients infected with hepatitis C genotype 3." | 3.83 | Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. ( Kalsekar, A; Kelley, C; Kim, S; Mu, F; Noviello, S; Signorovitch, J; Song, J; Swallow, E; Yuan, Y, 2016) |
| "The combination of ombitasvir, dasabuvir, and paritaprevir/ritonavir (considered as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients." | 3.83 | Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. ( Cattaneo, D; Clementi, E; Gervasoni, C; Milazzo, L; Riva, A, 2016) |
| "We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC)." | 3.83 | Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. ( Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N, 2016) |
| "During a phase 3 study evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV." | 3.83 | Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir. ( Chodavarapu, K; McNally, J; Moreno, C; Schreiber, J; Svarovskaia, E, 2016) |
| "We investigated the real-world effectiveness of sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in treatment of different subgroups of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, or 4." | 3.83 | Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. ( Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI, 2016) |
| "A 40-year-old man, diagnosed with decompensated liver cirrhosis because of hepatitis C virus, was on the wait list for a liver transplant when he began treatment with the direct-acting antivirals simeprevir 150 mg and sofosbuvir 400 mg." | 3.83 | First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List. ( Ashimkhanova, A; Kaliaskarova, K; Yesmembetov, K, 2016) |
| "Ombitasvir (ABT-267) is a hepatitis C virus (HCV) NS5A inhibitor with picomolar potency, pan-genotypic activity, and 50% effective concentrations (EC50s) of 0." | 3.81 | In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. ( Beyer, J; Campbell, A; Collins, C; DeGoey, D; Kati, W; Koev, G; Krishnan, P; Mistry, N; Molla, A; Pilot-Matias, T; Reisch, T; Setze, C; Williams, L; Xie, W, 2015) |
| " Previous chemical screens identified Daclatasvir (BMS-790052) as a potent nonstructural protein 5A (NS5A) inhibitor for Hepatitis C virus (HCV) infection with an unclear inhibitory mechanism." | 3.80 | A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity. ( Al-Mawsawi, LQ; Chen, SH; Chen, Z; Chu, V; Du, Y; Ke, R; Lin, CY; Lloyd-Smith, JO; Loverdo, C; Olson, CA; Qi, H; Remenyi, R; Su, SY; Sun, R; Truong, S; Wu, NC; Wu, TT; Zhong, W, 2014) |
| " A 49-year-old female developed a severe recurrent HCV genotype 1b infection 4 months after transplantation with severe cholestasis on biopsy, an HCV RNA level of 10,000,000 IU/mL, an alkaline phosphatase level of 1525 IU/mL, and a total bilirubin level of 8." | 3.78 | Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. ( Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA, 2012) |
| "The aim of this study was to compare amprenavir pharmacokinetics in HIV/hepatitis C virus (HCV)-co-infected cirrhotic patients receiving non-boosted fosamprenavir 700 mg twice daily with HCV/HIV-co-infected non-cirrhotic subjects and HIV-mono-infected subjects receiving fosamprenavir/ritonavir 700/100 mg twice daily." | 3.75 | Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. ( Bonora, S; Carosi, G; de Requena, DG; Gatti, F; Loregian, A; Matti, A; Nasta, P; Pagni, S; Palù, G; Parisi, SG; Prestini, K; Puoti, M, 2009) |
| "Ribavirin is ineffective against hepatitis C virus as mono-therapy but is critical in attaining both early virologic response and sustained virologic response when combined with pegylated interferon." | 3.75 | Ribavirin analogs. ( Pockros, PJ; Shields, WW, 2009) |
| " We describe the effect of the coadministration of Amprenavir/Ritonavir (APV/r) and FosAmprenavir (FosAPV) on cyclosporine (CsA) concentrations in two patients receiving OLT for end-stage liver disease due to hepatitis C Virus." | 3.73 | Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. ( Bonora, S; Cocchi, S; Codeluppi, M; Di Benedetto, F; Esposito, R; Gennari, W; Gerunda, GE; Guaraldi, G; Luzi, K; Masetti, M; Motta, A; Pecorari, M, 2006) |
| "Eliminating hepatitis C is hampered by the costs of direct-acting antiviral treatment and the need to treat hard-to-reach populations." | 2.94 | The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam. ( Barnes, E; Chau, NVV; Cooke, GS; McCabe, L; Pett, SL; Walker, AS; White, IR, 2020) |
| " Most adverse events (AEs) were consistent with clinical sequelae of advanced liver disease or known toxicities of ribavirin." | 2.90 | Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. ( Brainard, DM; Chayama, K; De-Oertel, S; Dvory-Sobol, H; Ikeda, F; Kanda, T; Kurosaki, M; Matsuda, T; Mita, E; Nishiguchi, S; Sakamoto, M; Sakamoto, N; Stamm, LM; Takehara, T; Takikawa, Y; Tamori, A; Tanaka, Y; Tatsumi, T; Ueno, Y; Yatsuhashi, H; Zhang, G, 2019) |
| "Direct-acting antivirals effectively treat chronic hepatitis C virus (HCV) infection but there is a paucity of data on their efficacy for acute HCV, when immediate treatment could prevent onward transmission." | 2.90 | Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. ( Ammerlaan, HSM; Arends, JE; Bierman, WF; Boerekamps, A; Claassen, MAA; De Weggheleire, A; den Hollander, J; Dofferhoff, ASM; Florence, E; Hullegie, SJ; Kootstra, GJ; Lauw, FN; Leyten, EM; Popping, S; Posthouwer, D; Rijnders, BJA; Schinkel, J; Soetekouw, R; van de Vijver, DACM; van den Berk, GE; van Kasteren, ME, 2019) |
| " Pharmacokinetics and safety assessments were performed, and pharmacokinetic parameters were calculated using non-compartmental methods and summarized using descriptive statistics and compared statistically by geometric least-squares mean ratios and 90% confidence intervals." | 2.87 | Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment. ( Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R, 2018) |
| " However, evening atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recommended in combination with the 3D regimen." | 2.82 | Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. ( Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H, 2016) |
| " The success of these dosing recommendations was evaluated by analyzing pharmacokinetic data from liver transplant recipients in the CORAL-I study." | 2.82 | Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ( Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016) |
| " Patients in the control group (n = 66) received a combination of boceprevir and PR, dosed in accordance with boceprevir's US product circular." | 2.79 | The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. ( Bacon, BR; Baruch, Y; Bruno, S; Caro, L; Cooreman, MP; Dutko, FJ; Fandozzi, C; Gilbert, CL; Gress, J; Howe, AY; Hwang, P; Manns, MP; Marcellin, P; Mobashery, N; Robertson, MN; Shaw, PM; Shibolet, O; Vierling, JM; Wahl, J, 2014) |
| "Population and selective clonal sequencing were performed at baseline and at virologic failure in the 4 MK-5172 dosing arms." | 2.79 | Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. ( Barnard, RJ; Black, S; Caro, L; Curry, S; DiNubile, MJ; Gilbert, C; Howe, AY; Hwang, PM; Liu, R; Ludmerer, SW; Mobashery, N; Newhard, W; Nickle, D, 2014) |
| "The pharmacokinetic data support coadministration of daclatasvir with atazanavir/ritonavir, efavirenz and/or tenofovir." | 2.78 | Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. ( Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M, 2013) |
| "Treatment for hepatitis C has escalated rapidly since the advent of direct-acting antivirals." | 2.61 | Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients. ( Kottilil, S; Mathur, P; Wilson, E, 2019) |
| " Areas covered: This article reviews the pharmacodynamic and pharmacokinetic properties of the DCV-TRIO combination." | 2.58 | Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. ( Esposito, I; Marciano, S; Trinks, J, 2018) |
| " While many of the second-generation DAAs are principally metabolized by the hepatic system, dosing in severe renal impairment (creatinine clearance [CrCl] <30 mL/min) or dialysis has remained questionable due to limited experience." | 2.55 | New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment. ( Cope, R; Friedman, ML; Sorbera, MA, 2017) |
| " Where interaction is possible, risk can be mitigated by paying careful attention to concomitant medications, adjusting drug dosage as needed, and monitoring patient response and/or clinical parameters." | 2.53 | Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. ( Badri, PS; Dutta, S; King, JR; McGovern, BH; Menon, RM; Polepally, AR, 2016) |
| "Patients suffering recurrence are known to have faster times to fibrosis and consequently higher rates of graft failure." | 2.52 | Hepatitis C management in post-transplant patients. ( Firpi, RJ; Hilgenfeldt, E, 2015) |
| "Although the combination with PrOD significantly affects the pharmacokinetics of CsA, it is effective and safe with regular monitoring of the CsA blood concentrations and appropriate CsA dose adjustment." | 1.72 | Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. ( Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022) |
| " Therefore, there is a need for effective and safe antiviral." | 1.72 | Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. ( Adinolfi, LE; De Lucia Sposito, P; Fusco, R; Gaglione, P; Izzi, A; Lumino, P; Maggi, P; Marrone, A; Messina, V; Nevola, R; Rega, R; Rinaldi, L; Sasso, FC; Simeone, F, 2022) |
| " Demographic information, HCV viral load (VL), profiles of lipid and sugar, and adverse events were recorded and reviewed." | 1.72 | Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C. ( Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD, 2022) |
| " Therefore, a simple, rapid, precise and accurate isocratic RP-HPLC method was developed and validated for quantification of daclatasvir dihydrochloride in pharmaceutical dosage form." | 1.62 | RP-HPLC method development and validation for quantification of daclatasvir dihydrochloride and its application to pharmaceutical dosage form. ( Ali, A; Anwer, S; Hussain Shah, SS; Kashif, M; Nasiri, MI; S Naqvi, SB; Sarwar, H, 2021) |
| " Retrospective analysis of the fractions of patients that achieved sustained virological response (SVR) was performed, and the incidence of adverse events was noted." | 1.62 | Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study. ( Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ, 2021) |
| " There were no adverse events related to the use of Sof-Vel, with no major fluctuations in cyclosporine levels." | 1.62 | Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation. ( Bhakuni, P; Chakrabarti, S; Gupta, M; Jaiswal, SR; Soni, M; Thatai, A, 2021) |
| "Direct-acting antiviral treatment for hepatitis C virus (HCV) has provided the opportunity for simplified models of care delivered in decentralised settings by non-specialist clinical personnel." | 1.62 | Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system. ( Balkan, S; Bunreth, V; Craig, J; Dousset, JP; Jolivet, P; Le Paih, M; Marquardt, T; O'Keefe, D; Samley, K; Zhang, M, 2021) |
| "In elderly HCV patients, poor frailty status strongly predicted new LTCI certification after DAA therapy." | 1.62 | Frailty Status Predicts New Long-term Care Insurance Certification in Hepatitis C Patients Receiving Antiviral Therapy. ( Hasuike, S; Iwakiri, H; Kuroki, K; Kusumoto, K; Matsuura, Y; Mukuda, T; Nagata, K; Nakamura, K; Ochiai, T; Ozono, Y; Shimoda, K; Tsuchimochi, M, 2021) |
| "Only fatigue was reported as side effect during the treatment." | 1.56 | Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient. ( Chen, J; Lei, P; Li, G; Li, Y, 2020) |
| "The recurrent hepatocellular carcinoma enlarged quite rapidly and induced multiple peritoneal disseminations and lung metastases." | 1.56 | Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report. ( Arai, J; Fukumura, Y; Imai, M; Kato, J; Kojima, K; Kondo, M; Kurokawa, K; Mori, M; Ohki, T; Seki, M; Shibata, C; Tagawa, K; Takagi, K; Toda, N, 2020) |
| "A stability-indicating ultraperformance liquid chromatographic method has been developed for the quantitative determination of degradation products and process-related impurities of daclatasvir in a pharmaceutical dosage form." | 1.51 | A Stability-Indicating UPLC Method for the Determination of Potential Impurities and Its Mass by a New QDa Mass Detector in Daclatasvir Drug Used to Treat Hepatitis C Infection. ( Jagadabi, V; Mahesh, K; Nagaraju, D; Nagendra Kumar, PV; Pamidi, S; Ramaprasad, LA, 2019) |
| "In the interferon era, the treatment of hepatitis C virus (HCV) infection in patients on haemodialysis (HD) was limited due to the significant number of treatment-related adverse events (AEs)." | 1.51 | Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. ( Arias, M; Belmar, L; González, LN; Laguno, M; Llovet, LP; Londoño, MC; Maduell, F; Mallolas, J; Martínez-Rebollar, M; Ojeda, R; Rodas, L; Rossi, F; Ugalde, J, 2019) |
| " The objectives of the analyses were to develop the daclatasvir, asunaprevir, and beclabuvir population pharmacokinetic models for the combination regimen." | 1.51 | Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects. ( Garimella, T; Ishikawa, H; Li, H; Osawa, M; Shiozaki, T; Ueno, T, 2019) |
| " The primary safety endpoint was treatment withdrawal rates secondary to severe adverse events." | 1.51 | Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. ( Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I, 2019) |
| " It also inhibited daclatasvir-resistant mutant strains of HCV, especially in combination with daclatasvir." | 1.51 | Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus. ( Hou, MC; Huang, YH; Lan, KH; Lan, KL; Lee, WP; Liao, SX, 2019) |
| "There were no recurrences of HCC, but there was one rejection episode and one cirrhosis decompensation episode, both 12 weeks after treatment." | 1.51 | Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center. ( Ataíde, EC; Boin, IFSF; Santos, AG; Stucchi, RSB; Zanaga, LP, 2019) |
| "Objective Since the majority of direct-acting antivirals (DAAs) that are used in the treatment of hepatitis C virus (HCV) infection are mainly metabolized by CYP3A4, it is hypothesized that inter-individual differences in CYP3A4 activity may be associated with the bioavailability of these agents." | 1.48 | Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. ( Hirayama, T; Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Yara, SI, 2018) |
| "Liver fibrosis was graded with the use of biopsies taken <12 months before treatment and stratified as early (0-1) or moderate to advanced (2-4) according to the Metavir score." | 1.48 | Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study. ( Bandeira de Mello Brandao, A; Costabeber, AM; Cracco Cantisani, GP; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Medeiros Fleck, A; Meine, MH; Mucenic, M; Sacco, FKF; Soares Schlindwein, E; Zanotelli, ML, 2018) |
| " Additionally it was possible to reduce prednisolone dosage to 5 mg/day." | 1.48 | Hepatitis C virus infection: 'beyond the liver'. ( Arrais de Castro, R; Borges-Costa, J; Tato Marinho, R; Vilas, P, 2018) |
| " Clinical and laboratory adverse events (AEs) were recorded from baseline to FU12." | 1.46 | Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. ( Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M, 2017) |
| " The aim of this study was to compare the efficacy and safety of PrOD-based therapy in hepatitis C genotype 1 patients with and without cirrhosis, and to explore pre-treatment factors predictive of sustained viral response (SVR) and serious adverse events (SAEs) on treatment." | 1.46 | Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. ( Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017) |
| " DCV-based DAA treatment is efficacious and safe in patients with HCV infection after LT." | 1.46 | Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study. ( Bañares, R; Casafont, F; Castellote, J; Castells, L; Cuervas-Mons, V; Espinosa, MD; Fernández, I; García-Gonzalez, M; González, A; González-Diéguez, L; Herrero, JI; Llaneras, J; Londoño, MC; Lorente, S; Molina Pérez, E; Montero Alvarez, JL; Narváez, I; Otero, A; Pascasio, JM; Pascual, S; Pons, JA; Prieto, M; Salcedo, M; Sánchez-Antolín, G; Sousa, JM; Testillano, M; Vinaixa, C, 2017) |
| "No drug-drug interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA)." | 1.46 | Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil. ( Bellissant, E; Ben Ali, Z; Boglione-Kerrien, C; Guyader, D; Jezequel, C; Lemaitre, F; Tron, C; Verdier, MC, 2017) |
| "At the age of 46, he was diagnosed with hepatocellular carcinoma with subsequent resection of the tumour in May 2015." | 1.46 | Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation. ( Rostkowska, K; Simon, K; Szymanek-Pasternak, A, 2017) |
| " One of the ZBDHW components, Penta-O-Galloyl-Glucose (PGG), was further analyzed for its mode of action in vitro, its antiviral activity in primary human hepatocytes as well as for its bioavailability and hepatotoxicity in mice." | 1.46 | Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. ( Alves, MP; Banda, D; Behrendt, P; Colpitts, CC; Manns, MP; Menzel, N; Meuleman, P; Perin, P; Pfaender, S; Pietschmann, T; Schang, LM; Steinmann, E; Thiel, V; Vondran, FWR, 2017) |
| "Although chronic hepatitis C is still the leading indication for liver transplantation (LT) in the United States and Europe, acute liver failure caused by hepatitis C is distinctly uncommon and transplantation for fulminant hepatitis C virus (HCV) has not been documented in the United States." | 1.46 | Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure. ( Bhasin, D; Pollinger, H; Rubin, RA; Shrestha, R; Stein, L; Tracy, B, 2017) |
| " After a median follow-up period of 26 months (interquartile range, 20-30 mo), no patients had a serious adverse event or relapse of vasculitis." | 1.46 | Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. ( Alric, L; Bouyer, AS; Cacoub, P; Comarmond, C; de Saint Martin, L; Ferfar, Y; Hezode, C; Musset, L; Pol, S; Poynard, T; Resche Rigon, M; Saadoun, D; Si Ahmed, SN, 2017) |
| "The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies." | 1.46 | Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study. ( Chae, HB; Cho, BW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Lee, BS; Lee, SH; Lee, TH; Song, IH, 2017) |
| " No discontinuations were attributed to treatment-related adverse events." | 1.43 | 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. ( Ackerman, P; Bhore, R; Luetkemeyer, AF; McDonald, C; Noviello, S; Ramgopal, M, 2016) |
| "DCV was dosed at week 4 and at week 8 of treatment, and RBV at week 8." | 1.43 | Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin. ( Andreis, S; Basso, M; Cattelan, AM; Cavinato, S; Dal Bello, F; Loregian, A; Messa, L; Nannetti, G; Palù, G; Parisi, SG; Scaggiante, R, 2016) |
| "DAA are highly effective in the treatment of hepatitis C in KTRs with good tolerance in general, making it possible to solve the problem and have a good chance to improve the prognosis in our transplantation patients." | 1.43 | Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study. ( Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S, 2016) |
| "The future treatment of hepatitis C virus (HCV) infection will be combinations of direct-acting antivirals (DAAs) that not only target multiple viral targets, but are also effective against different HCV genotypes." | 1.42 | Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden. ( Bondeson, K; Kjellin, M; Lannergard, A; Lennerstrand, J; Lindström, I; Palanisamy, N; Wesslén, L, 2015) |
| " Macrocyclic beta-strand scaffolds were designed that allowed the discovery of potent, highly selective, and orally bioavailable compounds." | 1.32 | The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic. ( Tsantrizos, YS, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (4.14) | 29.6817 |
| 2010's | 250 (73.96) | 24.3611 |
| 2020's | 74 (21.89) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, R | 1 |
| Li, D | 1 |
| Zhang, M | 3 |
| Yuan, X | 1 |
| El Kassas, M | 1 |
| Abdeen, N | 1 |
| Omran, D | 1 |
| Alboraie, M | 1 |
| Salaheldin, M | 1 |
| Eltabbakh, M | 1 |
| Farghaly, R | 1 |
| Emadeldeen, M | 1 |
| Afify, S | 1 |
| Sweedy, A | 1 |
| Ghalwash, A | 1 |
| Abbass, A | 1 |
| Ezzat, S | 1 |
| Tahoon, M | 1 |
| ELshazly, HM | 1 |
| Hamdy, H | 1 |
| Omar, H | 1 |
| Calvaruso, V | 2 |
| Petta, S | 1 |
| Ferraro, D | 1 |
| La Mantia, C | 1 |
| Gibilaro, G | 1 |
| Reina, G | 1 |
| Di Maio, VC | 1 |
| Licata, A | 1 |
| Ceccherini-Silberstein, F | 1 |
| Di Marco, V | 1 |
| Craxì, A | 3 |
| Hussain Shah, SS | 1 |
| Nasiri, MI | 1 |
| Sarwar, H | 1 |
| Ali, A | 1 |
| S Naqvi, SB | 1 |
| Anwer, S | 1 |
| Kashif, M | 1 |
| Lai, PC | 1 |
| Chen, CH | 1 |
| Jeng, LB | 1 |
| Yu, TM | 1 |
| Tsai, SF | 1 |
| Wu, MJ | 1 |
| Cheng, SB | 1 |
| Yang, SS | 4 |
| Lee, TY | 2 |
| Huang, YY | 1 |
| Huang, YH | 3 |
| Wu, TH | 1 |
| Loong, CC | 1 |
| Hsu, CC | 1 |
| Chou, YC | 1 |
| Chang, YL | 1 |
| Indolfi, G | 1 |
| Kelly, D | 1 |
| Nebbia, G | 1 |
| Iorio, R | 1 |
| Mania, A | 1 |
| Giacomet, V | 1 |
| Szenborn, L | 1 |
| Shao, J | 1 |
| Sang Yue, M | 1 |
| Hsueh, CH | 1 |
| Parhy, B | 1 |
| Kersey, K | 1 |
| Mangia, A | 3 |
| Pawlowska, M | 1 |
| Bansal, S | 1 |
| Messina, V | 1 |
| Nevola, R | 1 |
| Izzi, A | 1 |
| De Lucia Sposito, P | 1 |
| Marrone, A | 1 |
| Rega, R | 1 |
| Fusco, R | 1 |
| Lumino, P | 1 |
| Rinaldi, L | 1 |
| Gaglione, P | 1 |
| Simeone, F | 1 |
| Sasso, FC | 1 |
| Maggi, P | 1 |
| Adinolfi, LE | 1 |
| Öksüz, Z | 1 |
| Üçbilek, E | 1 |
| Serin, MS | 1 |
| Yaraş, S | 1 |
| Temel, GÖ | 1 |
| Sezgin, O | 1 |
| Chen, JJ | 2 |
| Chiu, YC | 2 |
| Lee, PL | 2 |
| Tung, HD | 1 |
| Chiu, HC | 1 |
| Chien, SC | 1 |
| Cheng, PN | 2 |
| Evon, DM | 1 |
| Dong, M | 1 |
| Reeve, BB | 1 |
| Peter, J | 1 |
| Michael, L | 1 |
| Lok, AS | 1 |
| Nelson, DR | 2 |
| Stewart, PW | 1 |
| Sonsuz, A | 1 |
| Bozcan, S | 1 |
| Hatemi, İ | 1 |
| Özdemir, S | 1 |
| Canbakan, B | 1 |
| Yıldırım, S | 1 |
| Gültürk, İ | 1 |
| Ar, C | 1 |
| Wong, YJ | 1 |
| Kumar, R | 3 |
| Tan, J | 2 |
| Liu, CH | 3 |
| Hui, VK | 1 |
| Tan, SS | 1 |
| Kao, JH | 3 |
| Wong, GH | 1 |
| Thurairajah, PH | 2 |
| Butt, ZA | 1 |
| Zhang, H | 1 |
| Liu, Q | 1 |
| Hu, S | 1 |
| Zhong, M | 1 |
| Peng, F | 1 |
| Guo, Y | 1 |
| Fang, C | 1 |
| Nie, M | 1 |
| Tan, L | 1 |
| Dai, H | 1 |
| Xie, X | 1 |
| Peng, L | 1 |
| Lan, G | 1 |
| Mashaal, AR | 1 |
| Abd El-Hameed, M | 1 |
| El Ray, AA | 1 |
| Mahmoud Diab, T | 1 |
| Dawood, RM | 1 |
| Shemis, MA | 1 |
| Seyam, M | 1 |
| Danış, N | 1 |
| Toz, H | 1 |
| Ünal, N | 1 |
| Yılmaz, M | 1 |
| Turan, İ | 1 |
| Günşar, F | 1 |
| Karasu, Z | 1 |
| Ersöz, G | 1 |
| Özkahya, M | 1 |
| Akarca, US | 1 |
| Zalawadiya, SK | 1 |
| Lindenfeld, J | 1 |
| Shah, A | 1 |
| Wigger, M | 1 |
| Danter, M | 1 |
| Brinkley, DM | 1 |
| Menachem, J | 1 |
| Punnoose, L | 1 |
| Balsara, K | 1 |
| Brown Sacks, S | 1 |
| Ooi, H | 1 |
| Perri, R | 1 |
| Awad, J | 1 |
| Smith, S | 1 |
| Fowler, R | 1 |
| O'Dell, H | 1 |
| Darragh, C | 1 |
| Ruzevich-Scholl, S | 1 |
| Schlendorf, K | 1 |
| Chugh, Y | 1 |
| Dhiman, RK | 1 |
| Premkumar, M | 1 |
| Prinja, S | 1 |
| Singh Grover, G | 1 |
| Bahuguna, P | 1 |
| Martinec, O | 1 |
| Huliciak, M | 1 |
| Staud, F | 1 |
| Cecka, F | 1 |
| Vokral, I | 1 |
| Cerveny, L | 1 |
| Rahman, M | 1 |
| Janjua, NZ | 2 |
| Shafiq, TKI | 1 |
| Chowdhury, EI | 1 |
| Sarker, MS | 1 |
| Khan, SI | 1 |
| Reza, M | 1 |
| Faruque, MO | 1 |
| Kabir, A | 1 |
| Anis, AH | 1 |
| Azim, T | 1 |
| Mandimika, C | 2 |
| Ogbuagu, O | 2 |
| Boyle, A | 1 |
| Marra, F | 1 |
| Peters, E | 1 |
| Datta, S | 1 |
| Ritchie, T | 1 |
| Priest, M | 1 |
| Heydtmann, M | 1 |
| Barclay, ST | 2 |
| Zarębska-Michaluk, D | 1 |
| Piekarska, A | 1 |
| Jaroszewicz, J | 1 |
| Klapaczyński, J | 1 |
| Mazur, W | 1 |
| Krygier, R | 1 |
| Belica-Wdowik, T | 1 |
| Baka-Ćwierz, B | 1 |
| Janczewska, E | 1 |
| Pabjan, P | 1 |
| Dobracka, B | 1 |
| Lorenc, B | 1 |
| Tudrujek-Zdunek, M | 1 |
| Tomasiewicz, K | 1 |
| Sitko, M | 1 |
| Garlicki, A | 1 |
| Czauż-Andrzejuk, A | 1 |
| Citko, J | 1 |
| Dybowska, D | 1 |
| Halota, W | 1 |
| Pawłowska, M | 1 |
| Laurans, Ł | 1 |
| Deroń, Z | 1 |
| Buczyńska, I | 1 |
| Simon, K | 2 |
| Białkowska, J | 1 |
| Tronina, O | 2 |
| Flisiak, R | 3 |
| Rabaan, AA | 1 |
| Al-Ahmed, SH | 1 |
| Bazzi, AM | 1 |
| Alfouzan, WA | 1 |
| Alsuliman, SA | 1 |
| Aldrazi, FA | 1 |
| Haque, S | 1 |
| Shafie, AA | 1 |
| Abu Hassan, MR | 1 |
| Ong, SC | 1 |
| Virabhak, S | 1 |
| Gonzalez, YS | 2 |
| Poustchi, H | 2 |
| Majd Jabbari, S | 1 |
| Merat, S | 2 |
| Sharifi, AH | 1 |
| Shayesteh, AA | 1 |
| Shayesteh, E | 1 |
| Minakari, M | 1 |
| Fattahi, MR | 1 |
| Moini, M | 1 |
| Roozbeh, F | 1 |
| Mansour-Ghanaei, F | 1 |
| Afshar, B | 1 |
| Mokhtare, M | 1 |
| Amiriani, T | 1 |
| Sofian, M | 1 |
| Somi, MH | 1 |
| Agah, S | 1 |
| Maleki, I | 1 |
| Latifnia, M | 1 |
| Fattahi Abdizadeh, M | 1 |
| Hormati, A | 1 |
| Khoshnia, M | 1 |
| Sohrabi, M | 1 |
| Malekzadeh, Z | 1 |
| Merat, D | 1 |
| Malekzadeh, R | 2 |
| Lee, KS | 1 |
| Quintiliani, L | 1 |
| Heinz, A | 1 |
| Johnson, NL | 1 |
| Xuan, Z | 1 |
| Truong, V | 1 |
| Lasser, KE | 1 |
| Patel, SV | 1 |
| Jayaweera, DT | 1 |
| Althoff, KN | 1 |
| Eron, JJ | 1 |
| Radtchenko, J | 1 |
| Mills, A | 1 |
| Moyle, G | 1 |
| Santiago, S | 1 |
| Sax, PE | 1 |
| Gillman, J | 1 |
| Mounzer, K | 1 |
| Elion, RA | 1 |
| Huhn, GD | 1 |
| Junger, H | 1 |
| Knoppke, B | 1 |
| Weigand, K | 1 |
| Evert, K | 1 |
| Brennfleck, FW | 1 |
| Melter, M | 1 |
| Schlitt, HJ | 1 |
| Brunner, SM | 1 |
| Abdel Moneim, A | 1 |
| Suleiman, HA | 1 |
| Mahmoud, B | 2 |
| Mabrouk, D | 1 |
| Zaky, MY | 1 |
| Lalanne, S | 1 |
| Jézéquel, C | 2 |
| Tron, C | 2 |
| Verdier, MC | 2 |
| Mercerolle, M | 1 |
| Pronier, C | 1 |
| Guyader, D | 2 |
| Lemaitre, F | 2 |
| Deutsch, L | 1 |
| Houri, I | 1 |
| Ben-Ari, Z | 1 |
| Shlomai, A | 1 |
| Veitsman, E | 1 |
| Cohen-Ezra, O | 1 |
| Issachar, A | 1 |
| Mor, O | 1 |
| Gozlan, Y | 1 |
| Bruck, R | 1 |
| Menachem, Y | 1 |
| Zelber-Sagi, S | 1 |
| Katchman, H | 1 |
| Shibolet, O | 2 |
| Margusino-Framiñán, L | 2 |
| Cid-Silva, P | 2 |
| Rotea-Salvo, S | 1 |
| Mena-de-Cea, Á | 2 |
| Suárez-López, F | 1 |
| Vázquez-Rodríguez, P | 1 |
| Delgado-Blanco, M | 2 |
| Sanclaudio-Luhia, AI | 1 |
| Martín-Herranz, I | 2 |
| Castro-Iglesias, Á | 2 |
| Chen, J | 2 |
| Li, Y | 1 |
| Li, G | 1 |
| Lei, P | 1 |
| Hinrichsen, H | 1 |
| Stoehr, A | 2 |
| Cornberg, M | 1 |
| Klinker, H | 2 |
| Heyne, R | 2 |
| John, C | 2 |
| Simon, KG | 2 |
| Guenther, V | 1 |
| Martin, K | 1 |
| Witte, V | 1 |
| Zeuzem, S | 5 |
| O'Keefe, D | 2 |
| Iwamoto, M | 3 |
| Sann, K | 1 |
| Kien, A | 1 |
| Hang, V | 1 |
| Brucker, C | 1 |
| Jolivet, P | 2 |
| Ly, S | 1 |
| Chhit, D | 1 |
| Balkan, S | 2 |
| Marquardt, T | 2 |
| Le Paih, M | 2 |
| Dousset, JP | 2 |
| Abergel, A | 2 |
| Asselah, T | 2 |
| Mallat, A | 2 |
| Chanteranne, B | 1 |
| Faure, F | 1 |
| Larrey, D | 2 |
| Gournay, J | 1 |
| Loustaud-Ratti, V | 1 |
| Di Martino, V | 2 |
| Fouchard-Hubert, I | 1 |
| Pol, S | 5 |
| Bailly, F | 1 |
| Samuel, D | 4 |
| Tran, A | 3 |
| Dodel, M | 1 |
| Andant, N | 1 |
| Lamblin, G | 1 |
| Muti, L | 1 |
| Reymond, M | 1 |
| Teilhet, C | 1 |
| Pereira, B | 1 |
| Buchard, B | 1 |
| McCabe, L | 1 |
| White, IR | 1 |
| Chau, NVV | 1 |
| Barnes, E | 2 |
| Pett, SL | 1 |
| Cooke, GS | 1 |
| Walker, AS | 1 |
| de Lédinghen, V | 4 |
| Lusivika-Nzinga, C | 1 |
| Bronowicki, JP | 1 |
| Zoulim, F | 1 |
| Metivier, S | 1 |
| Marcellin, P | 3 |
| Chazouillères, O | 1 |
| Chevaliez, S | 2 |
| Dorival, C | 1 |
| Fontaine, H | 2 |
| Pawlotsky, JM | 3 |
| Carrat, F | 2 |
| Drysdale, K | 1 |
| Ntuli, Y | 1 |
| Bestwick, J | 1 |
| Gelson, W | 1 |
| Agarwal, K | 3 |
| Forton, D | 1 |
| Mutimer, D | 1 |
| Elsharkawy, AM | 1 |
| Townley, C | 1 |
| Mahomed, F | 1 |
| Foster, GR | 2 |
| Milligan, S | 1 |
| Khalili, M | 1 |
| Fagiuoli, S | 2 |
| Shafran, SD | 2 |
| Ouzan, D | 1 |
| Papatheodoridis, G | 1 |
| Ramji, A | 2 |
| Borgia, SM | 1 |
| Wedemeyer, H | 3 |
| Losappio, R | 2 |
| Pérez-Hernandez, F | 1 |
| Wick, N | 1 |
| Brown, RS | 1 |
| Lampertico, P | 1 |
| Doucette, K | 1 |
| Ntalla, I | 1 |
| Ramroth, H | 1 |
| Mertens, M | 1 |
| Vanstraelen, K | 1 |
| Turnes, J | 2 |
| Kurokawa, K | 1 |
| Ohki, T | 1 |
| Kato, J | 1 |
| Fukumura, Y | 1 |
| Imai, M | 1 |
| Shibata, C | 1 |
| Arai, J | 1 |
| Kondo, M | 1 |
| Takagi, K | 1 |
| Kojima, K | 1 |
| Seki, M | 1 |
| Mori, M | 1 |
| Toda, N | 1 |
| Tagawa, K | 1 |
| Radley, A | 1 |
| de Bruin, M | 1 |
| Inglis, SK | 1 |
| Donnan, PT | 1 |
| Hapca, A | 1 |
| Fraser, A | 1 |
| Dillon, JF | 1 |
| Jang, ES | 1 |
| Kim, KA | 1 |
| Kim, YS | 1 |
| Kim, IH | 1 |
| Lee, BS | 2 |
| Lee, YJ | 2 |
| Chung, WJ | 2 |
| Jeong, SH | 1 |
| Da, BL | 1 |
| Lourdusamy, V | 1 |
| Kushner, T | 1 |
| Dieterich, D | 3 |
| Saberi, B | 1 |
| Morishita, N | 2 |
| Sakamori, R | 3 |
| Yamada, T | 1 |
| Kai, Y | 3 |
| Tahata, Y | 2 |
| Urabe, A | 1 |
| Yamada, R | 3 |
| Kodama, T | 2 |
| Hikita, H | 3 |
| Doi, Y | 1 |
| Tamura, S | 2 |
| Hagiwara, H | 2 |
| Imai, Y | 2 |
| Iio, S | 2 |
| Tatsumi, T | 4 |
| Takehara, T | 4 |
| Aschenbrenner, DS | 3 |
| Takaki, S | 1 |
| Imamura, M | 4 |
| Yamaguchi, S | 1 |
| Fukuhara, T | 2 |
| Mori, N | 1 |
| Tsuji, K | 1 |
| Ohya, K | 1 |
| Hayes, CN | 3 |
| Aikata, H | 3 |
| Chayama, K | 9 |
| Lens, S | 3 |
| Miquel, M | 1 |
| Mateos-Muñoz, B | 1 |
| García-Samaniego, J | 1 |
| Forns, X | 3 |
| Devi, S | 1 |
| Micallef, S | 1 |
| Gauci, J | 1 |
| Gerada, J | 1 |
| Ma, CD | 1 |
| Talley, DC | 1 |
| Rolt, A | 1 |
| Xu, X | 1 |
| Wang, AQ | 1 |
| Le, D | 1 |
| Uchida, T | 3 |
| Osawa, M | 4 |
| Teraoka, Y | 2 |
| Li, K | 1 |
| Hu, X | 1 |
| Park, SB | 1 |
| Chalasani, N | 1 |
| Irvin, PH | 1 |
| Dulcey, AE | 1 |
| Southall, N | 1 |
| Marugan, JJ | 1 |
| Hu, Z | 1 |
| Frankowski, KJ | 1 |
| Liang, TJ | 2 |
| Freriksen, JJM | 1 |
| Meijerhof, M | 1 |
| van Drongelen, J | 1 |
| Drenth, JPH | 1 |
| Burger, DM | 2 |
| Russel, FGM | 1 |
| Colbers, A | 1 |
| Greupink, R | 1 |
| Papaluca, T | 2 |
| Roberts, SK | 4 |
| Strasser, SI | 2 |
| Stuart, KA | 2 |
| Farrell, G | 1 |
| MacQuillan, G | 2 |
| Dore, GJ | 4 |
| Wade, AJ | 1 |
| George, J | 3 |
| Hazeldine, S | 1 |
| O'Beirne, J | 1 |
| Wigg, A | 2 |
| Fisher, L | 1 |
| McGarity, B | 1 |
| Sawhney, R | 1 |
| Sinclair, M | 2 |
| Thomas, J | 1 |
| Valiozis, I | 1 |
| Weltman, M | 2 |
| Wilson, M | 1 |
| Woodward, A | 1 |
| Ahlenstiel, G | 1 |
| Haque, M | 1 |
| Levy, M | 3 |
| Prewett, E | 1 |
| Sievert, W | 2 |
| Sood, S | 1 |
| Tse, E | 2 |
| Valaydon, Z | 1 |
| Bowden, S | 2 |
| Douglas, M | 1 |
| New, K | 1 |
| O'Keefe, J | 2 |
| Hellard, M | 3 |
| Doyle, J | 2 |
| Stoove, M | 2 |
| Thompson, AJ | 1 |
| Young, J | 1 |
| Wong, S | 1 |
| Klein, MB | 1 |
| Ward, JC | 1 |
| Bowyer, S | 1 |
| Chen, S | 2 |
| Fernandes Campos, GR | 2 |
| Ramirez, S | 1 |
| Bukh, J | 2 |
| Harris, M | 4 |
| Chayanupatkul, M | 1 |
| Chittmittraprap, S | 1 |
| Pratedrat, P | 1 |
| Chuaypen, N | 1 |
| Avihingsanon, A | 1 |
| Tangkijvanich, P | 1 |
| Takakusagi, S | 1 |
| Shimizu, M | 1 |
| Yokoyama, Y | 1 |
| Kizawa, K | 1 |
| Marubashi, K | 1 |
| Kosone, T | 1 |
| Sato, K | 2 |
| Kakizaki, S | 1 |
| Takagi, H | 1 |
| Uraoka, T | 1 |
| Terrault, NA | 1 |
| Burton, J | 1 |
| Ghobrial, M | 1 |
| Verna, E | 1 |
| Bayer, J | 1 |
| Klein, C | 1 |
| Victor, D | 1 |
| Mohan, S | 1 |
| Trotter, J | 1 |
| Dodge, J | 1 |
| Niemann, CU | 1 |
| Rubin, RA | 2 |
| Stein, K | 1 |
| Teuber, G | 1 |
| Naumann, U | 1 |
| Serfert, Y | 1 |
| Niederau, C | 1 |
| Berg, T | 1 |
| Wiegand, J | 1 |
| Jaiswal, SR | 1 |
| Bhakuni, P | 1 |
| Soni, M | 1 |
| Gupta, M | 1 |
| Thatai, A | 1 |
| Chakrabarti, S | 1 |
| Goel, A | 3 |
| Bhadauria, DS | 2 |
| Kaul, A | 2 |
| Verma, A | 1 |
| Tiwari, P | 1 |
| Rungta, S | 1 |
| Rai, P | 2 |
| Gupta, A | 2 |
| Aggarwal, R | 3 |
| Ward, J | 1 |
| Bittar, C | 1 |
| Vilela Rodrigues, JP | 1 |
| Martinelli, ALC | 1 |
| Souza, FF | 1 |
| Pereira, LRL | 1 |
| Rahal, P | 1 |
| Ridruejo, E | 1 |
| Piñero, F | 1 |
| Mendizabal, M | 1 |
| Silva, M | 1 |
| Elsadek, HM | 1 |
| Abdelbaser, ES | 1 |
| Emara, MH | 1 |
| Soliman, HH | 1 |
| Farag, AA | 1 |
| Yu, ML | 2 |
| Huang, CF | 1 |
| Wei, YJ | 1 |
| Lin, WY | 1 |
| Lin, YH | 1 |
| Hsu, PY | 1 |
| Hsu, CT | 1 |
| Liu, TW | 1 |
| Lee, JJ | 1 |
| Niu, SW | 1 |
| Huang, JC | 1 |
| Hung, TS | 1 |
| Yeh, ML | 1 |
| Huang, CI | 1 |
| Liang, PC | 1 |
| Hsieh, MY | 1 |
| Chen, SC | 1 |
| Huang, JF | 1 |
| Chang, JM | 1 |
| Chiu, YW | 1 |
| Dai, CY | 1 |
| Hwang, SJ | 1 |
| Chuang, WL | 1 |
| de Camargo Vieira, MC | 1 |
| Gonçalves, WRB | 1 |
| Guerra, RA | 1 |
| Callegaro, FS | 1 |
| Lazaretti-Castro, M | 1 |
| Maeda, SS | 1 |
| Hussain, N | 1 |
| Farooq, N | 1 |
| Maqsood, M | 1 |
| Rajoka, MSR | 1 |
| Bilal, M | 1 |
| Macías, J | 3 |
| Téllez, F | 3 |
| de Los Santos, I | 2 |
| Morano, LE | 1 |
| Merino, D | 4 |
| Granados, R | 1 |
| Vera-Mendez, F | 1 |
| González-Serna, A | 1 |
| Campo-Moneo, E | 1 |
| García-Fraile, L | 1 |
| García, F | 2 |
| Real, LM | 1 |
| Pineda, JA | 5 |
| Craig, J | 1 |
| Samley, K | 1 |
| Bunreth, V | 1 |
| Matthews, GV | 2 |
| Bhagani, S | 2 |
| Van der Valk, M | 2 |
| Rockstroh, J | 1 |
| Feld, JJ | 2 |
| Rauch, A | 1 |
| Thurnheer, C | 1 |
| Bruneau, J | 1 |
| Kim, A | 1 |
| Shaw, D | 2 |
| Gane, E | 4 |
| Nelson, M | 3 |
| Ingiliz, P | 2 |
| Applegate, TL | 2 |
| Grebely, J | 3 |
| Marks, P | 2 |
| Martinello, M | 2 |
| Petoumenos, K | 2 |
| Huang, YT | 1 |
| Hsieh, YY | 1 |
| Chen, WM | 1 |
| Tung, SY | 1 |
| Wei, KL | 1 |
| Shen, CH | 1 |
| Chang, KC | 1 |
| Lu, CK | 1 |
| Yen, CW | 1 |
| Lu, SN | 1 |
| Hung, CH | 1 |
| Chang, TS | 1 |
| Gupta, G | 1 |
| Yakubu, I | 1 |
| Zhang, Y | 3 |
| Kimball, P | 1 |
| Kang, L | 1 |
| Mitchell, K | 1 |
| Ijioma, S | 1 |
| Carroll, N | 1 |
| Patterson, J | 1 |
| Shinbashi, M | 1 |
| Kumar, D | 1 |
| Moinuddin, I | 1 |
| Kamal, L | 1 |
| King, A | 1 |
| Bhati, C | 1 |
| Cotterell, A | 1 |
| Khan, A | 1 |
| Sharma, A | 1 |
| Sterling, R | 1 |
| Havens, JR | 1 |
| Schaninger, T | 1 |
| Fraser, H | 1 |
| Lofwall, M | 1 |
| Staton, M | 1 |
| Young, AM | 1 |
| Hoven, A | 1 |
| Walsh, SL | 1 |
| Vickerman, P | 1 |
| Chen, CY | 2 |
| Su, WW | 1 |
| Liu, CJ | 2 |
| Lo, CC | 1 |
| Huang, KJ | 1 |
| Tseng, KC | 1 |
| Chang, CY | 1 |
| Peng, CY | 2 |
| Shih, YL | 2 |
| Huang, CS | 1 |
| Kao, WY | 1 |
| Tsai, MC | 1 |
| Wu, JH | 1 |
| Chen, PY | 1 |
| Su, PY | 1 |
| Hwang, JJ | 1 |
| Fang, YJ | 2 |
| Tseng, CW | 1 |
| Lee, FJ | 1 |
| Lai, HC | 1 |
| Hsieh, TY | 2 |
| Chang, CC | 1 |
| Chang, CH | 1 |
| Huang, YJ | 1 |
| Nakamura, K | 2 |
| Kusumoto, K | 1 |
| Ozono, Y | 1 |
| Kuroki, K | 1 |
| Matsuura, Y | 1 |
| Mukuda, T | 1 |
| Ochiai, T | 1 |
| Tsuchimochi, M | 1 |
| Iwakiri, H | 1 |
| Hasuike, S | 1 |
| Shimoda, K | 1 |
| Nagata, K | 1 |
| Bloom, DE | 1 |
| Khoury, A | 1 |
| Srinivasan, V | 1 |
| Wyles, D | 3 |
| Saag, M | 1 |
| Viani, RM | 1 |
| Lalezari, J | 1 |
| Adeyemi, O | 2 |
| Bhatti, L | 1 |
| Khatri, A | 4 |
| King, JR | 3 |
| Hu, YB | 2 |
| Trinh, R | 2 |
| Shulman, NS | 2 |
| Ruane, P | 2 |
| Akhil, MS | 1 |
| Kirushnan, B | 1 |
| Martin, M | 1 |
| Arumugam, K | 1 |
| Ganesh Prasad, NK | 1 |
| Ravichandran, R | 1 |
| Prasad, N | 1 |
| Sharma, RK | 1 |
| Shimada, M | 2 |
| Nakamura, N | 1 |
| Endo, T | 1 |
| Yamabe, H | 1 |
| Nakamura, M | 1 |
| Murakami, R | 1 |
| Narita, I | 1 |
| Tomita, H | 1 |
| Taton, A | 1 |
| Colson, P | 1 |
| Dhiver, C | 1 |
| Ruiz, JM | 1 |
| Bregigeon, S | 1 |
| Tomei, C | 1 |
| Ressiot, E | 1 |
| Menard, A | 1 |
| Poizot-Martin, I | 1 |
| Ravaux, I | 1 |
| Lacarelle, B | 1 |
| Solas, C | 1 |
| Bräu, N | 1 |
| Kottilil, S | 3 |
| Daar, ES | 2 |
| Workowski, K | 1 |
| Luetkemeyer, A | 2 |
| Kim, AY | 2 |
| Doehle, B | 1 |
| Huang, KC | 2 |
| Mogalian, E | 3 |
| Osinusi, A | 2 |
| McNally, J | 4 |
| Brainard, DM | 8 |
| McHutchison, JG | 4 |
| Naggie, S | 1 |
| Sulkowski, M | 3 |
| Hézode, C | 3 |
| Fourati, S | 1 |
| Scoazec, G | 1 |
| Soulier, A | 1 |
| Varaut, A | 1 |
| François, M | 1 |
| Ruiz, I | 1 |
| Roudot-Thoraval, F | 1 |
| Martin, MT | 1 |
| Deming, P | 1 |
| Durlik, M | 1 |
| Wawrzynowicz-Syczewska, M | 1 |
| Buivydiene, A | 1 |
| Katzarov, K | 1 |
| Kupcinskas, L | 1 |
| Tolmane, I | 1 |
| Karpińska, E | 1 |
| Pisula, A | 1 |
| Karwowska, KM | 1 |
| Bolewska, B | 1 |
| Jabłkowski, M | 1 |
| Rostkowska, K | 2 |
| Jakutiene, J | 1 |
| Simonova, M | 1 |
| Yang, CM | 1 |
| Yoon, JC | 1 |
| Park, JH | 1 |
| Lee, JM | 1 |
| Lubel, J | 1 |
| Strasser, S | 1 |
| Dore, G | 1 |
| Thompson, A | 2 |
| Pianko, S | 3 |
| Bollipo, S | 1 |
| Mitchell, JL | 1 |
| Fragomeli, V | 1 |
| Jones, T | 1 |
| Chivers, S | 1 |
| Gow, P | 2 |
| Iser, D | 2 |
| Gazzola, A | 1 |
| Cheng, W | 1 |
| Nazareth, S | 1 |
| Galhenage, S | 1 |
| Wade, A | 1 |
| Sasadeusz, J | 2 |
| Zekry, A | 1 |
| Hayashi, K | 1 |
| Ishigami, M | 1 |
| Ishizu, Y | 1 |
| Kuzuya, T | 1 |
| Honda, T | 1 |
| Kawashima, H | 1 |
| Ishikawa, T | 1 |
| Tachi, Y | 1 |
| Hattori, M | 1 |
| Katano, Y | 1 |
| Goto, H | 1 |
| Hirooka, Y | 1 |
| Nahass, R | 1 |
| Luketic, V | 1 |
| Asante-Appiah, E | 3 |
| Hwang, P | 4 |
| Robertson, M | 2 |
| Wahl, J | 3 |
| Barr, E | 2 |
| Haber, B | 3 |
| Younossi, ZM | 2 |
| Stepanova, M | 2 |
| Hunt, S | 2 |
| Sankhyan, P | 1 |
| Gonzalez-Estrada, A | 1 |
| Zuckerman, E | 1 |
| Pangerl, A | 1 |
| Zhang, Z | 1 |
| Martinez, M | 1 |
| Bao, Y | 2 |
| Calleja, JL | 2 |
| Alves, K | 1 |
| Toyoda, H | 1 |
| Suzuki, F | 3 |
| Kato, K | 1 |
| Rodrigues, L | 3 |
| Zhang, X | 2 |
| Setze, C | 3 |
| Pilot-Matias, T | 4 |
| Burroughs, M | 2 |
| Redman, R | 2 |
| Kumada, H | 6 |
| Bourlière, M | 1 |
| Gordon, SC | 2 |
| Flamm, SL | 1 |
| Cooper, CL | 1 |
| Tong, M | 1 |
| Ravendhran, N | 2 |
| Vierling, JM | 2 |
| Tran, TT | 1 |
| Bansal, MB | 1 |
| Hyland, RH | 3 |
| Stamm, LM | 5 |
| Dvory-Sobol, H | 2 |
| Svarovskaia, E | 3 |
| Zhang, J | 1 |
| Subramanian, GM | 2 |
| Verna, EC | 1 |
| Buggisch, P | 1 |
| Landis, CS | 1 |
| Younes, ZH | 2 |
| Curry, MP | 1 |
| Schiff, ER | 1 |
| Reddy, KR | 4 |
| Manns, MP | 4 |
| Kowdley, KV | 2 |
| Salcedo, M | 1 |
| Prieto, M | 1 |
| Castells, L | 1 |
| Pascasio, JM | 2 |
| Montero Alvarez, JL | 1 |
| Fernández, I | 1 |
| Sánchez-Antolín, G | 1 |
| González-Diéguez, L | 1 |
| García-Gonzalez, M | 1 |
| Otero, A | 1 |
| Lorente, S | 1 |
| Espinosa, MD | 1 |
| Testillano, M | 1 |
| González, A | 1 |
| Castellote, J | 1 |
| Casafont, F | 1 |
| Londoño, MC | 2 |
| Pons, JA | 1 |
| Molina Pérez, E | 1 |
| Cuervas-Mons, V | 1 |
| Pascual, S | 1 |
| Herrero, JI | 1 |
| Narváez, I | 1 |
| Vinaixa, C | 1 |
| Llaneras, J | 1 |
| Sousa, JM | 1 |
| Bañares, R | 1 |
| Bielen, R | 1 |
| Moreno, C | 4 |
| Van Vlierberghe, H | 1 |
| Bourgeois, S | 1 |
| Mulkay, JP | 1 |
| Vanwolleghem, T | 2 |
| Verlinden, W | 1 |
| Brixko, C | 1 |
| Decaestecker, J | 1 |
| De Galocsy, C | 1 |
| Janssens, F | 1 |
| Cool, M | 1 |
| Van Overbeke, L | 1 |
| Van Steenkiste, C | 1 |
| D'heygere, F | 1 |
| Cools, W | 1 |
| Nevens, F | 1 |
| Robaeys, G | 1 |
| Morisawa, N | 1 |
| Koshima, Y | 1 |
| Kuriyama, S | 1 |
| Matsuyama, M | 1 |
| Hayashi, N | 1 |
| Satoh, JI | 1 |
| Amemiya, M | 1 |
| Yokoo, T | 1 |
| Sokol, R | 1 |
| Kinoshita, K | 1 |
| Iwasa, T | 1 |
| Ben Ali, Z | 1 |
| Boglione-Kerrien, C | 1 |
| Bellissant, E | 1 |
| Soriano, V | 1 |
| Benítez-Gutiérrez, L | 1 |
| Arias, A | 1 |
| Carrasco, I | 1 |
| Barreiro, P | 1 |
| Peña, JM | 1 |
| de Mendoza, C | 1 |
| Mehta, R | 1 |
| Kabrawala, M | 1 |
| Nandwani, S | 1 |
| Desai, P | 1 |
| Bhayani, V | 1 |
| Patel, S | 1 |
| Parekh, V | 1 |
| Britto, K | 1 |
| Cheung, W | 1 |
| Cameron, R | 1 |
| Kemp, W | 1 |
| Charafeddine, M | 1 |
| Abunimeh, M | 2 |
| Pothacamury, RK | 1 |
| Fu, B | 1 |
| Cohen, E | 2 |
| Cohen, DE | 2 |
| Ikegami, T | 3 |
| Ueda, Y | 1 |
| Akamatsu, N | 1 |
| Ishiyama, K | 1 |
| Goto, R | 1 |
| Soyama, A | 1 |
| Kuramitsu, K | 1 |
| Honda, M | 1 |
| Shinoda, M | 1 |
| Yoshizumi, T | 2 |
| Okajima, H | 1 |
| Kitagawa, Y | 1 |
| Inomata, Y | 1 |
| Ku, Y | 1 |
| Eguchi, S | 1 |
| Taketomi, A | 1 |
| Ohdan, H | 1 |
| Kokudo, N | 1 |
| Yanaga, K | 1 |
| Furukawa, H | 1 |
| Uemoto, S | 1 |
| Maehara, Y | 2 |
| Smolders, EJ | 1 |
| Smit, C | 1 |
| T M M de Kanter, C | 1 |
| Dofferiiof, ASM | 1 |
| Arends, JE | 2 |
| Brinkman, K | 1 |
| Rijnders, B | 1 |
| Reiss, P | 1 |
| Szymanek-Pasternak, A | 1 |
| Gheorghe, L | 1 |
| Iacob, S | 1 |
| Curescu, M | 1 |
| Brisc, C | 1 |
| Cijevschi, C | 1 |
| Caruntu, F | 1 |
| Stanciu, C | 1 |
| Simionov, I | 1 |
| Sporea, I | 1 |
| Gheorghe, C | 1 |
| Iacob, R | 1 |
| Arama, V | 1 |
| Sirli, R | 1 |
| Trifan, A | 1 |
| Behrendt, P | 1 |
| Perin, P | 1 |
| Menzel, N | 1 |
| Banda, D | 1 |
| Pfaender, S | 1 |
| Alves, MP | 1 |
| Thiel, V | 1 |
| Meuleman, P | 2 |
| Colpitts, CC | 1 |
| Schang, LM | 1 |
| Vondran, FWR | 1 |
| Steinmann, E | 1 |
| Pietschmann, T | 1 |
| Weil, C | 1 |
| Mehta, D | 2 |
| Koren, G | 1 |
| Pinsky, B | 2 |
| Samp, JC | 1 |
| Chodick, G | 1 |
| Shalev, V | 1 |
| Struble, K | 1 |
| Chan-Tack, K | 1 |
| Qi, K | 1 |
| Naeger, LK | 1 |
| Birnkrant, D | 1 |
| Cusato, J | 1 |
| De Nicolò, A | 1 |
| Boglione, L | 1 |
| Favata, F | 1 |
| Ariaudo, A | 1 |
| Mornese Pinna, S | 1 |
| Guido, F | 1 |
| Avataneo, V | 1 |
| Carcieri, C | 1 |
| Cariti, G | 1 |
| Di Perri, G | 1 |
| D'Avolio, A | 2 |
| Frey, A | 1 |
| Piras-Straub, K | 1 |
| Walker, A | 1 |
| Timm, J | 3 |
| Gerken, G | 1 |
| Herzer, K | 1 |
| Chahine, EB | 2 |
| Kelley, D | 1 |
| Childs-Kean, LM | 1 |
| Teegen, EM | 1 |
| Globke, B | 1 |
| Schott, E | 1 |
| Pratschke, J | 1 |
| Eurich, D | 1 |
| Lionetti, R | 1 |
| Piccolo, P | 1 |
| Mancusi, RL | 1 |
| Mazzarelli, C | 1 |
| Montalbano, M | 1 |
| Lenci, I | 1 |
| Carrai, P | 1 |
| Guaraldi, G | 2 |
| Visco-Comandini, U | 1 |
| Milana, M | 1 |
| Biolato, M | 1 |
| Loiacono, L | 1 |
| Valente, G | 1 |
| Angelico, M | 1 |
| D'offizi, G | 1 |
| Ordeig, L | 1 |
| Garcia-Cehic, D | 1 |
| Gregori, J | 1 |
| Soria, ME | 1 |
| Nieto-Aponte, L | 1 |
| Perales, C | 1 |
| Llorens, M | 1 |
| Chen, Q | 2 |
| Riveiro-Barciela, M | 2 |
| Buti, M | 2 |
| Esteban, R | 2 |
| Esteban, JI | 1 |
| Rodriguez-Frias, F | 1 |
| Quer, J | 1 |
| He, YL | 1 |
| Yang, SJ | 1 |
| Hu, CH | 1 |
| Dong, J | 1 |
| Gao, H | 1 |
| Yan, TT | 1 |
| Liu, JF | 1 |
| Yang, Y | 2 |
| Ren, DF | 1 |
| Zhu, L | 1 |
| Zhao, YR | 1 |
| Chen, TY | 1 |
| Notari, S | 1 |
| Tempestilli, M | 1 |
| Fabbri, G | 1 |
| Libertone, R | 1 |
| Antinori, A | 1 |
| Ammassari, A | 1 |
| Agrati, C | 1 |
| Hirayama, T | 1 |
| Honda, A | 1 |
| Miyazaki, T | 1 |
| Yara, SI | 1 |
| Kohjima, M | 1 |
| Nakamuta, M | 1 |
| Matsuzaki, Y | 1 |
| Ibrahim, AE | 1 |
| Hashem, H | 1 |
| Elhenawee, M | 1 |
| Saleh, H | 1 |
| El-Khayat, H | 1 |
| Fouad, Y | 1 |
| Mohamed, HI | 1 |
| El-Amin, H | 1 |
| Kamal, EM | 1 |
| Maher, M | 1 |
| Risk, A | 1 |
| Saab, S | 3 |
| Hudgens, S | 1 |
| Grunow, N | 1 |
| Navarro-Triviño, FJ | 1 |
| Muñoz-Medina, L | 1 |
| Navarro-Navarro, I | 1 |
| Ruiz-Villaverde, R | 1 |
| Bernstein, DE | 2 |
| Younes, Z | 1 |
| Vlierberghe, HV | 1 |
| Larsen, L | 1 |
| Tatsch, F | 1 |
| Ferenci, P | 2 |
| Smith, D | 2 |
| Magri, A | 1 |
| Bonsall, D | 1 |
| Ip, CLC | 1 |
| Trebes, A | 1 |
| Brown, A | 1 |
| Piazza, P | 1 |
| Bowden, R | 1 |
| Nguyen, D | 1 |
| Ansari, MA | 1 |
| Simmonds, P | 1 |
| Sun, J | 1 |
| Liang, X | 1 |
| Fan, R | 1 |
| Hou, J | 1 |
| Rivero-Juárez, A | 3 |
| Collado, A | 1 |
| Morano-Amado, LE | 1 |
| Ríos, MJ | 1 |
| Pérez-Pérez, M | 1 |
| Palacios, R | 1 |
| Pérez, AB | 2 |
| Mancebo, M | 1 |
| Rivero, A | 4 |
| Liu, B | 1 |
| Gai, K | 1 |
| Qin, H | 1 |
| Liu, X | 1 |
| Cao, Y | 2 |
| Lu, Q | 1 |
| Lu, D | 1 |
| Chen, D | 1 |
| Shen, H | 1 |
| Song, W | 1 |
| Wang, X | 2 |
| Xu, H | 1 |
| Wilder, JM | 1 |
| Muir, A | 1 |
| Durand, CM | 1 |
| Bowring, MG | 1 |
| Brown, DM | 1 |
| Chattergoon, MA | 1 |
| Massaccesi, G | 1 |
| Bair, N | 1 |
| Wesson, R | 1 |
| Reyad, A | 1 |
| Naqvi, FF | 1 |
| Ostrander, D | 1 |
| Sugarman, J | 1 |
| Segev, DL | 1 |
| Desai, NM | 1 |
| Moorehead, L | 1 |
| Murray, B | 2 |
| Ling, KHJ | 1 |
| Perry, R | 1 |
| Curtis, C | 1 |
| Lawitz, E | 4 |
| Lasseter, K | 1 |
| Marbury, T | 1 |
| Mathias, A | 2 |
| von Felden, J | 2 |
| Vermehren, J | 2 |
| Mauss, S | 1 |
| Lutz, T | 1 |
| Busch, HW | 1 |
| Baumgarten, A | 1 |
| Schewe, K | 1 |
| Hueppe, D | 1 |
| Boesecke, C | 1 |
| Rockstroh, JK | 1 |
| Daeumer, M | 1 |
| Luebke, N | 1 |
| Schulze Zur Wiesch, J | 3 |
| Sarrazin, C | 2 |
| Christensen, S | 2 |
| Li, C | 1 |
| Hu, J | 1 |
| Orkin, C | 1 |
| Cooke, G | 1 |
| Tu, E | 1 |
| Pagani, N | 1 |
| Mucenic, M | 1 |
| Bandeira de Mello Brandao, A | 1 |
| Marroni, CA | 1 |
| Medeiros Fleck, A | 1 |
| Zanotelli, ML | 1 |
| Kiss, G | 1 |
| Meine, MH | 1 |
| Leipnitz, I | 1 |
| Soares Schlindwein, E | 1 |
| Martini, J | 1 |
| Costabeber, AM | 1 |
| Sacco, FKF | 1 |
| Cracco Cantisani, GP | 1 |
| Alao, H | 1 |
| Cam, M | 1 |
| Keembiyehetty, C | 1 |
| Zhang, F | 1 |
| Serti, E | 1 |
| Suarez, D | 1 |
| Park, H | 1 |
| Fourie, NH | 1 |
| Wright, EC | 1 |
| Henderson, WA | 1 |
| Li, Q | 1 |
| Rehermann, B | 1 |
| Ghany, MG | 1 |
| Hassany, M | 1 |
| Elsharkawy, A | 1 |
| Maged, A | 1 |
| Mehrez, M | 1 |
| Asem, N | 1 |
| Gomaa, A | 1 |
| Mostafa, Z | 1 |
| Abbas, B | 1 |
| Soliman, M | 1 |
| Esmat, G | 1 |
| Uribe-Noguez, LA | 1 |
| Ocaña-Mondragón, A | 1 |
| Mata-Marín, JA | 1 |
| Cázares-Cortázar, A | 1 |
| Ribas-Aparicio, RM | 1 |
| Gómez-Torres, ME | 1 |
| Gaytán-Martínez, J | 1 |
| Martínez-Rodríguez, ML | 1 |
| Kramer, JR | 1 |
| Puenpatom, A | 1 |
| Erickson, KF | 1 |
| El-Serag, HB | 1 |
| Kanwal, F | 1 |
| Esposito, I | 1 |
| Marciano, S | 1 |
| Trinks, J | 1 |
| Chhatwal, J | 1 |
| Atia, NN | 1 |
| El-Shaboury, SR | 1 |
| El-Gizawy, SM | 1 |
| Abo-Zeid, MN | 1 |
| Summers, BB | 1 |
| Sadler, MD | 1 |
| Hiraga, N | 2 |
| Kan, H | 2 |
| Saito, Y | 2 |
| Tsuge, M | 2 |
| Abe-Chayama, H | 1 |
| Makokha, GN | 1 |
| Miki, D | 2 |
| Ochi, H | 2 |
| Ishida, Y | 2 |
| Tateno, C | 2 |
| Zhai, PB | 1 |
| Qing, J | 1 |
| Li, B | 1 |
| Zhang, LQ | 1 |
| Ma, L | 1 |
| Chen, L | 1 |
| Potluri, VS | 1 |
| Bloom, RD | 2 |
| Casado, M | 2 |
| Rodríguez, M | 1 |
| Morano Amado, LE | 1 |
| Morillas, RM | 1 |
| Pascasio Acevedo, JM | 1 |
| Andrade, RJ | 1 |
| Carrión, JA | 1 |
| McNabb, B | 1 |
| Zhang, G | 2 |
| Camus, G | 1 |
| Arrais de Castro, R | 1 |
| Vilas, P | 1 |
| Borges-Costa, J | 1 |
| Tato Marinho, R | 1 |
| Gane, EJ | 2 |
| Stedman, CA | 2 |
| Schwabe, C | 2 |
| Vijgen, L | 1 |
| Chanda, S | 1 |
| Kakuda, TN | 1 |
| Fry, J | 1 |
| Blatt, LM | 1 |
| McClure, MW | 1 |
| Nagral, A | 1 |
| Jhaveri, A | 1 |
| Sawant, S | 1 |
| Parikh, NS | 1 |
| Nagral, N | 1 |
| Merchant, R | 1 |
| Gandhi, M | 1 |
| Wada, N | 1 |
| Ikeda, F | 2 |
| Mori, C | 1 |
| Takaguchi, K | 1 |
| Fujioka, SI | 1 |
| Kobashi, H | 1 |
| Morimoto, Y | 1 |
| Kariyama, K | 1 |
| Sakaguchi, K | 1 |
| Hashimoto, N | 1 |
| Moriya, A | 1 |
| Kawaguchi, M | 1 |
| Miyatake, H | 1 |
| Hagihara, H | 1 |
| Kubota, J | 1 |
| Takayama, H | 1 |
| Takeuchi, Y | 1 |
| Yasunaka, T | 1 |
| Takaki, A | 1 |
| Iwasaki, Y | 1 |
| Okada, H | 1 |
| Omar, MA | 1 |
| Abdel-Lateef, MA | 1 |
| Ali, R | 1 |
| Derayea, SM | 1 |
| Jagadabi, V | 1 |
| Nagendra Kumar, PV | 1 |
| Mahesh, K | 1 |
| Pamidi, S | 1 |
| Ramaprasad, LA | 1 |
| Nagaraju, D | 1 |
| Harada, N | 1 |
| Itoh, S | 1 |
| Furusho, N | 1 |
| Kato, M | 1 |
| Shimoda, S | 1 |
| Soejima, Y | 1 |
| Jacobson, IM | 2 |
| Sakamoto, N | 1 |
| Nishiguchi, S | 1 |
| Ueno, Y | 1 |
| Yatsuhashi, H | 1 |
| Takikawa, Y | 1 |
| Kanda, T | 2 |
| Sakamoto, M | 1 |
| Tamori, A | 2 |
| Mita, E | 1 |
| De-Oertel, S | 1 |
| Matsuda, T | 1 |
| Tanaka, Y | 2 |
| Kurosaki, M | 1 |
| Bartlett, C | 2 |
| Curd, A | 1 |
| Peckham, M | 1 |
| Mathur, P | 1 |
| Wilson, E | 1 |
| Maduell, F | 1 |
| Belmar, L | 1 |
| Ugalde, J | 1 |
| Laguno, M | 1 |
| Martínez-Rebollar, M | 1 |
| Ojeda, R | 1 |
| Arias, M | 1 |
| Rodas, L | 1 |
| Rossi, F | 1 |
| Llovet, LP | 1 |
| González, LN | 1 |
| Mallolas, J | 1 |
| Schulz, TR | 1 |
| Kanhutu, K | 1 |
| Watkinson, S | 1 |
| Biggs, BA | 1 |
| Kuchay, S | 1 |
| Saeed, M | 1 |
| Giorgi, C | 1 |
| Li, J | 2 |
| Hoffmann, HH | 1 |
| Pinton, P | 1 |
| Rice, CM | 2 |
| Pagano, M | 1 |
| Jung, BH | 1 |
| Park, JI | 1 |
| Lee, SG | 1 |
| Okada, M | 1 |
| Hai, H | 1 |
| Uchida-Kobayashi, S | 1 |
| Enomoto, M | 1 |
| Kawada, N | 1 |
| Isakov, V | 1 |
| Chulanov, V | 1 |
| Abdurakhmanov, D | 1 |
| Burnevich, E | 1 |
| Nurmukhametova, E | 1 |
| Kozhevnikova, G | 1 |
| Gankina, N | 1 |
| Zhuravel, S | 1 |
| Romanova, S | 2 |
| Lu, S | 1 |
| Svarovskaia, ES | 1 |
| Ivashkin, V | 1 |
| Morozov, V | 1 |
| Bakulin, I | 1 |
| Lagging, M | 1 |
| Zhdanov, K | 1 |
| Weiland, O | 2 |
| Hsiang, JC | 1 |
| Feng, HP | 2 |
| Guo, Z | 3 |
| Ross, LL | 1 |
| Fraser, I | 1 |
| Panebianco, D | 2 |
| Jumes, P | 2 |
| Fandozzi, C | 3 |
| Caro, L | 4 |
| Talaty, J | 2 |
| Ma, J | 1 |
| Mangin, E | 1 |
| Huang, X | 3 |
| Marshall, WL | 2 |
| Butterton, JR | 2 |
| Yeh, WW | 2 |
| Muljono, DH | 1 |
| Elmowafy, AY | 1 |
| El Maghrabi, HM | 1 |
| Zahab, MA | 1 |
| Elwasif, SM | 1 |
| Bakr, MA | 1 |
| Kimura, K | 1 |
| Ueno, T | 2 |
| Shiozaki, T | 2 |
| Ishikawa, H | 3 |
| Li, H | 1 |
| Garimella, T | 2 |
| Boerekamps, A | 1 |
| De Weggheleire, A | 1 |
| van den Berk, GE | 1 |
| Lauw, FN | 1 |
| Claassen, MAA | 1 |
| Posthouwer, D | 1 |
| Bierman, WF | 1 |
| Hullegie, SJ | 1 |
| Popping, S | 1 |
| van de Vijver, DACM | 1 |
| Dofferhoff, ASM | 1 |
| Kootstra, GJ | 1 |
| Leyten, EM | 1 |
| den Hollander, J | 1 |
| van Kasteren, ME | 1 |
| Soetekouw, R | 1 |
| Ammerlaan, HSM | 1 |
| Schinkel, J | 1 |
| Florence, E | 1 |
| Rijnders, BJA | 1 |
| Green, M | 1 |
| Doi, A | 1 |
| Nakabori, T | 2 |
| Murayama, A | 1 |
| Nitta, S | 1 |
| Asahina, Y | 1 |
| Suemizu, H | 2 |
| Kato, T | 2 |
| Clément, V | 1 |
| Raimond, V | 1 |
| Chu, X | 1 |
| Dunnington, K | 1 |
| Du, L | 1 |
| Hanley, WD | 1 |
| Fraser, IP | 1 |
| Mitselos, A | 1 |
| Denef, JF | 1 |
| De Lepeleire, I | 1 |
| de Hoon, JN | 1 |
| Vandermeulen, C | 1 |
| Martinho, M | 1 |
| Valesky, R | 1 |
| Rodríguez-Osorio, I | 1 |
| Pernas-Souto, B | 1 |
| Pertega-Díaz, S | 1 |
| McLean, RC | 1 |
| Reese, PP | 1 |
| Acker, M | 1 |
| Atluri, P | 1 |
| Bermudez, C | 1 |
| Goldberg, LR | 1 |
| Abt, PL | 1 |
| Blumberg, EA | 1 |
| Van Deerlin, VM | 1 |
| Hasz, R | 1 |
| Suplee, L | 1 |
| Sicilia, A | 1 |
| Woodards, A | 1 |
| Zahid, MN | 1 |
| Bar, KJ | 1 |
| Porrett, P | 1 |
| Levine, MH | 1 |
| Hornsby, N | 1 |
| Gentile, C | 1 |
| Smith, J | 1 |
| Goldberg, DS | 1 |
| Marciniewicz, E | 1 |
| Podgórski, P | 1 |
| Pawłowski, T | 1 |
| Małyszczak, K | 1 |
| Fleischer-Stępniewska, K | 1 |
| Knysz, B | 1 |
| Waliszewska-Prosół, M | 1 |
| Żelwetro, A | 1 |
| Rymer, W | 1 |
| Inglot, M | 1 |
| Ejma, M | 1 |
| Sąsiadek, M | 1 |
| Bladowska, J | 1 |
| Hanif, FM | 1 |
| Mandhwani, R | 1 |
| Lail, G | 1 |
| Luck, NH | 1 |
| Aziz, T | 1 |
| Lee, WP | 1 |
| Lan, KL | 1 |
| Liao, SX | 1 |
| Hou, MC | 2 |
| Lan, KH | 1 |
| Lin, CL | 1 |
| Su, TH | 1 |
| Yang, HC | 1 |
| Chen, PJ | 1 |
| Chen, DS | 1 |
| Woolley, AE | 1 |
| Singh, SK | 1 |
| Goldberg, HJ | 1 |
| Mallidi, HR | 1 |
| Givertz, MM | 1 |
| Mehra, MR | 1 |
| Coppolino, A | 1 |
| Kusztos, AE | 1 |
| Johnson, ME | 1 |
| Chen, K | 1 |
| Haddad, EA | 1 |
| Fanikos, J | 1 |
| Harrington, DP | 1 |
| Camp, PC | 1 |
| Baden, LR | 1 |
| Douglas, MW | 1 |
| Tay, ES | 1 |
| Eden, JS | 1 |
| Parigi, TL | 1 |
| Torres, MCP | 1 |
| Aghemo, A | 1 |
| Maughan, A | 1 |
| Sadigh, K | 1 |
| Angulo-Diaz, V | 1 |
| Villanueva, M | 1 |
| Lim, JK | 1 |
| Costa, VD | 1 |
| Brandão-Mello, CE | 1 |
| Nunes, EP | 1 |
| Dos Santos Silva, PGC | 1 |
| de Souza Rodrigues, LLLX | 1 |
| Lampe, E | 1 |
| do Amaral Mello, FC | 1 |
| Piazzolla, V | 1 |
| Giannelli, A | 1 |
| Visaggi, E | 1 |
| Minerva, N | 1 |
| Palmieri, V | 1 |
| Carraturo, I | 1 |
| Potenza, D | 1 |
| Napoli, N | 1 |
| Lauletta, G | 1 |
| Tagarielli, V | 1 |
| Santoro, R | 1 |
| Piccigallo, E | 1 |
| De Gioia, S | 1 |
| Chimenti, A | 1 |
| Cuccorese, G | 1 |
| Metrangolo, A | 1 |
| Mazzola, M | 1 |
| Agostinacchio, E | 1 |
| Mennea, G | 1 |
| Sabbà, C | 1 |
| Cela, M | 1 |
| Copetti, M | 1 |
| Heo, J | 1 |
| Kim, DY | 1 |
| Tak, WY | 1 |
| Kim, YJ | 1 |
| Paik, SW | 1 |
| Sim, E | 1 |
| Kulasingam, S | 1 |
| Talwani, R | 1 |
| Wu, SH | 1 |
| Chu, CJ | 1 |
| Chueca, N | 1 |
| García-Deltoro, M | 1 |
| Martínez-Sapiña, AM | 1 |
| Lara-Pérez, MM | 1 |
| García-Bujalance, S | 1 |
| Aldámiz-Echevarría, T | 1 |
| Vera-Méndez, FJ | 1 |
| Salmerón, J | 1 |
| Alados-Arboledas, JC | 1 |
| Poyato, A | 1 |
| Vivancos-Gallego, MJ | 1 |
| Rosales-Zábal, JM | 1 |
| Alavi, M | 1 |
| Kaveh-Ei, S | 1 |
| Rahimi-Movaghar, A | 1 |
| Shadloo, B | 1 |
| Hajarizadeh, B | 1 |
| Wahid, B | 1 |
| Xiao, H | 1 |
| Wang, J | 1 |
| Yang, F | 1 |
| Lu, H | 1 |
| Arachchi, N | 1 |
| Cameron, K | 1 |
| Barrail-Tran, A | 1 |
| Goldwirt, L | 1 |
| Gelé, T | 1 |
| Laforest, C | 1 |
| Lavenu, A | 1 |
| Danjou, H | 1 |
| Radenne, S | 3 |
| Leroy, V | 3 |
| Houssel-Debry, P | 3 |
| Duvoux, C | 2 |
| Kamar, N | 3 |
| Canva, V | 2 |
| Conti, F | 2 |
| Durand, F | 2 |
| D'Alteroche, L | 3 |
| Botta-Fridlund, D | 3 |
| Cagnot, C | 1 |
| Fougerou-Leurent, C | 3 |
| Pageaux, GP | 3 |
| Duclos-Vallée, JC | 3 |
| Taburet, AM | 1 |
| Coilly, A | 3 |
| Zanaga, LP | 2 |
| Santos, AG | 1 |
| Ataíde, EC | 1 |
| Boin, IFSF | 1 |
| Stucchi, RSB | 1 |
| Bifano, M | 4 |
| Hwang, C | 1 |
| Oosterhuis, B | 1 |
| Hartstra, J | 1 |
| Grasela, D | 1 |
| Tiessen, R | 1 |
| Velinova-Donga, M | 1 |
| Kandoussi, H | 2 |
| Sevinsky, H | 1 |
| Bertz, R | 1 |
| Vallet-Pichard, A | 1 |
| Corouge, M | 1 |
| Martel-Laferrière, V | 1 |
| Dieterich, DT | 1 |
| Schinazi, R | 1 |
| Halfon, P | 1 |
| Hill, A | 1 |
| Khoo, S | 1 |
| Fortunak, J | 1 |
| Simmons, B | 1 |
| Ford, N | 1 |
| Nakamoto, S | 1 |
| Wu, S | 1 |
| Shirasawa, H | 1 |
| Yokosuka, O | 1 |
| Gentile, I | 4 |
| Buonomo, AR | 4 |
| Borgia, F | 1 |
| Zappulo, E | 3 |
| Castaldo, G | 1 |
| Borgia, G | 4 |
| Qi, H | 1 |
| Olson, CA | 1 |
| Wu, NC | 1 |
| Ke, R | 1 |
| Loverdo, C | 1 |
| Chu, V | 1 |
| Truong, S | 1 |
| Remenyi, R | 1 |
| Chen, Z | 1 |
| Du, Y | 1 |
| Su, SY | 1 |
| Al-Mawsawi, LQ | 1 |
| Wu, TT | 1 |
| Chen, SH | 1 |
| Lin, CY | 1 |
| Zhong, W | 1 |
| Lloyd-Smith, JO | 1 |
| Sun, R | 1 |
| Bacon, BR | 1 |
| Bruno, S | 1 |
| Baruch, Y | 1 |
| Howe, AY | 2 |
| Gress, J | 1 |
| Gilbert, CL | 1 |
| Shaw, PM | 1 |
| Cooreman, MP | 1 |
| Robertson, MN | 1 |
| Dutko, FJ | 2 |
| Mobashery, N | 2 |
| Andreone, P | 3 |
| Colombo, MG | 1 |
| Enejosa, JV | 1 |
| Koksal, I | 1 |
| Maieron, A | 1 |
| Müllhaupt, B | 1 |
| Horsmans, Y | 1 |
| Reesink, HW | 1 |
| Podsadecki, T | 4 |
| Bernstein, B | 2 |
| Xiao, F | 1 |
| Fofana, I | 1 |
| Heydmann, L | 1 |
| Barth, H | 1 |
| Soulier, E | 1 |
| Habersetzer, F | 1 |
| Doffoël, M | 1 |
| Patel, AH | 1 |
| Zeisel, MB | 1 |
| Baumert, TF | 1 |
| Adler, H | 1 |
| Lambert, JS | 1 |
| Izumi, N | 1 |
| Black, S | 2 |
| Curry, S | 2 |
| Ludmerer, SW | 1 |
| Liu, R | 1 |
| Barnard, RJ | 1 |
| Newhard, W | 1 |
| Hwang, PM | 1 |
| Nickle, D | 1 |
| Gilbert, C | 1 |
| DiNubile, MJ | 1 |
| Stirnimann, G | 1 |
| Hilgenfeldt, E | 1 |
| Firpi, RJ | 1 |
| Krishnan, P | 2 |
| Beyer, J | 2 |
| Mistry, N | 1 |
| Koev, G | 1 |
| Reisch, T | 2 |
| DeGoey, D | 1 |
| Kati, W | 1 |
| Campbell, A | 1 |
| Williams, L | 1 |
| Xie, W | 1 |
| Molla, A | 1 |
| Collins, C | 2 |
| Serfaty, L | 1 |
| Chukkapalli, V | 1 |
| Berger, KL | 1 |
| Kelly, SM | 1 |
| Thomas, M | 1 |
| Deiters, A | 1 |
| Randall, G | 1 |
| Ghosh, AK | 1 |
| Brindisi, M | 1 |
| Cooper, JN | 1 |
| Lalezari, JP | 1 |
| Pockros, PJ | 3 |
| Gitlin, N | 1 |
| Freilich, BF | 1 |
| Harlan, W | 1 |
| Ghalib, R | 1 |
| Oguchi, G | 1 |
| Thuluvath, PJ | 1 |
| Ortiz-Lasanta, G | 1 |
| Rabinovitz, M | 1 |
| Bernstein, D | 1 |
| Bennett, M | 2 |
| Hawkins, T | 1 |
| Sheikh, AM | 1 |
| Varunok, P | 1 |
| Hennicken, D | 1 |
| McPhee, F | 5 |
| Rana, K | 1 |
| Hughes, EA | 2 |
| Trivella, JP | 1 |
| Gutierrez, J | 1 |
| Martin, P | 1 |
| Badri, P | 1 |
| Dutta, S | 5 |
| Coakley, E | 1 |
| Cohen, D | 1 |
| Ding, B | 2 |
| Awni, W | 2 |
| Menon, R | 2 |
| Stewart, H | 1 |
| Ross-Thriepland, D | 1 |
| Shaw, J | 1 |
| Griffin, S | 1 |
| Hayward, P | 1 |
| Lindström, I | 1 |
| Kjellin, M | 1 |
| Palanisamy, N | 1 |
| Bondeson, K | 1 |
| Wesslén, L | 1 |
| Lannergard, A | 1 |
| Lennerstrand, J | 1 |
| Dumortier, J | 2 |
| Sebagh, M | 1 |
| Botta, D | 1 |
| Silvain, C | 1 |
| Lebray, P | 2 |
| Petrov-Sanchez, V | 1 |
| Diallo, A | 2 |
| Gamal, N | 2 |
| Kalafateli, M | 1 |
| Dusheiko, G | 1 |
| Manousou, P | 1 |
| Zhou, N | 2 |
| Hernandez, D | 2 |
| Ueland, J | 1 |
| Yang, X | 1 |
| Yu, F | 1 |
| Sims, K | 1 |
| Yin, PD | 1 |
| Mariño, Z | 1 |
| Gambato, M | 1 |
| Suzuki, Y | 2 |
| Toyota, J | 2 |
| Karino, Y | 2 |
| Kawakami, Y | 1 |
| Fujiyama, S | 1 |
| Ito, T | 1 |
| Itoh, Y | 1 |
| Tamura, E | 1 |
| Ueki, T | 1 |
| Hu, W | 1 |
| Linaberry, M | 1 |
| Hughes, E | 2 |
| Badri, PS | 2 |
| Polepally, AR | 2 |
| McGovern, BH | 1 |
| Menon, RM | 4 |
| Swallow, E | 1 |
| Song, J | 1 |
| Yuan, Y | 1 |
| Kalsekar, A | 1 |
| Kelley, C | 1 |
| Mu, F | 1 |
| Kim, S | 1 |
| Noviello, S | 2 |
| Signorovitch, J | 1 |
| Wang, Y | 2 |
| Rao, HY | 1 |
| Xie, XW | 1 |
| Wei, L | 2 |
| Sollima, S | 2 |
| Milazzo, L | 3 |
| Torre, A | 1 |
| Calvi, E | 1 |
| Regalia, E | 1 |
| Antinori, S | 1 |
| Smith, MA | 1 |
| Regal, RE | 1 |
| Mohammad, RA | 1 |
| Sun, JH | 3 |
| O'Boyle, DR | 3 |
| Fridell, RA | 3 |
| Langley, DR | 2 |
| Wang, C | 3 |
| Roberts, SB | 1 |
| Nower, P | 2 |
| Johnson, BM | 1 |
| Moulin, F | 1 |
| Nophsker, MJ | 1 |
| Wang, YK | 1 |
| Liu, M | 1 |
| Rigat, K | 1 |
| Tu, Y | 1 |
| Hewawasam, P | 1 |
| Kadow, J | 1 |
| Meanwell, NA | 3 |
| Cockett, M | 1 |
| Lemm, JA | 2 |
| Kramer, M | 1 |
| Belema, M | 2 |
| Gao, M | 3 |
| Miyaki, E | 1 |
| Abe, H | 1 |
| Jafri, SM | 1 |
| Huber, C | 1 |
| Wang, A | 1 |
| Juday, T | 1 |
| Schnell, G | 1 |
| Tripathi, R | 1 |
| Wang, H | 1 |
| Sorbera, MA | 1 |
| Friedman, ML | 1 |
| Cope, R | 1 |
| Cattaneo, D | 2 |
| Riva, A | 1 |
| Clementi, E | 2 |
| Gervasoni, C | 2 |
| Scotto, R | 1 |
| Pinchera, B | 1 |
| Krastev, Z | 1 |
| Jelev, D | 1 |
| Antonov, K | 1 |
| Petkova, T | 1 |
| Atanasova, E | 1 |
| Zheleva, N | 1 |
| Tomov, B | 1 |
| Boyanova, Y | 1 |
| Mateva, L | 1 |
| Feld, J | 1 |
| Jacobson, I | 1 |
| Nader, F | 1 |
| Henry, L | 1 |
| Mantry, PS | 1 |
| Sulkowski, MS | 1 |
| Wang, D | 1 |
| Park, SH | 1 |
| Luetkemeyer, AF | 1 |
| McDonald, C | 1 |
| Ramgopal, M | 1 |
| Bhore, R | 1 |
| Ackerman, P | 1 |
| Micheli, V | 1 |
| Schreiber, J | 1 |
| Chodavarapu, K | 1 |
| Ioannou, GN | 1 |
| Beste, LA | 1 |
| Chang, MF | 1 |
| Green, PK | 1 |
| Lowy, E | 1 |
| Tsui, JI | 1 |
| Su, F | 1 |
| Berry, K | 1 |
| Ampuero, J | 1 |
| Romero-Gomez, M | 1 |
| Parikh, A | 1 |
| Coakley, EP | 1 |
| Awni, WM | 2 |
| Casanovas, T | 1 |
| Roca, J | 1 |
| Niubó, J | 1 |
| Chidi, AP | 1 |
| Bryce, CL | 1 |
| Donohue, JM | 1 |
| Fine, MJ | 1 |
| Landsittel, DP | 1 |
| Myaskovsky, L | 1 |
| Rogal, SS | 1 |
| Switzer, GE | 1 |
| Tsung, A | 1 |
| Smith, KJ | 1 |
| Francoz, C | 1 |
| Besch, C | 1 |
| Rohel, A | 1 |
| Rossignol, E | 1 |
| Parisi, SG | 2 |
| Loregian, A | 2 |
| Andreis, S | 1 |
| Nannetti, G | 1 |
| Cavinato, S | 1 |
| Basso, M | 1 |
| Scaggiante, R | 1 |
| Dal Bello, F | 1 |
| Messa, L | 1 |
| Cattelan, AM | 1 |
| Palù, G | 2 |
| Suraweera, D | 1 |
| Weeratunga, AN | 1 |
| Gentili, M | 1 |
| Magni, C | 1 |
| Carnovale, C | 1 |
| Bolis, M | 1 |
| Landonio, S | 1 |
| Niero, F | 1 |
| Antoniazzi, S | 1 |
| Radice, S | 1 |
| Marshall, G | 1 |
| Sucher, AJ | 1 |
| Hemstreet, BA | 1 |
| Mensing, S | 1 |
| Eckert, D | 1 |
| Sharma, S | 1 |
| Podsadecki, TJ | 1 |
| Poordad, F | 1 |
| Gutierrez, JA | 1 |
| Wells, JT | 1 |
| Landaverde, CE | 1 |
| Evans, B | 1 |
| Howe, A | 1 |
| Huang, HC | 1 |
| Li, JJ | 1 |
| Miotto, N | 1 |
| Mendes, LC | 1 |
| Stucchi, RS | 1 |
| Vigani, AG | 1 |
| Otoguro, T | 1 |
| Tanaka, T | 1 |
| Kasai, H | 1 |
| Yamashita, A | 1 |
| Moriishi, K | 1 |
| Yesmembetov, K | 1 |
| Ashimkhanova, A | 1 |
| Kaliaskarova, K | 1 |
| Hachicha, M | 1 |
| Ozieranski, P | 1 |
| King, L | 1 |
| Gentil, MA | 1 |
| González-Corvillo, C | 1 |
| Perelló, M | 1 |
| Zarraga, S | 1 |
| Jiménez-Martín, C | 1 |
| Lauzurica, LR | 1 |
| Alonso, A | 1 |
| Franco, A | 1 |
| Hernández-Marrero, D | 1 |
| Sánchez-Fructuoso, A | 1 |
| Ahmed, M | 1 |
| Pal, A | 1 |
| Houghton, M | 1 |
| Barakat, K | 1 |
| Inoue, J | 1 |
| Kanno, A | 1 |
| Wakui, Y | 1 |
| Miura, M | 1 |
| Kobayashi, T | 1 |
| Morosawa, T | 1 |
| Kogure, T | 1 |
| Kakazu, E | 1 |
| Ninomiya, M | 1 |
| Fujisaka, Y | 1 |
| Umetsu, T | 1 |
| Takai, S | 1 |
| Nakamura, T | 1 |
| Shimosegawa, T | 1 |
| Liao, H | 1 |
| Tan, P | 1 |
| Zhu, Z | 1 |
| Yan, X | 1 |
| Huang, J | 1 |
| Murai, K | 1 |
| Tsutsui, S | 1 |
| Naito, M | 1 |
| Nishiuchi, M | 1 |
| Kondo, Y | 1 |
| Oze, T | 1 |
| Yakushijin, T | 1 |
| Hiramatsu, N | 1 |
| Brieva, T | 1 |
| Abad, S | 1 |
| Vega, A | 1 |
| Hernández, E | 1 |
| Mérida, E | 1 |
| de Sequera, P | 1 |
| Albalate, M | 1 |
| Macías, N | 1 |
| Milla, M | 1 |
| López-Gómez, JM | 1 |
| Baker, MM | 1 |
| El-Kafrawy, DS | 1 |
| Mahrous, MS | 1 |
| Belal, TS | 1 |
| German, P | 1 |
| Kearney, BP | 1 |
| Yang, CY | 1 |
| Brainard, D | 1 |
| Link, J | 1 |
| Han, L | 1 |
| Ling, J | 1 |
| Bhattacharya, D | 1 |
| Belperio, PS | 1 |
| Shahoumian, TA | 1 |
| Loomis, TP | 1 |
| Goetz, MB | 1 |
| Mole, LA | 1 |
| Backus, LI | 1 |
| Lim, SG | 1 |
| Hu, Y | 1 |
| McMonagle, P | 1 |
| Ingravallo, P | 1 |
| Chase, R | 1 |
| Tracy, B | 1 |
| Shrestha, R | 1 |
| Stein, L | 1 |
| Bhasin, D | 1 |
| Pollinger, H | 1 |
| Comarmond, C | 2 |
| Garrido, M | 1 |
| Desbois, AC | 1 |
| Costopoulos, M | 1 |
| Le Garff-Tavernier, M | 1 |
| Si Ahmed, SN | 2 |
| Alric, L | 2 |
| Bellier, B | 1 |
| Maciejewski, A | 1 |
| Rosenzwajg, M | 1 |
| Klatzmann, D | 1 |
| Musset, L | 2 |
| Poynard, T | 2 |
| Cacoub, P | 2 |
| Saadoun, D | 2 |
| Rubio, R | 1 |
| Lazzarin, A | 1 |
| Conway, B | 1 |
| Molina, JM | 1 |
| Xu, D | 1 |
| Srinivasan, S | 1 |
| Portsmouth, S | 1 |
| Vavassori, A | 1 |
| Lanza, P | 1 |
| Izzo, I | 1 |
| Casari, S | 1 |
| Odolini, S | 1 |
| Zaltron, S | 1 |
| Festa, E | 1 |
| Castelli, F | 1 |
| Ferfar, Y | 1 |
| de Saint Martin, L | 1 |
| Bouyer, AS | 1 |
| Resche Rigon, M | 1 |
| Cho, BW | 1 |
| Kim, SB | 1 |
| Song, IH | 1 |
| Lee, SH | 1 |
| Kim, HS | 1 |
| Lee, TH | 1 |
| Kang, YW | 1 |
| Kim, SH | 1 |
| Chae, HB | 1 |
| López-Labrador, FX | 1 |
| Moya, A | 1 |
| Gonzàlez-Candelas, F | 1 |
| Kuntzen, T | 1 |
| Berical, A | 1 |
| Lennon, N | 1 |
| Berlin, AM | 1 |
| Young, SK | 1 |
| Lee, B | 1 |
| Heckerman, D | 1 |
| Carlson, J | 1 |
| Reyor, LL | 1 |
| Kleyman, M | 1 |
| McMahon, CM | 1 |
| Birch, C | 1 |
| Ledlie, T | 1 |
| Koehrsen, M | 1 |
| Kodira, C | 1 |
| Roberts, AD | 1 |
| Lauer, GM | 1 |
| Rosen, HR | 1 |
| Bihl, F | 1 |
| Cerny, A | 1 |
| Spengler, U | 1 |
| Liu, Z | 1 |
| Xing, Y | 1 |
| Schneidewind, A | 1 |
| Madey, MA | 1 |
| Fleckenstein, JF | 1 |
| Park, VM | 1 |
| Galagan, JE | 1 |
| Nusbaum, C | 1 |
| Walker, BD | 1 |
| Lake-Bakaar, GV | 1 |
| Gomperts, ED | 1 |
| Edlin, BR | 1 |
| Donfield, SM | 1 |
| Chung, RT | 1 |
| Talal, AH | 1 |
| Marion, T | 1 |
| Birren, BW | 1 |
| Henn, MR | 1 |
| Allen, TM | 1 |
| Gatti, F | 1 |
| Nasta, P | 1 |
| Puoti, M | 1 |
| Matti, A | 1 |
| Pagni, S | 1 |
| de Requena, DG | 1 |
| Prestini, K | 1 |
| Bonora, S | 2 |
| Carosi, G | 1 |
| Shields, WW | 1 |
| Nettles, RE | 2 |
| Snyder, LB | 1 |
| Nguyen, VN | 1 |
| Serrano-Wu, MH | 1 |
| Knipe, JO | 1 |
| Chien, C | 1 |
| Colonno, RJ | 1 |
| Grasela, DM | 1 |
| Hamann, LG | 1 |
| Mo, H | 1 |
| Yang, C | 1 |
| Wang, K | 1 |
| Huang, M | 1 |
| Qi, X | 1 |
| Sun, SC | 1 |
| Deshpande, M | 1 |
| Rhodes, G | 1 |
| Miller, MD | 1 |
| Schmitz, J | 1 |
| Merchante, N | 1 |
| López-Cortés, LF | 1 |
| Delgado-Fernández, M | 1 |
| Ríos-Villegas, MJ | 1 |
| Márquez-Solero, M | 1 |
| Pasquau, J | 1 |
| García-Figueras, C | 1 |
| Martínez-Pérez, MA | 1 |
| Omar, M | 1 |
| Mata, R | 1 |
| Valera, L | 1 |
| Qiu, D | 1 |
| Roberts, S | 1 |
| Kienzle, B | 1 |
| Gish, RG | 1 |
| Lee, C | 1 |
| Takahashi, S | 1 |
| Ikeda, K | 2 |
| Watanabe, H | 1 |
| Jiang, H | 1 |
| Zeng, J | 1 |
| Liu, Y | 1 |
| Cojocaru, L | 1 |
| Ryan, J | 1 |
| Arnold, ME | 1 |
| Sezaki, H | 1 |
| Akuta, N | 1 |
| Seko, Y | 1 |
| Kawamura, Y | 1 |
| Hosaka, T | 1 |
| Kobayashi, M | 2 |
| Saito, S | 1 |
| Arase, Y | 1 |
| Mineta, R | 1 |
| Watahiki, S | 1 |
| Miyakawa, Y | 1 |
| Fontana, RJ | 1 |
| Appelman, H | 1 |
| Hindes, R | 1 |
| Dimitrova, D | 1 |
| Chatterjee, A | 1 |
| Smith, PF | 1 |
| Perelson, AS | 1 |
| Suk-Fong Lok, A | 1 |
| Lamarre, D | 1 |
| Anderson, PC | 1 |
| Bailey, M | 1 |
| Beaulieu, P | 1 |
| Bolger, G | 1 |
| Bonneau, P | 1 |
| Bös, M | 1 |
| Cameron, DR | 1 |
| Cartier, M | 1 |
| Cordingley, MG | 1 |
| Faucher, AM | 1 |
| Goudreau, N | 1 |
| Kawai, SH | 1 |
| Kukolj, G | 1 |
| Lagacé, L | 1 |
| LaPlante, SR | 1 |
| Narjes, H | 1 |
| Poupart, MA | 1 |
| Rancourt, J | 1 |
| Sentjens, RE | 1 |
| St George, R | 1 |
| Simoneau, B | 1 |
| Steinmann, G | 1 |
| Thibeault, D | 1 |
| Tsantrizos, YS | 2 |
| Weldon, SM | 1 |
| Yong, CL | 1 |
| Llinàs-Brunet, M | 1 |
| Kneteman, NM | 1 |
| Weiner, AJ | 2 |
| O'Connell, J | 1 |
| Collett, M | 1 |
| Gao, T | 1 |
| Aukerman, L | 1 |
| Kovelsky, R | 1 |
| Ni, ZJ | 1 |
| Zhu, Q | 2 |
| Hashash, A | 1 |
| Kline, J | 1 |
| Hsi, B | 1 |
| Schiller, D | 1 |
| Douglas, D | 1 |
| Tyrrell, DL | 1 |
| Mercer, DF | 1 |
| Cocchi, S | 1 |
| Codeluppi, M | 1 |
| Di Benedetto, F | 1 |
| Motta, A | 1 |
| Luzi, K | 1 |
| Pecorari, M | 1 |
| Gennari, W | 1 |
| Masetti, M | 1 |
| Gerunda, GE | 1 |
| Esposito, R | 1 |
| Oei, Y | 1 |
| Mendel, DB | 1 |
| Garrett, EN | 1 |
| Patawaran, MB | 1 |
| Hollenbach, PW | 1 |
| Aukerman, SL | 1 |
| Libbrecht, L | 1 |
| Roskams, T | 1 |
| De Vos, R | 1 |
| Leroux-Roels, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Cohort Study of Grazoprevir/Elbasvir Combination Therapy for Patients With Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation[NCT03723824] | Phase 4 | 14 participants (Actual) | Interventional | 2019-02-14 | Terminated (stopped due to COV-19 pandemic) | ||
| THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders[NCT02786537] | Phase 4 | 1,275 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Efficacy and Safety of Sofosbuvir and Daclatasvir in Treating Patients With Hepatitis C and Renal Failure.[NCT03063879] | Phase 4 | 95 participants (Actual) | Interventional | 2017-04-01 | Completed | ||
| An Open-label, Multi-center Study to Evaluate Sustained Virologic Response With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Genotype 1 Chronic Hepatitis C Virus Infected Patients With Past PI Failure[NCT02646111] | Phase 3 | 120 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| A Cluster Randomised Trial of Pharmacy Led HCV Therapy Versus Conventional Treatment Pathways for HCV Positive Patients Receiving Daily OST in Pharmacies in Health Boards Within NHS Scotland[NCT02706223] | 356 participants (Actual) | Interventional | 2016-12-31 | Completed | |||
| Micro-elimination of Hepatitis C Virus Infection With Pan-genotypic DAA Regimen in Hepatitis C Highly Endemic and Contagious Community (ERASE-C)[NCT03891550] | Phase 3 | 135 participants (Anticipated) | Interventional | 2019-05-13 | Active, not recruiting | ||
| Comprehensive Surveillance of HCV Infecion in Uremics Under Maintenance Hemodialysis and Linking to Medical Care in Taiwan[NCT03803410] | 2,973 participants (Actual) | Observational | 2019-01-07 | Completed | |||
| A Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in People Who Inject Drugs and People With HIV Coinfection.[NCT02625909] | Phase 3 | 222 participants (Actual) | Interventional | 2017-03-09 | Completed | ||
| Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: The Kentucky Viral Hepatitis Treatment (KeY Treat) Study[NCT03949764] | Phase 4 | 374 participants (Actual) | Interventional | 2019-09-23 | Active, not recruiting | ||
| A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection[NCT02480712] | Phase 3 | 107 participants (Actual) | Interventional | 2015-07-01 | Completed | ||
| A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection[NCT01717326] | Phase 2 | 573 participants (Actual) | Interventional | 2013-02-07 | Completed | ||
| An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Naïve and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis[NCT02023112] | Phase 3 | 171 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjec[NCT02639247] | Phase 3 | 333 participants (Actual) | Interventional | 2015-12-23 | Completed | ||
| A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HC[NCT02607735] | Phase 3 | 416 participants (Actual) | Interventional | 2015-11-11 | Completed | ||
| A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus [NCT02292719] | Phase 2 | 70 participants (Actual) | Interventional | 2014-12-19 | Completed | ||
| A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin in Treatment-Experienced Subjects With Genotype 1b Chronic[NCT01674725] | Phase 3 | 187 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus [NCT01716585] | Phase 3 | 636 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C V[NCT01715415] | Phase 3 | 395 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis [NCT01767116] | Phase 3 | 419 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis [NCT01833533] | Phase 3 | 305 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOIS[NCT01704755] | Phase 3 | 381 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs[NCT04943588] | 25,000 participants (Anticipated) | Observational [Patient Registry] | 2021-11-01 | Recruiting | |||
| Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan[NCT05248919] | 318 participants (Anticipated) | Interventional | 2023-06-01 | Enrolling by invitation | |||
| Transplantation of HCV Donor Kidneys in HCV Negative or Previously Successfully Treated Recipients[NCT04605679] | 31 participants (Actual) | Interventional | 2020-05-06 | Active, not recruiting | |||
| An Open-label Pilot Study to Determine the Tolerability and Efficacy of Fixed-dose Grazoprevir/Elbasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors[NCT02781649] | Phase 4 | 10 participants (Actual) | Interventional | 2016-07-20 | Completed | ||
| An Open Label, Proof of Concept Study to Evaluate the Feasibility and Safety of Kidney Transplant From HCV Positive Donors Into HCV Negative Recipient[NCT03801707] | Phase 2/Phase 3 | 54 participants (Actual) | Interventional | 2019-03-22 | Completed | ||
| Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access[NCT04614142] | Phase 4 | 0 participants (Actual) | Interventional | 2020-11-13 | Withdrawn (stopped due to Single patient the protocol was written for consented to another study.) | ||
| Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC[NCT02771405] | Phase 3 | 150 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | ||
| A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis[NCT02781558] | Phase 2 | 204 participants (Actual) | Interventional | 2016-07-29 | Completed | ||
| Occult Hepatitis C Virus Infection In Hemodialysis Patients Who Achieved A Sustained Virological Response To Directly Acting Antiviral Drugs: Is It A Concern ?[NCT04719338] | 30 participants (Actual) | Interventional | 2021-03-01 | Completed | |||
| A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection[NCT02722837] | Phase 3 | 119 participants (Actual) | Interventional | 2016-04-04 | Completed | ||
| Grazoprevir (MK-5172)+ Elbasvir (MK-8742) for the Treatment of Acute Hepatitis C Genotype 1/4. The Dutch Acute HCV in HIV Study (DAHHS-2)[NCT02600325] | Phase 3 | 80 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Transplanting Organs From Hepatitis C Positive Donors to Hepatitis C Uninfected Recipients[NCT03086044] | Phase 4 | 148 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor to HCVNegative Organ Transplant Recipient - Pilot Trial[NCT04596475] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2021-05-28 | Completed | ||
| Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents[NCT01944527] | 699 participants (Actual) | Observational | 2013-10-31 | Active, not recruiting | |||
| A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Ch[NCT01353911] | Phase 2 | 368 participants (Actual) | Interventional | 2011-06-27 | Completed | ||
| A Blinded, Randomized, Placebo-Controlled Study in Healthy and HCV Genotype 1-infected Adults, to Evaluate the Safety, Tolerability, Antiviral Activity, Pharmacokinetics (Including the Effect of Food) and Resistance Profile of Single and Multiple Doses of[NCT01181427] | Phase 1 | 137 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Naive and Treatment Experienced Subjects With Genotype 3 Chronic Hepatitis C Infection[NCT02032901] | Phase 3 | 173 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal[NCT02207088] | Phase 3 | 68 participants (Actual) | Interventional | 2014-09-23 | Completed | ||
| A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)[NCT02032888] | Phase 3 | 238 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection[NCT02202980] | Phase 2 | 273 participants (Actual) | Interventional | 2014-08-04 | Completed | ||
| The Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, Non-Cirrhotic, HCV GT4-Infected Patients: A Single-Center, Single-Arm, Open-Label, Phase III Trial[NCT03578640] | Phase 3 | 30 participants (Actual) | Interventional | 2018-07-01 | Completed | ||
| A Phase II Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172, MK-8742, and Sofosbuvir in Treatment-Naïve Subjects With Chronic HCV GT1 or GT3 Infection[NCT02133131] | Phase 2 | 143 participants (Actual) | Interventional | 2014-06-13 | Completed | ||
| Phase 3 Open Label Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination With Ribavirin and Daclatasvir, for Treatment of Chronic HCV Infection With Treatment naïve Genotypes 1, 2, 3 or 4 in Subjects Co-infected With H[NCT01866930] | Phase 3 | 453 participants (Actual) | Interventional | 2013-07-11 | Terminated (stopped due to Sponsor decision not based on any new unexpected safety findings or efficacy observations.) | ||
| Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents.[NCT03894696] | 200 participants (Anticipated) | Observational | 2019-08-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Efficacy of Hepatitis C Virus (HCV) Treatment with Zepatier (Elbasvir/Grazobevir) with Ribavirin (RBV) for 16 weeks when used in Genotype 1a patients with Baseline RASs (NS5a Resistance Associated Substitutions or RAPs -Resistance Associated Polymorphisms).~Efficacy defined as HCV RNA undetectable 12 weeks post treatment. Table excludes Genotype 1b patients." (NCT02786537)
Timeframe: 12 weeks post treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| EBR/GZR With RBV-16 Weeks | 34 |
Number/Percentage of patients with persistence of viral cure, SVR (SVR = Sustained Virologic Response)- defined as undetectable HCV RNA at least 24 weeks following HCV Treatment. (NCT02786537)
Timeframe: 24 weeks post-end of treatment up to 153 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| EBR/GZR | 255 |
| EBR/GZR With Ribavirin | 17 |
| SOF/LDV | 146 |
| SOF/LDV With RBV | 2 |
| PrOD | 14 |
| PrOD With RBV | 36 |
Percentage of Cirrhotic patients with persistence of viral cure, SVR, (SVR= Sustained Virologic Response) defined as undetectable HCV RNA at least 24 weeks following HCV Treatment. (NCT02786537)
Timeframe: Up to 132 weeks post HCV treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| EBR/GZR | 43 |
| EBR/GZR With RBV | 7 |
| SOF/LDV | 35 |
| SOF/LDV With RBV | 7 |
| PrOD | 6 |
| PrOD With RBV | 7 |
Fatigue severity collected from validated, Patient Reported Outcomes survey (PROs), 'PROMIS Fatigue Short Form'. PROMIS® T-scores were computated to compare difference between baseline value of PROMIS score to the highest (worst) score during treatment. Results presented as computated t-score from baseline to average of on Treatment Scores. A positive (+) score suggests improvements in functional well-being. A negative (-) PRO change score is suggestive of symptom improvement or lack of drug side effect. PROMIS Fatigue Score scale per question: 1=Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Always with 7 questions for a total maximum score of 35. (NCT02786537)
Timeframe: Baseline and Average On-Treatment Score
| Intervention | score on a scale (Mean) |
|---|---|
| EBR/GZR With RBV | -1.0 |
| EBR/GZR | -2.1 |
| SOF/LDV With RBV | -3.7 |
| SOF/LDV | -2.2 |
Fatigue severity collected from validated, Patient Reported Outcomes survey (PROs), 'PROMIS Fatigue Short Form'. PROMIS® T-scores were computated to compare difference between baseline value of PROMIS score to the highest (worst) score during treatment. Results presented as computated t-score from baseline to average of on Treatment Scores. A positive (+) score suggests improvements in functional well-being. A negative (-) PRO change score is suggestive of symptom improvement or lack of drug side effect. PROMIS Fatigue Score scale per question: 1=Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Always with 7 questions for a total maximum score of 35. (NCT02786537)
Timeframe: Baseline to On-treatment
| Intervention | units on a scale (Mean) |
|---|---|
| EBR/GZR With RBV | 1.5 |
| EBR/GZR | -1.2 |
| SOF/LDV With RBV | -7.2 |
| SOF/LDV | -2.0 |
| PrOD With RBV | -1.9 |
| PrOD | -3.0 |
"HCV-PRO, a survey for patients with HCV that measures physical, emotional, and social functioning, productivity, intimacy, and perception of quality of life, was used to assess 'overall functioning and well-being'. In general, lower score is worst outcome and higher scores indicate greater well-being and functioning. However, for ease of interpretation, HCV-PRO scale has been transformed by using '100 - HCV-PRO' ultimately revising the score to mean 0 (lowest score) is best to 100 (worst outcome). A positive change (End of treatment to baseline) suggests improvements in functional well-being.~Total score = (SUM-N)/(4*N)*100, where N is the number of questions answered." (NCT02786537)
Timeframe: Baseline to End of Treatment
| Intervention | units on a scale (Mean) |
|---|---|
| EBR/GZR With RBV | -0.9 |
| EBR/GZR | 5.6 |
| SOF/LDV With RBV | 2.5 |
| SOF/LDV | 6.9 |
| PrOD With RBV | 3.2 |
| PrOD | 9.9 |
"HCV-PRO, a survey designed to assess functional status of patients with HCV and measures physical, emotional, and social functioning, productivity, intimacy, and perception of quality of life, was used to assess functional well-being. In general, lower score is worst outcome and higher scores indicate greater well-being and functioning. However, for ease of interpretation, HCV-PRO scale has been transformed by using '100 - HCV-PRO' ultimately revising the score to mean 0 (lowest score) is best to 100 (worst outcome). A positive change (End of treatment to baseline) suggests improvements in functional well-being.~Total score = (SUM-N)/(4*N)*100, where N is the number of questions answered. End of Treatment -Baseline were used to calculate CHANGE in outcome. Number of subjects reflects participants from both Phase 1 and 2." (NCT02786537)
Timeframe: End of Treatment - Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| EBR/GZR With RBV | 3.2 |
| EBR/GZR | 6.1 |
| SOF/LDV With RBV | 6.3 |
| SOF/LDV | 6.8 |
Headache was evaluated by the HIT-6 score, a validated, Patient Reported Outcomes survey (PROs) 'PROMIS Headache Impact Test (HIT)' with scores ranging from 36 to 78 with higher score reflecting greater impact. Mean change in headache side effect was evaluated using difference between baseline value of HIT-6 score to the highest (worst) score during treatment. Estimates of mean change and differences obtained from a constrained longitudinal linear mixed-effects model that treated baseline score as one of outcomes. Negative values for mean change represent improvement, while negative values for 'difference' indicate LDV/SOF performed better than PrOD (NCT02786537)
Timeframe: Baseline to On-Treatment
| Intervention | units on a scale (Mean) |
|---|---|
| EBR/GZR With RBV | -0.8 |
| EBR/GZR | -0.7 |
| SOF/LDV With RBV | 0.4 |
| SOF/LDV | -0.8 |
Headache was evaluated by the HIT-6 score, a validated, Patient Reported Outcomes survey (PROs) 'PROMIS Headache Impact Test (HIT)' with scores ranging from 36 to 78 with higher score reflecting greater impact. Mean change in headache side effect was evaluated using difference between baseline value of HIT-6 score to the highest (worst) score during treatment. Estimates of mean change and differences obtained from a constrained longitudinal linear mixed-effects model that treated baseline score as one of outcomes. Negative values for mean change represent improvement in symptom. (NCT02786537)
Timeframe: Baseline to On-Treatment
| Intervention | units on a scale (Mean) |
|---|---|
| EBR/GZR With Ribavirin (RBV) | 0.0 |
| EBR/GZR Regimen | -0.8 |
| SOF/LDV With RBV | -0.7 |
| SOF/LDV | -0.5 |
| PrOD With RBV Regimen | -0.2 |
| PrOD | -2.2 |
"Patients completed the PROMIS® Nausea Short Form at Baseline (T1) and on-treatment. PROMIS raw scores from each of the completed questionnaires were converted to standardized T-scores. Change was calculated as the difference between baseline and on-treatment score. T-scores for the PROMIS Nausea and Vomiting 4a scale range from 45.0 - 80.1. Higher scores indicate worse nausea. Negative values for mean change represent improvement.~The estimates of mean change and differences were obtained from a constrained longitudinal linear mixed-effects model that treated the baseline score as one of the outcomes. The model expressed mean score as a function of DAA regimen, cirrhosis status, HCV genotype, sex, age, race, and previous treatment status." (NCT02786537)
Timeframe: Baseline to On-Treatment
| Intervention | units on a scale (Mean) |
|---|---|
| EBR/GZR With RBV | 1.3 |
| EBR/GZR | -1.4 |
| SOF/LDV With RBV | -3.9 |
| SOF/LDV | -0.7 |
| PrOD With RBV | 2.5 |
| PrOD | 0.7 |
"Participants completed the Patient Reported Outcomes surveys (PROs) 'PROMIS Nausea/Vomiting -4 Short Form' at baseline and during treatment. Raw scores are converted to standardized T-scores with a range of 45.0-80.1. Higher scores indicate worse nausea/vomiting.~Results presented as mean difference from baseline to average of on Treatment Scores (highest/worst) score during treatment.~A negative (-) PROMIS change score is suggestive of symptom improvement or lack of drug side effect. Estimates of mean change were obtained from a constrained longitudinal linear mixed-effects model that treated the baseline score as one of the outcomes." (NCT02786537)
Timeframe: Baseline and Average On-Treatment Score
| Intervention | units on a scale (Mean) |
|---|---|
| EBR/GZR With RBV | -0.3 |
| EBR/GZR | -0.6 |
| SOF/LDV With RBV | -1.6 |
| SOF/LDV | -0.4 |
Fatigue severity collected from validated, Patient Reported Outcomes survey (PROs), 'PROMIS Fatigue Short Form'. PROMIS® T-scores were computated to compare difference between baseline value of PROMIS score to the highest (worst) score during treatment. Results presented as computated t-score from baseline to average of on Treatment Scores. A positive (+) score suggests improvements in functional well-being. A negative (-) PRO change score is suggestive of symptom improvement or lack of drug side effect. PROMIS Fatigue Score scale per question: 1=Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Always with 7 questions for a total maximum score of 35. (NCT02786537)
Timeframe: Baseline to End of Treatment
| Intervention | units on a scale (Median) |
|---|---|
| EBR/GZR With RBV | 2.2 |
| EBR/GZR Regimen | -0.9 |
| SOF/LDV With RBV | -10.2 |
| SOF/LDV | -3.4 |
| PrOD Regimen With RBV | -0.2 |
| PrOD | -4.1 |
Fatigue severity collected from validated, Patient Reported Outcomes survey (PROs), 'PROMIS Fatigue Short Form'. PROMIS® T-scores were computated to compare difference between baseline value of PROMIS score to the highest (worst) score during treatment. Results presented as computated t-score from baseline to average of on Treatment Scores. A positive (+) score suggests improvements in functional well-being. A negative (-) PRO change score is suggestive of symptom improvement or lack of drug side effect. PROMIS Fatigue Score scale per question: 1=Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Always with 7 questions for a total maximum score of 35. (NCT02786537)
Timeframe: Baseline-On Treatment (up to 16 weeks)
| Intervention | units on a scale (Median) |
|---|---|
| EBR/GZR With RBV | -1.3 |
| EBR/GZR | -1.2 |
| SOF/LDV With RBV | -2.4 |
| SOF/LDV | -1.4 |
"HCV-PRO, a survey for patients with HCV that measures physical, emotional, and social functioning, productivity, intimacy, and perception of quality of life, was used to assess 'Overall Functioning and Well-being'. In general, lower score is worst outcome and higher scores indicate greater well-being and functioning. However, for ease of interpretation, HCV-PRO scale has been transformed by using '100 - HCV-PRO' ultimately revising the score to mean 0 (lowest score) is best to 100 (worst outcome). A positive change (End of treatment to baseline) suggests improvements in functional well-being.~Total score = (SUM-N)/(4*N)*100, where N is the number of questions answered." (NCT02786537)
Timeframe: Baseline to End of Treatment
| Intervention | score on a scale (Median) |
|---|---|
| EBR/GZR With RBV | 0.0 |
| EBR/GZR | 4.3 |
| SOF/LDV With RBV | 4.7 |
| SOF/LDV | 4.7 |
| PrOD With RBV | 3.1 |
| PrOD | 8.6 |
Headache was evaluated by the HIT-6 score, a validated, Patient Reported Outcomes survey (PROs) 'PROMIS Headache Impact Test (HIT)' with scores ranging from 36 to 78 with higher score reflecting greater impact. Median change in headache side effect was evaluated using difference between baseline value of HIT-6 score to the highest (worst) score during treatment. Estimates of mean change and differences obtained from a constrained longitudinal linear mixed-effects model that treated baseline score as one of outcomes. Negative values for change represent improvement, while negative values for 'difference' indicate LDV/SOF performed better than PrOD (NCT02786537)
Timeframe: 12 weeks (Baseline and Average On-treatment Score)
| Intervention | units on a scale (Median) |
|---|---|
| EBR/GZR (Elbasvir/Grazoprevir) With RBV | 0.0 |
| EBR/GZR (Elbasvir/Grazoprevir) | 0.0 |
| SOF/LDV (Sofosbuvir/Ledipasvir) With RBV | -2.0 |
| SOF/LDV (Sofosbuvir/Ledipasvir) | -1.0 |
| PrOD (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) With RBV (Phase 1 Only) | 0.0 |
| PrOD (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) | -1.0 |
Headache was evaluated by the HIT-6 score, a validated, Patient Reported Outcomes survey (PROs) 'PROMIS Headache Impact Test (HIT)' with scores ranging from 36 to 78 with higher score reflecting greater impact. Median change in headache side effect was evaluated using difference between baseline value of HIT-6 score to the highest (worst) score during treatment. Estimates of median change and differences obtained from a constrained longitudinal linear mixed-effects model that treated baseline score as one of outcomes. Negative values for mean change represent improvement, while negative values for 'difference' indicate LDV/SOF performed better than PrOD (NCT02786537)
Timeframe: Baseline -on Treatment (12-16 weeks)
| Intervention | units on a scale (Median) |
|---|---|
| EBR/GZR With RBV | -1.0 |
| EBR/GZR | 0.0 |
| SOF/LDV With RBV | 0.5 |
| SOF/LDV | -0.5 |
"Patients completed the PROMIS® Nausea Short Form at Baseline (T1) and on-treatment. PROMIS raw scores from each of the completed questionnaires were converted to standardized T-scores. Change was calculated as the difference between baseline and on-treatment score. T-scores for the PROMIS Nausea and Vomiting 4a scale range from 45.0 - 80.1. Higher scores indicate worse nausea. Negative values for mean change represent improvement.~The estimates of change and differences were obtained from a constrained longitudinal linear mixed-effects model that treated the baseline score as one of the outcomes." (NCT02786537)
Timeframe: Baseline to end of treatment
| Intervention | units on a scale (Median) |
|---|---|
| EBR/GZR With RBV | 0.4 |
| EBR/GZR | 0.0 |
| SOF/LDV With RBV | -6.1 |
| SOF/LDV | 0.0 |
| PrOD With RBV | 0.0 |
| PrOD | 0.0 |
"Patients completed the PROMIS® Nausea Short Form at Baseline (T1) and on-treatment. PROMIS raw scores from each of the completed questionnaires were converted to standardized T-scores. Change was calculated as the difference between baseline and on-treatment score. T-scores for the PROMIS Nausea and Vomiting 4a scale range from 45.0 - 80.1. Higher scores indicate worse nausea. Negative values for change represent improvement.~The estimates of change and differences were obtained from a constrained longitudinal linear mixed-effects model that treated the baseline score as one of the outcomes." (NCT02786537)
Timeframe: Baseline- On Treatment (up to 16 weeks)
| Intervention | score on a scale (Median) |
|---|---|
| EBR/GZR With RBV | 0.0 |
| EBR/GZR | 0.0 |
| SOF/LDV With RBV | 0.0 |
| SOF/LDV | 0.0 |
The number of participants with adverse events that led to early treatment discontinuation (defined as duration less than originally prescribed treatment regimen) (NCT02786537)
Timeframe: Treatment start date through treatment completion (up to 24 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| EBR/GZR Regimen | 12 |
| SOF/LDV Regimen | 4 |
"SVR (Sustained Virologic Response) 12 will be defined as undetectable hepatitis C virus (HCV) RNA at 12 week follow-up visit (12 -24 weeks after HCV treatment discontinuation as dictated by standard of care at each individual site).~Number of subjects reflects participants randomized during Phase 1 only." (NCT02786537)
Timeframe: 12 -24 weeks post-treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| EBR/GZR With RBV | 9 |
| EBR/GZR | 108 |
| SOF/LDV With RBV | 6 |
| SOF/LDV | 88 |
| PrOD With RBV | 77 |
| PrOD (Phase 1 Only) | 42 |
"SVR (Sustained Virologic Response) 12 will be defined as patients who have undetectable hepatitis C virus (HCV) RNA at 12 week follow-up visit (12 -24 weeks after HCV treatment discontinuation as dictated by standard of care at each individual site).~mITT with imputation (missing=failure). Total number of subjects reflects participants from Phase 1 only." (NCT02786537)
Timeframe: 12 weeks post-treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| EBR/GZR With RBV | 9 |
| EBR/GZR | 108 |
| SOF/LDV With RBV | 6 |
| SOF/LDV | 88 |
| PrOD With RBV | 77 |
| PrOD | 42 |
"SVR (Sustained Virologic Response) 12 will be defined as undetectable hepatitis C virus (HCV) RNA at 12 week follow-up visit (12 -24 weeks after HCV treatment discontinuation as dictated by standard of care at each individual site).~Number of subjects reflects participants who started EBR/GZR or SOF/LDV- based treatment (with or without RBV) during Phase 1 and 2." (NCT02786537)
Timeframe: 12-24 weeks post HCV treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| EBR/GZR With RBV | 40 |
| EBR/GZR | 516 |
| SOF/LDV With RBV | 14 |
| SOF/LDV | 335 |
Mean change (delta) in FIB-4, an indirect non-invasive measure of liver fibrosis, calculated as baseline median -long term follow up median, following SVR after any of the study treatment regimens. Change in FIB-4 where negative values indicate improvement in liver fibrosis score and positive values indicate worsening of fibrosis score. There is no upper or lower limit for change. FIB-4 = age (years) * AST(IU/L)/Platelets (10^3/L) * ALT^.5(IU/L). In general, Score of 0-1.29 is low risk for advanced fibrosis, 1.30-1.67: intermediate risk for advanced liver fibrosis, >2.67: high risk for advanced fibrosis. (NCT02786537)
Timeframe: Baseline to up to 3 years post treatment discontinuation
| Intervention | score on a scale (Median) |
|---|---|
| EBR/GZR, SOF/LDV or PrOD Based HCV Treatment | -1.36 |
"SVR (Sustained Virologic Response) 12 will be defined as undetectable hepatitis C virus (HCV) RNA at 12 week follow-up visit (12 -24 weeks after HCV treatment discontinuation at discretion of provider).~mITT with imputation (missing=failure). Total number of subjects reflects participants from EBR/GZR with or without RBV and SOF/LDV with or without RBV randomized during Phase 1 and Phase 2." (NCT02786537)
Timeframe: 12 weeks post-treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| EBR/GZR With RBV | 40 |
| EBR/GZR | 516 |
| SOF/LDV With RBV | 14 |
| SOF/LDV | 335 |
"The Voils Medication Adherence Survey (VMAS) was used to evaluate medication adherence during HCV treatment. Participants responded to three questions about the extent of adherence during the past seven days of treatment (during early and late on-treatment occasions). Participants responded using a five-point ordinal scale of missed dosing from 1 (none of the time) to 5 (all of the time). On each occasion participants were coded as being Non-adherent if any response was > 1, otherwise they were coded as Adherent. Probability estimates of percentage of patients reporting non-adherence were calculated per HCV treatment (Direct Acting Antiviral-DAA) regimen: 1)EBR/GZV (elbasvir/grazoprevir, 2)SOF/LDV (sofosbuvir/ledipasvir), 3)PrOD" (NCT02786537)
Timeframe: 12-16 weeks of HCV treatment
| Intervention | percentage of patients (Number) |
|---|---|
| EBR/GZR | 23 |
| SOF/LDV | 19 |
| PrOD | 26 |
"HCV-PRO score, a validated PROMIS survey used to evaluate overall functioning and well-being in HCV patients, was utilized to compare long-term 'within treatment' changes of functional well-being. In general, lower score is worst outcome and higher scores indicate greater well-being and functioning. However, for ease of interpretation, HCV-PRO scale has been transformed by using '100 - HCV-PRO' ultimately revising the score to mean 0 (lowest score) is best to 100 (worst outcome). A positive estimate (Post treatment to baseline) suggests baseline functional well-being improvement.~Total score = (SUM-N)/(4*N)*100, where N is the number of questions answered." (NCT02786537)
Timeframe: Treatment start date up to 2 years post-treatment
| Intervention | score on a scale (Mean) | |
|---|---|---|
| 9 months post treatment | 20 months post treatment | |
| EBR/GZR Regimen | 8.02 | 9.87 |
| SOF/LDV Regimen | 9.90 | 11.54 |
Change in HCV-associated symptoms was calculated as the mean differences of mean scores from multiple surveys from the NIH Patient-Reported Outcomes Measurement Information System (PROMIS)-- Fatigue, nausea, belly pain, sleep disturbance, and diarrhea) and functional status (well-being) when comparing baseline to early post-treatment and late post treatment surveys. Mean change scores were calculated by comparing baseline to early post-treatment (1 yr) and late post-treatment (approximately 3 years) surveys. T-scores for the PROMIS Nausea and Vomiting 4a scale range from 45.0 - 80.1. Higher scores indicate worse nausea. Negative values for mean change represent improvement.Negative numbers suggest better symptoms (improvement in HCV-associated symptoms). PROMIS Fatigue Score scale per question: 1=Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Always with 7 questions for a total maximum score of 35.HCV-PRO positive estimates suggest baseline functional well-being improvement. (NCT02786537)
Timeframe: 1 year post treatment discontinuation (Early post-tx)
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Nausea | Belly Pain | Diarrhea | Fatigue | Sleep Disturbance | Cognitive Impairment | HCV-PRO | |
| EBR/GZR Regimen | 0.00 | -0.82 | -1.12 | -2.08 | 0.65 | -0.54 | 8.02 |
| SOF/LDV Regimen | -4.99 | -6.47 | -5.77 | -7.59 | -1.72 | -4.48 | 9.90 |
Number of participants who achieved SVR (sustained virologic response), defined as undetectable HCV RNA 12 weeks post-treatment with RASs (Resistant Associated Substitutions) after treatment with EBR/GZR or SOF/LDV regimen (NCT02786537)
Timeframe: 12 weeks post HCV treatment
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| With NS5a RAS | Without NS5a RAS | |
| EBR/GZR Regimen | 47 | 485 |
| SOF/LDV Regimen | 42 | 286 |
To evaluate the proportion of participants with HCV RNA below the level of quantification at 12 weeks post treatment following SOF/VEL for 6 weeks as compared with 12 weeks in people with recent HCV infection- among intention-to-treat (ITT) population The ITT population included all randomized participants, with loss to follow-up deemed treatment failure. (NCT02625909)
Timeframe: 12 weeks post treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Drug: SOF/VEL for 6 Weeks | 76 |
| Drug: SOF/VEL for 12 Weeks | 86 |
To evaluate the proportion of participants with HCV RNA below the level of quantification at 12 weeks post treatment following SOF/VEL for 6 weeks as compared with 12 weeks in people with recent HCV infection- among modified intention-to-treat (ITT) population The modified ITT population included participants in the ITT population, but excluded those with non-virological reasons for treatment failure (including death and loss to follow-up) and reinfection. (NCT02625909)
Timeframe: 12 Weeks Post End of Treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Drug: SOF/VEL for 6 Weeks | 76 |
| Drug: SOF/VEL for 12 Weeks | 86 |
To evaluate the proportion of participants with HCV RNA below the level of quantification at 12 weeks post treatment following SOF/VEL for 6 weeks as compared with 12 weeks in people with recent HCV infection- among Per Protocol (PP) population The per protocol population included participants who received >90% of scheduled treatment for >90% of the scheduled treatment period with follow-up virologic data at SVR12 (excluding reinfection and retreatments) (NCT02625909)
Timeframe: 12 weeks post treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Drug: SOF/VEL for 6 Weeks | 69 |
| Drug: SOF/VEL for 12 Weeks | 77 |
To evaluate the proportion of participants with HCV RNA below the level of quantification at end of treatment of SOF/VEL for 6 Weeks as compared With 12 Weeks in People With Recent HCV Infection The ITT population included all randomized participants, with loss to follow-up deemed treatment failure. (NCT02625909)
Timeframe: End of treatment - week 6 of the shortened treatment duration arm, and week 12 of the standard treatment duration arm
| Intervention | Participants (Count of Participants) |
|---|---|
| Drug: SOF/VEL for 6 Weeks | 85 |
| Drug: SOF/VEL for 12 Weeks | 87 |
(NCT02480712)
Timeframe: Up to 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL 12 Weeks | 1.9 |
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug. (NCT02480712)
Timeframe: Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL 12 Weeks | 95.3 |
"Virologic failure was defined as:~On-treatment virologic failure:~Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while on treatment), or~Rebound (confirmed > 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or~Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)~Virologic relapse:~Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at last on-treatment visit" (NCT02480712)
Timeframe: Up to Posttreatment Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL 12 Weeks | 1.9 |
(NCT02480712)
Timeframe: Baseline to Week 12
| Intervention | log10 IU/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Change at Week 1 | Change at Week 2 | Change at Week 4 | Change at Week 6 | Change at Week 8 | Change at Week 10 | Change at Week 12 | |
| SOF/VEL 12 Weeks | -4.47 | -4.97 | -5.15 | -5.18 | -5.17 | -5.17 | -5.17 |
(NCT02480712)
Timeframe: Up to 12 Weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 4 | Week 8 | Week 12 | |
| SOF/VEL 12 Weeks (Boosted TDF Containing Regimens) | 94.4 | 96.3 | 96.2 |
| SOF/VEL 12 Weeks (Non TDF Containing Regimens) | 100 | 100 | 92.9 |
| SOF/VEL 12 Weeks (Non-Boosted TDF Containing Regimens) | 97.1 | 97.1 | 100 |
(NCT02480712)
Timeframe: Up to 12 Weeks
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 | |
| SOF/VEL 12 Weeks | 25.7 | 68.0 | 92.2 | 99.0 | 100.0 | 100.0 | 100.0 |
SVR4 and SVR24 were defined as HCV RNA < LLOQ at 4 and 24 weeks following the last dose of study drug, respectively. (NCT02480712)
Timeframe: Posttreatment Weeks 4 and 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| SVR4 | SVR24 | |
| SOF/VEL 12 Weeks | 95.3 | 95.3 |
(NCT02480712)
Timeframe: Week 12; Posttreatment Week 12
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Change at Week 12 | Change at Posttreatment Week 12 | |
| SOF/VEL 12 Weeks (Boosted TDF Containing Regimens) | 0.09 | 0.04 |
| SOF/VEL 12 Weeks (Non TDF Containing Regimens) | 0.00 | -0.06 |
| SOF/VEL 12 Weeks (Non-Boosted TDF Containing Regimens) | 0.04 | 0.02 |
Blood was drawn from each participant to assess HCV RNA plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. Kaplan Meier summary statistics were used to characterize the time to first achievement of undetectable HCV RNA. (NCT01717326)
Timeframe: From first dose of study medication until first achievement of undetectable HCV RNA (up to 18 weeks of treatment)
| Intervention | days (Mean) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 21.7 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 19.2 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 23.4 |
| B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 27.9 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 30.7 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 32.0 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 37.0 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 33.2 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 33.1 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 33.7 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 31.9 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 37.4 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 37.4 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 42.7 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 27.6 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 29.0 |
| C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 23.7 |
| C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-8 wk | 34.5 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 30.1 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 19.8 |
HCV-RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test (v.2.0) on blood samples drawn from each participant during treatment at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a LLoQ of 25 IU/mL and a limit of detection of 15.1 IU/mL (in plasma). The percentage of participants achieving HCV RNA levels <25 IU/ml and accompanying 95% CIs were reported at TW12 for each treatment arm of the PP Population (as applicable). 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01717326)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 100.0 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 100.0 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 100.0 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 100.0 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 100.0 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 93.3 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 100.0 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 100.0 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 100.0 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 100.0 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 100.0 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 100.0 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 96.9 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 100.0 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 92.9 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 47.4 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 75.0 |
HCV-RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test (v.2.0) on blood samples drawn from each participant during treatment at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a LLoQ of 25 IU/mL and a limit of detection of 15.1 IU/mL (in plasma). The percentage of participants achieving HCV RNA levels <25 IU/ml and accompanying 95% CIs were reported at TW2 for each treatment arm of the PP Population. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01717326)
Timeframe: Week 2
| Intervention | percentage of participants (Number) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 91.3 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 92.0 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 91.7 |
| B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 86.2 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 73.3 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 77.4 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 60.0 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 79.3 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 78.1 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 67.7 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 77.4 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 66.7 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 57.6 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 62.5 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 89.7 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 76.7 |
| C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 76.7 |
| C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-8 wk | 61.3 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 70.0 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 85.0 |
HCV-RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test (v.2.0) on blood samples drawn from each participant during treatment at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a LLoQ of 25 IU/mL and a limit of detection of 15.1 IU/mL (in plasma). The percentage of participants achieving HCV RNA levels <25 IU/ml and accompanying 95% CIs were reported at TW4 for each treatment arm of the PP Population. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01717326)
Timeframe: Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 100.0 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 100.0 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 100.0 |
| B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 100.0 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 100.0 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 100.0 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 90.0 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 100.0 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 100.0 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 90.3 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 100.0 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 96.9 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 97.0 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 93.8 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 100.0 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 100.0 |
| C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 100.0 |
| C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-8 wk | 96.8 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 65.0 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 83.3 |
Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 15.1 IU/mL (in plasma). SVR12 was defined as HCV RNA <25 IU/ml at 12 weeks after the end of all study therapy. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01717326)
Timeframe: 12 weeks after end of therapy (up to 30 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 100.0 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 95.8 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 100.0 |
| B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 82.8 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 100.0 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 96.8 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 90.0 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 96.6 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 100.0 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 93.5 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 100.0 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 90.9 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 100.0 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 96.9 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 96.6 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 92.9 |
| C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 93.1 |
| C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-8 wk | 93.5 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 47.4 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 61.1 |
Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a LLoQ of 25 IU/mL and a limit of detection of 15.1 IU/mL (in plasma). SVR24 was defined as HCV RNA <25 IU/ml at 24 weeks after the end of all study therapy. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01717326)
Timeframe: 24 weeks after end of therapy (up to 42 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 100.0 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 95.8 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 100.0 |
| B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 78.6 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 100.0 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 96.8 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 90.0 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 96.6 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 100.0 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 93.1 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 100.0 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 90.9 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 100.0 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 96.9 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 96.6 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 88.9 |
| C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 93.1 |
| C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-8 wk | 93.5 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 47.4 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 58.8 |
Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a LLoQ of 25 IU/mL and a limit of detection of 15.1 IU/mL (in plasma). SVR4 was defined as HCV RNA <25 IU/ml at 4 weeks after the end of all study therapy. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01717326)
Timeframe: 4 weeks after end of therapy (up to 22 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 100.0 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 95.8 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 100.0 |
| B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 93.3 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 100.0 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 96.8 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 96.7 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 96.6 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 100.0 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 96.8 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 100.0 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 93.9 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 100.0 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 96.9 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 96.6 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 93.1 |
| C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 93.1 |
| C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-8 wk | 96.8 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 50.0 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 61.1 |
HCV-RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test (v.2.0) on blood samples drawn from each participant during treatment at various time points prior to, during, and after dosing. Undetectable HCV RNA was defined as below the 15.1 IU/ml limit of detection. The percentage of participants achieving undetectable HCV RNA and accompanying 95% CIs were reported at TW12 for each treatment arm of the PP Population (as applicable). 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01717326)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 100.0 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 100.0 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 100.0 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 100.0 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 100.0 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 93.3 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 96.6 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 100.0 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 100.0 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 100.0 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 93.8 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 100.0 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 96.9 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 93.1 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 92.9 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 47.7 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 65.0 |
HCV-RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test (v.2.0) on blood samples drawn from each participant during treatment at various time points prior to, during, and after dosing. Undetectable HCV RNA was defined as below the 15.1 IU/ml limit of detection. The percentage of participants achieving undetectable HCV RNA and accompanying 95% CIs were reported at TW2 for each treatment arm of the PP Population. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01717326)
Timeframe: Week 2
| Intervention | percentage of participants (Number) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 52.2 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 44.0 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 41.7 |
| B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 44.8 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 20.0 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 16.1 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 6.7 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 10.3 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 25.0 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 16.1 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 12.9 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 6.1 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 6.1 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 6.3 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 37.9 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 40.0 |
| C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 46.7 |
| C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-8 wk | 12.9 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 40.0 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 70.0 |
HCV-RNA levels in plasma were measured using the Roche COBAS™ Taqman™ HCV Test (v.2.0) on blood samples drawn from each participant during treatment at various time points prior to, during, and after dosing. Undetectable HCV RNA was defined as below the 15.1 IU/ml limit of detection. The percentage of participants achieving undetectable HCV RNA and accompanying 95% CIs were reported at TW4 for each treatment arm of the PP Population. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01717326)
Timeframe: Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 73.9 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 91.7 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 75.0 |
| B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 73.3 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 83.3 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 77.4 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 60.0 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 79.3 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 71.9 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 71.0 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 83.3 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 68.8 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 69.7 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 53.1 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 75.9 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 78.6 |
| C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 86.7 |
| C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-8 wk | 74.2 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 50.0 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 77.8 |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product, was also an AE. (NCT01717326)
Timeframe: From Day 1 [post-dose] through 14 days following last dose of study drug (up to 20 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 0.0 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 0.0 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 0.0 |
| B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 0.0 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 0.0 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 0.0 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 0.0 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 0.0 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 6.3 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 0.0 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 3.1 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 0.0 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 0.0 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 0.0 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 0.0 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 0.0 |
| C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 0.0 |
| C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-8 wk | 0.0 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 0.0 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 4.8 |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product, was also an AE. (NCT01717326)
Timeframe: From Day 1 [post-dose] through 14 days following last dose of study drug (up to 20 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk | 88.0 |
| A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 85.7 |
| A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 91.7 |
| B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 90.0 |
| B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 72.7 |
| B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 87.1 |
| B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 77.4 |
| B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk | 65.5 |
| B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 87.5 |
| B7: TN C Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 83.9 |
| B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk | 81.3 |
| B9: NR Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 78.8 |
| B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 97.0 |
| B11: NR Grazoprevir 100 mg + Elbasvir 50 Mg-18 wk | 81.3 |
| B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 65.5 |
| B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 Mg-12 wk | 53.3 |
| C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk | 73.3 |
| C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 Mg-8 wk | 54.8 |
| D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk | 85.0 |
| D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk | 90.5 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT02023112)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 Plus RBV for 12 Weeks | 75.0 |
| ABT-450/r/ABT-267 Plus RBV for 16 Weeks | 91.5 |
Relapse by post-treatment Week 12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug for a participant with HCV RNA < LLOQ at the final treatment visit and who completed study treatment. Completion of treatment was defined as a study drug duration ≥ 77 days for the 12-week treatment arm or ≥ 105 days for the 16-week treatment arm. (NCT02023112)
Timeframe: within 12 weeks after the last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 Plus RBV for 12 Weeks | 12.2 |
| ABT-450/r/ABT-267 Plus RBV for 16 Weeks | 0 |
On-treatment virologic failure was defined as rebound (confirmed HCV RNA ≥ LLOQ after HCV RNA < LLOQ during treatment, or confirmed increase from nadir in HCV RNA [> 1 log10 IU/mL above nadir] at any time point during treatment) or failure to suppress HCV during treatment (all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment). (NCT02023112)
Timeframe: 12 or 16 weeks (end of treatment period)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Overall | Rebound | Failure to suppress | |
| ABT-450/r/ABT-267 Plus RBV for 12 Weeks | 8.3 | 8.3 | 0 |
| ABT-450/r/ABT-267 Plus RBV for 16 Weeks | 8.5 | 8.5 | 0 |
"The percentage of participants with on-treatment virologic failure in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; participants with compensated cirrhosis.~On-treatment virologic failure was defined as rebound (confirmed HCV RNA ≥ LLOQ after HCV RNA < LLOQ during treatment, or confirmed increase from nadir in HCV RNA [> 1 log10 IU/mL above nadir] at any time point during treatment) or failure to suppress HCV during treatment (all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment)." (NCT02023112)
Timeframe: 12 or 16 weeks (end of treatment period)
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Participants: Overall; n=85, 86 | All Participants: Rebound; n=85, 86 | All Participants: Failure to Suppress; n=85, 86 | Noncirrhotic: Overall; n=80, 80 | Noncirrhotic: Rebound; n=80, 80 | Noncirrhotic: Failure to Suppress; n=80, 80 | Noncirrhotic T-exp: Overall; n=32, 33 | Noncirrhotic T-exp: Rebound; n=32, 33 | Noncirrhotic T-exp: Failure to Suppress; n=32, 33 | Cirrhotic: Overall; n=5, 6 | Cirrhotic: Rebound; n=5, 6 | Cirrhotic: Failure to Suppress; n=5, 6 | |
| ABT-450/r/ABT-267 Plus RBV for 12 Weeks | 15.3 | 15.3 | 4.7 | 15.0 | 15.0 | 3.8 | 25.0 | 25.0 | 9.4 | 20.0 | 20.0 | 20.0 |
| ABT-450/r/ABT-267 Plus RBV for 16 Weeks | 16.3 | 15.1 | 4.7 | 13.8 | 12.5 | 3.8 | 21.2 | 18.2 | 9.1 | 50.0 | 50.0 | 16.7 |
"The percentage of participants with relapse by post-treatment Week 12 in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; participants with compensated cirrhosis.~Relapse by post-treatment Week 12 was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug for a participant with HCV RNA < LLOQ at the final treatment visit and who completed study treatment. Completion of treatment was defined as a study drug duration ≥ 77 days for the 12-week treatment arm or ≥ 105 days for the 16-week treatment arm." (NCT02023112)
Timeframe: within 12 weeks after the last dose of study drug
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| All Participants; n=69, 70 | Noncirrhotic Participants; n=65, 68 | Noncirrhotic T-exp Participants; n=24, 25 | Cirrhotic Participants; n=4, 2 | |
| ABT-450/r/ABT-267 Plus RBV for 12 Weeks | 10.1 | 10.8 | 8.3 | 0 |
| ABT-450/r/ABT-267 Plus RBV for 16 Weeks | 0 | 0 | 0 | 0 |
The percentage of participants with SVR12 in each treatment arm within the following subpopulations: noncirrhotic participants; noncirrhotic treatment-experienced (T-exp) participants; noncirrhotic participants who relapsed after prior IFN-based therapy (relapsers); noncirrhotic T-exp participants who were non-responders to prior IFN-based therapy; noncirrhotic T-exp participants who were intolerant to IFN-based therapy; participants with compensated cirrhosis. (NCT02023112)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| All participants; n=85, 86 | Noncirrhotic participants; n=80, 80 | Noncirrhotic T-exp; n=32, 33 | Noncirrhotic T-exp Relapser; n=15, 16 | Noncirrhotic T-exp Nonresponder; n=5, 6 | Noncirrhotic T-exp IFN-intolerant; n=12, 11 | Cirrhotic Participants; n=5, 6 | |
| ABT-450/r/ABT-267 Plus RBV for 12 Weeks | 72.9 | 72.5 | 68.8 | 80.0 | 40.0 | 66.7 | 80.0 |
| ABT-450/r/ABT-267 Plus RBV for 16 Weeks | 81.4 | 85.0 | 75.8 | 93.8 | 50.0 | 63.6 | 33.3 |
(NCT02639247)
Timeframe: Up to 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL/VOX 12 Weeks | 0 |
| SOF/VEL 12 Weeks | 0.7 |
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment. (NCT02639247)
Timeframe: Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL/VOX 12 Weeks | 97.8 |
| SOF/VEL 12 Weeks | 90.1 |
"On-treatment virologic failure:~Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while on treatment), or~Rebound (confirmed > 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or~Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)~Virologic relapse:~Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at last on-treatment visit." (NCT02639247)
Timeframe: Up to Posttreatment Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL/VOX 12 Weeks | 0.5 |
| SOF/VEL 12 Weeks | 9.9 |
(NCT02639247)
Timeframe: Weeks 1, 2, 4, 8, and 12
| Intervention | log10 IU/mL (Mean) | ||||
|---|---|---|---|---|---|
| Change at Week 1 | Change at Week 2 | Change at Week 4 | Change at Week 8 | Change at Week 12 | |
| SOF/VEL 12 Weeks | -4.17 | -4.78 | -5.06 | -5.08 | -5.09 |
| SOF/VEL/VOX 12 Weeks | -4.29 | -4.93 | -5.13 | -5.17 | -5.17 |
(NCT02639247)
Timeframe: Weeks 1, 2, 4, 8 and 12
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | |
| SOF/VEL 12 Weeks | 17.2 | 56.3 | 90.7 | 98.7 | 99.3 |
| SOF/VEL/VOX 12 Weeks | 15.9 | 62.6 | 88.5 | 100.0 | 98.9 |
SVR4 and SVR24 were defined as HCV RNA < LLOQ at 4 and 24 weeks after stopping study treatment, respectively. (NCT02639247)
Timeframe: Posttreatment Weeks 4 and 24
| Intervention | percentage of participcants (Number) | |
|---|---|---|
| SVR4 | SVR24 | |
| SOF/VEL 12 Weeks | 91.4 | 90.1 |
| SOF/VEL/VOX 12 Weeks | 98.4 | 97.8 |
(NCT02607735)
Timeframe: Up to 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL/VOX (Primary Study) | 0.4 |
| Placebo (Primary Study) | 2.0 |
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment. (NCT02607735)
Timeframe: Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL/VOX (Primary Study) | 96.2 |
SVR24 was defined as HCV RNA < LLOQ at 24 weeks after stopping study treatment. (NCT02607735)
Timeframe: Posttreatment Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL/VOX (Primary Study) | 96.2 |
SVR4 was defined as HCV RNA < LLOQ at 4 weeks after stopping study treatment, respectively. (NCT02607735)
Timeframe: Posttreatment Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL/VOX (Primary Study) | 97.7 |
| Placebo (Primary Study) | 0 |
"Virologic failure is defined as:~On-treatment virologic failure:~Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA LLOQ while on treatment), or~Rebound (confirmed 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or~Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)~Virologic relapse:~Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA LLOQ at last on-treatment visit." (NCT02607735)
Timeframe: Up to Posttreatment Week 24 (Deferred Treatment Substudy)
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL/VOX (Deferred Treatment Substudy) | 2.7 |
"Virologic failure is defined as:~On-treatment virologic failure:~Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA LLOQ while on treatment), or~Rebound (confirmed 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or~Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)~Virologic relapse:~Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA LLOQ at last on-treatment visit." (NCT02607735)
Timeframe: Up to Posttreatment Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL/VOX (Primary Study) | 2.7 |
(NCT02607735)
Timeframe: Baseline; Weeks 1, 2, 4, 8, and 12 (Deferred Treatment Substudy)
| Intervention | log10 IU/mL (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | |
| SOF/VEL/VOX (Deferred Treatment Substudy) | -4.30 | -4.93 | -5.16 | -5.20 | -5.20 |
(NCT02607735)
Timeframe: Baseline; Weeks 1, 2, 4, 8 and 12
| Intervention | log10 IU/mL (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | |
| Placebo (Primary Study) | 0.02 | 0.02 | -0.01 | 0.05 | 0.03 |
| SOF/VEL/VOX (Primary Study) | -4.20 | -4.81 | -5.07 | -5.11 | -5.10 |
(NCT02607735)
Timeframe: Weeks 1, 2, 4, 8 and 12 (Deferred Treatment Substudy)
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | |
| SOF/VEL/VOX (Deferred Treatment Substudy) | 14.3 | 62.6 | 93.2 | 100.0 | 100.0 |
(NCT02607735)
Timeframe: Weeks 1, 2, 4, 8 and 12
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | |
| Placebo (Primary Study) | 0 | 0 | 0 | 0 | 0 |
| SOF/VEL/VOX (Primary Study) | 15.6 | 56.7 | 92.7 | 100.0 | 99.6 |
SVR4, SVR12 and SVR24 was defined as HCV RNA < LLOQ at 4, 12 and 24 weeks after stopping study treatment, respectively. (NCT02607735)
Timeframe: Posttreatment Weeks 4, 12, and 24 (Deferred Treatment Substudy)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| SVR4 | SVR12 | SVR24 | |
| SOF/VEL/VOX (Deferred Treatment Substudy) | 98.6 | 97.3 | 97.3 |
On-treatment virologic failure was defined as confirmed increase of > 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment; confirmed HCV RNA ≥ LLOQ after HCV RNA < LLOQ during treatment, or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment for 12-week and 8-week treatment or at least 26 days of treatments for 6-week treatment. (NCT02292719)
Timeframe: Up to Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (Genotype [GT]3, Noncirrhotic) | 0 |
| Arm B (GT3, Noncirrhotic) | 0 |
| Arm C (GT2, Noncirrhotic) | 0 |
| Arm D (GT2, Noncirrhotic) | 0 |
| Arm E (GT3, Cirrhotic) | 0 |
| Arm F (GT3, Noncirrhotic) | 0 |
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA levels < LLOQ at the end of treatment. (NCT02292719)
Timeframe: Up to 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (Genotype [GT]3, Noncirrhotic) | 0 |
| Arm B (GT3, Noncirrhotic) | 0 |
| Arm C (GT2, Noncirrhotic) | 10.0 |
| Arm D (GT2, Noncirrhotic) | 55.6 |
| Arm E (GT3, Cirrhotic) | 0 |
| Arm F (GT3, Noncirrhotic) | 0 |
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification [
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (Genotype [GT]3, Noncirrhotic) | 100 |
| Arm B (GT3, Noncirrhotic) | 90.9 |
| Arm C (GT2, Noncirrhotic) | 90.0 |
| Arm D (GT2, Noncirrhotic) | 44.4 |
| Arm E (GT3, Cirrhotic) | 100 |
| Arm F (GT3, Noncirrhotic) | 100 |
The percentage of participants with a decrease in hemoglobin from greater than or equal to the lower limit of normal (≥ LLN) at baseline to < LLN at the end of treatment. (NCT01674725)
Timeframe: Baseline (Day 1) and Week 12 (End of Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 42.0 |
| ABT-450/r/ABT-267 and ABT-333 | 5.5 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.~The primary efficacy endpoints were noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333 with and without RBV) compared with the historical control rate for noncirrhotic, treatment-experienced participants with HCV GT1b infection treated with telaprevir and peginterferon (pegIFN)/RBV." (NCT01674725)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.7 |
| ABT-450/r/ABT-267 and ABT-333 | 100 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug.~The secondary efficacy endpoints were superiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333 with and without RBV) compared with the historical control rate for noncirrhotic, treatment-experienced participants with HCV GT1b treated with telaprevir and pegIFN/RBV; and the noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment who received ABT-450/r/ABT-267 and ABT-333 compared with those who received ABT-450/r/ABT-267 and ABT-333, plus RBV." (NCT01674725)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.7 |
| ABT-450/r/ABT-267 and ABT-333 | 100 |
Participants who completed treatment with plasma HCV RNA less than the lower limit of quantification (
Timeframe: Between End of Treatment (Week 12) and Post-treatment (up to Week 12 Post-Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0 |
| ABT-450/r/ABT-267 and ABT-333 | 0 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log10 IU/mL above the lowest value post baseline] at any time point during treatment), or failure to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01674725)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Rebound | Failure to Suppress | |
| ABT-450/r/ABT-267 and ABT-333 | 0 | 0 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0 | 0 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01716585)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 95.7 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01716585)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 98.0 |
Normalization is defined as alanine aminotransferase less than or equal to the upper limit of normal (ULN) at final treatment visit for participants with alanine aminotransferase greater than ULN at baseline. (NCT01716585)
Timeframe: At 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.0 |
| Placebo | 15.8 |
Virologic failure was defined as rebound (hepatitis C virus ribonucleic acid [HCV RNA] ≥ lower limit of quantification [LLOQ] after HCV RNA < LLOQ or increase in HCV RNA of at least 1 log10 IU/mL) or failure to suppress (all on-treatment values of plasma HCV RNA ≥ LLOQ with at least 36 days of treatment) during treatment. (NCT01716585)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0.2 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01716585)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 96.4 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma hepatitis C virus ribonucleic acid (HCV RNA) greater than or equal to the lower limit of quantification (≥ LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01716585)
Timeframe: Within 12 weeks post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 1.5 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01715415)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 96.0 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01715415)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 96.7 |
Normalization is defined as alanine aminotransferase less than or equal to the upper limit of normal (ULN) at final treatment visit for participants with alanine aminotransferase greater than ULN at baseline. (NCT01715415)
Timeframe: At 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 96.9 |
| Placebo | 12.8 |
Virologic failure was defined as rebound (hepatitis C virus ribonucleic acid [HCV RNA] ≥ lower limit of quantification [LLOQ] after HCV RNA < LLOQ or increase in HCV RNA of at least 1 log10 IU/mL) or failure to suppress (all on-treatment values of plasma HCV RNA ≥ LLOQ with at least 36 days of treatment) during treatment. (NCT01715415)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01715415)
Timeframe: 12 weeks after the last actual dose of active study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 96.3 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma hepatitis C virus ribonucleic acid (HCV RNA) greater than or equal to the lower limit of quantification (≥ LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01715415)
Timeframe: Within 12 weeks post-treatment
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 2.4 |
The percentage of participants with a decrease in hemoglobin from greater than or equal to the lower limit of normal (≥ LLN) at baseline to < LLN at the end of treatment. (NCT01767116)
Timeframe: Baseline (Day 1) and Week 12 (End of Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 51.2 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 3.4 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.~The primary efficacy endpoints were noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1b infection treated with telaprevir and peginterferon/RBV (pegIFN)." (NCT01767116)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 99.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 100.0 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug.~The secondary endpoint was the noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment who received ABT-450/r/ABT-267 and ABT-333, plus placebo RBV compared with those who received ABT-450/r/ABT-267 and ABT-333, plus RBV." (NCT01767116)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 99.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 100 |
"The percentage of participants with sustained virologic response (plasma HCV RNA less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug.~The secondary efficacy endpoints were superiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1b treated with telaprevir and pegIFN/RBV." (NCT01767116)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of particpants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 99.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 100 |
Participants who completed treatment with plasma HCV RNA less than the lower limit of quantification (
Timeframe: Between End of Treatment (Week 12) and Post-treatment (up to Week 12 Post-treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 0 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log10 IU/mL above the lowest value post baseline] at any time point during treatment), or failure to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01767116)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Rebound | Failure to suppress | |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 0 | 0 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0.5 | 0 |
The percentage of participants with a decrease in hemoglobin from greater than or equal to the lower limit of normal (≥ LLN) at baseline to < LLN at the end of treatment. (NCT01833533)
Timeframe: Baseline (Day 1) and Week 12 (End of Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 42.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 3.9 |
"The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. The LLOQ for the assay was 25 IU/mL.~The primary efficacy endpoints were noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1a infection treated with telaprevir and peginterferon(pegIFN)/RBV." (NCT01833533)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 90.2 |
"The percentage of participants with sustained virologic response (plasma HCV RNA less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug.~The secondary efficacy endpoints were superiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm (ABT-450/r/ABT-267 and ABT-333, plus either placebo RBV or RBV) compared with the historical control rate for noncirrhotic, treatment-naïve participants with HCV GT1a infection treated with telaprevir and pegIFN/RBV; and the noninferiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment who received ABT-450/r/ABT-267 and ABT-333, plus placebo RBV compared with those who received ABT-450/r/ABT-267 and ABT-333, plus RBV." (NCT01833533)
Timeframe: 12 weeks after last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 90.2 |
Participants who completed treatment with plasma HCV RNA less than the lower limit of quantification (
Timeframe: Between End of Treatment (Week 12) and Post-treatment (up to Week 12 Post-Treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 1.0 |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 5.2 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log10 IU/mL above the lowest value post baseline] at any time point during treatment), or failure to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01833533)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Rebound | Failure to suppress | |
| ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV | 2.9 | 0 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 1.0 | 0 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01704755)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 0.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 1.7 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
A sustained virologic response is defined as plasma Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (< LLOQ) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01704755)
Timeframe: within 12 weeks after the last dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 5.9 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 0.6 |
Number of kidney transplant recipients who become reactive for HCV antibody (NCT02781649)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Donor Genotype 1a no Resistance or 1b | 3 |
| Donor Genotype 1a With Resistance | 0 |
| Donor Genotype 2 or 3 | 2 |
Serum creatinine mg/dL at 12 months following transplantation (NCT02781649)
Timeframe: 12 months following transplantation
| Intervention | mg/dL (Median) |
|---|---|
| Donor Genotype 1a no Resistance or 1b | 1.0 |
| Donor Genotype 2 or 3 | 1.3 |
Serum creatinine mg/dL at 6 months following transplantation (NCT02781649)
Timeframe: 6 months following transplantation
| Intervention | mg/dL (Median) |
|---|---|
| Donor Genotype 1a no Resistance or 1b | 1.12 |
| Donor Genotype 2 or 3 | 0.9 |
Proportion of participants with grade 3 or higher treatment-related adverse events (AE) as assessed by US Department of Health and Human Services Common Terminology of AEs version 4. An AE is an unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5. Grade 3 Severe or medically significant but not life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. The investigator will determine if the AE is related to the treatment. (NCT02781649)
Timeframe: 12 weeks after transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Donor Genotype 1a no Resistance or 1b | 0 |
| Donor Genotype 1a With Resistance | 0 |
| Donor Genotype 2 or 3 | 0 |
"Number of participants with NS5A resistance mutations in the HCV population from the deceased donors.~Number of donors with NS5A resistance mutations" (NCT02781649)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Donor Genotype 1a no Resistance or 1b | 0 |
| Donor Genotype 1a With Resistance | 0 |
| Donor Genotype 2 or 3 | 0 |
This is the number of participants with undetectable hepatitis C RNA in the blood at 12 weeks after stopping treatment. Proportion of kidney transplant recipients with HCV RNA < Lower Limit Of Quantification (LLOQ) at week 12 (NCT02781649)
Timeframe: 12 weeks after completing treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Donor Genotype 1a no Resistance or 1b | 7 |
| Donor Genotype 1a With Resistance | 0 |
| Donor Genotype 2 or 3 | 3 |
Proportion of patients with undetectable hepatitis C virus (HCV) polymerase chain reaction (PCR) at 12 weeks after completion of HCV treatment was to test the efficacy of the treatment. (NCT03801707)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Group | 28 |
Estimated glomerular filtration rate (eGFR) at 6 and 12 months post-transplant was to test the safety of utilizing of HepC positive kidneys. (NCT03801707)
Timeframe: 6 and 12 months
| Intervention | ml/min/1.73m^2 (Median) | |
|---|---|---|
| eGFR at 6 months | eGFR at 12 months | |
| Intervention Group | 54 | 46 |
Graft survival at 6 and 12 months measuring safety of utilizing HepC positive kidneys. (NCT03801707)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 6 months graft survival | 12 months graft survival | |
| Intervention Group | 30 | 30 |
Patient's survival at 6 and 12 months measuring safety of utilizing of HepC positive kidneys. (NCT03801707)
Timeframe: 6 and 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 6 months patient survival | 12 months patient survival | |
| Intervention Group | 30 | 30 |
(NCT02781558)
Timeframe: Baseline; Week 12
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | -5.04 |
| SOF/VEL + RBV | -5.13 |
(NCT02781558)
Timeframe: Baseline; Week 2
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | -4.67 |
| SOF/VEL + RBV | -4.80 |
(NCT02781558)
Timeframe: Baseline; Week 4
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | -4.96 |
| SOF/VEL + RBV | -5.09 |
(NCT02781558)
Timeframe: Baseline; Week 8
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | -5.04 |
| SOF/VEL + RBV | -5.13 |
(NCT02781558)
Timeframe: Week 12
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | 1.15 |
| SOF/VEL + RBV | 1.15 |
(NCT02781558)
Timeframe: Week 2
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | 1.52 |
| SOF/VEL + RBV | 1.47 |
(NCT02781558)
Timeframe: Week 4
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | 1.22 |
| SOF/VEL + RBV | 1.19 |
(NCT02781558)
Timeframe: Week 8
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | 1.15 |
| SOF/VEL + RBV | 1.15 |
SVR4 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 4 weeks after stopping study treatment. (NCT02781558)
Timeframe: Posttreatment Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 93.1 |
| SOF/VEL + RBV | 97.1 |
(NCT02781558)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 99.0 |
| SOF/VEL + RBV | 100.0 |
(NCT02781558)
Timeframe: Week 2
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 51.0 |
| SOF/VEL + RBV | 44.7 |
(NCT02781558)
Timeframe: Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 85.0 |
| SOF/VEL + RBV | 90.3 |
(NCT02781558)
Timeframe: Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 99.0 |
| SOF/VEL + RBV | 100.0 |
(NCT02781558)
Timeframe: Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 1.0 |
| SOF/VEL + RBV | 1.9 |
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment. (NCT02781558)
Timeframe: Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 91.1 |
| SOF/VEL + RBV | 96.1 |
"Virologic failure was defined as~On-treatment virologic failure:~Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ on 2 consecutive measurements while on treatment), or~Rebound (confirmed > 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or~Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)~Virologic relapse:~HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement" (NCT02781558)
Timeframe: Up to Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 5.9 |
| SOF/VEL + RBV | 1.9 |
(NCT02722837)
Timeframe: Baseline (Day 1); Week 1
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | -4.17 |
(NCT02722837)
Timeframe: Baseline (Day 1); Week 12
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | -4.93 |
(NCT02722837)
Timeframe: Baseline (Day 1); Week 2
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | -4.70 |
(NCT02722837)
Timeframe: Baseline (Day 1); Week 4
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | -4.90 |
(NCT02722837)
Timeframe: Baseline (Day 1); Week 8
| Intervention | log10 IU/mL (Mean) |
|---|---|
| SOF/VEL | -4.93 |
(NCT02722837)
Timeframe: Up to 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 0 |
SVR24 was defined as HCV RNA < LLOQ at 24 weeks after stopping study treatment. (NCT02722837)
Timeframe: Posttreatment Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 99.2 |
SVR4 was defined as HCV RNA < LLOQ at 4 weeks after stopping study treatment. (NCT02722837)
Timeframe: Posttreatment Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 100.0 |
(NCT02722837)
Timeframe: Week 1
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 21.0 |
(NCT02722837)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 100.0 |
(NCT02722837)
Timeframe: Week 2
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 64.7 |
(NCT02722837)
Timeframe: Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 96.6 |
(NCT02722837)
Timeframe: Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 100.0 |
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment. (NCT02722837)
Timeframe: Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 99.2 |
"Virologic failure was defined as:~Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while on treatment), or~Rebound (confirmed > 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or~Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment), or~Relapse (HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement)" (NCT02722837)
Timeframe: Up to Posttreatment Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| SOF/VEL | 0.8 |
Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are considered failure (NCT02600325)
Timeframe: week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Group | 75 |
Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are not considered failure (NCT02600325)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment Group | 79 |
Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. Undetectable HCV RNA (target not detected [TND]) was defined as below the 9.3 IU/ml limit of detection. Kaplan Meier summary statistics were calculated for each treatment arm. (NCT01353911)
Timeframe: From first dose of study medication until first achievement of undetectable HCV RNA (up to 48 weeks of treatment)
| Intervention | days (Median) |
|---|---|
| OL Grazoprevir 100 mg | 22.0 |
| Grazoprevir 100 mg | 15.0 |
| Grazoprevir 200 mg | 28.0 |
| Grazoprevir 400 mg | 16.0 |
| Grazoprevir 800 mg | 16.5 |
| Grazoprevir 400 mg/100 mg | 27.0 |
| Grazoprevir 800 mg/100 mg | 29.0 |
| Boceprevir 800 mg | 57.0 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product, was also an AE. (NCT01353911)
Timeframe: Treatment period plus the first 14 days of follow-up (up to 50 weeks)
| Intervention | participants (Number) |
|---|---|
| OL Grazoprevir 100 mg | 34 |
| Grazoprevir 100 mg | 65 |
| Grazoprevir 200 mg | 66 |
| Grazoprevir 400 mg | 23 |
| Grazoprevir 800 mg | 28 |
| Grazoprevir 400 mg/100 mg | 42 |
| Grazoprevir 800 mg/100 mg | 35 |
| Boceprevir 800 mg | 64 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR's product, was also an AE. (NCT01353911)
Timeframe: Treatment period plus the first 14 days of follow-up (up to 50 weeks)
| Intervention | participants (Number) |
|---|---|
| OL Grazoprevir 100 mg | 2 |
| Grazoprevir 100 mg | 3 |
| Grazoprevir 200 mg | 4 |
| Grazoprevir 400 mg | 2 |
| Grazoprevir 800 mg | 3 |
| Grazoprevir 400 mg/100 mg | 4 |
| Grazoprevir 800 mg/100 mg | 2 |
| Boceprevir 800 mg | 9 |
Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). cEVR was defined as undetectable HCV RNA (target not detected [TND]) at Week 12. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01353911)
Timeframe: After 12 weeks of treatment with grazoprevir/boceprevir
| Intervention | percentage of participants (Number) |
|---|---|
| OL Grazoprevir 100 mg | 94.4 |
| Grazoprevir 100 mg | 80.3 |
| Grazoprevir 200 mg | 85.3 |
| Grazoprevir 400 mg | 87.5 |
| Grazoprevir 800 mg | 75.9 |
| Grazoprevir 400 mg/100 mg | 86.0 |
| Grazoprevir 800 mg/100 mg | 86.1 |
| Boceprevir 800 mg | 69.7 |
Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). RVR was defined as undetectable (TND) HCV RNA at Week 4 of study therapy. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01353911)
Timeframe: After 4 weeks of treatment with grazoprevir/boceprevir
| Intervention | percentage of participants (Number) |
|---|---|
| OL Grazoprevir 100 mg | 72.2 |
| Grazoprevir 100 mg | 90.9 |
| Grazoprevir 200 mg | 91.2 |
| Grazoprevir 400 mg | 87.5 |
| Grazoprevir 800 mg | 86.2 |
| Grazoprevir 400 mg/100 mg | 81.4 |
| Grazoprevir 800 mg/100 mg | 83.3 |
| Boceprevir 800 mg | 59.1 |
Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). SVR12 was defined as undetectable (TND) HCV RNA at 12 weeks after the end of all study therapy. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01353911)
Timeframe: 12 weeks after the end of all treatment (up to 60 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| OL Grazoprevir 100 mg | 72.2 |
| Grazoprevir 100 mg | 89.4 |
| Grazoprevir 200 mg | 91.2 |
| Grazoprevir 400 mg | 87.5 |
| Grazoprevir 800 mg | 79.3 |
| Grazoprevir 400 mg/100 mg | 93.0 |
| Grazoprevir 800 mg/100 mg | 91.7 |
| Boceprevir 800 mg | 60.6 |
Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. The Roche COBAS Taqman HCV Test, v2.0 assay (High Pure System) had a lower limit of quantification of 25 IU/mL and a limit of detection of 9.3 IU/mL (in plasma). SVR24 was defined as undetectable (TND) HCV RNA at 24 weeks after the end of all study therapy. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01353911)
Timeframe: 24 weeks after the end of all treatment (up to 72 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| OL Grazoprevir 100 mg | 72.2 |
| Grazoprevir 100 mg | 86.4 |
| Grazoprevir 200 mg | 92.6 |
| Grazoprevir 400 mg | 87.5 |
| Grazoprevir 800 mg | 79.3 |
| Grazoprevir 400 mg/100 mg | 93.0 |
| Grazoprevir 800 mg/100 mg | 91.7 |
| Boceprevir 800 mg | 57.6 |
Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS™ Taqman™ HCV Test, v2.0 at various time points prior to, during, and after dosing. Undetectable HCV RNA (target not detected [TND]) was defined as below the 9.3 IU/ml limit of detection. 95% confidence intervals provided based on the Clopper-Pearson method. (NCT01353911)
Timeframe: Week 72
| Intervention | percentage of participants (Number) |
|---|---|
| OL Grazoprevir 100 mg | 69.4 |
| Grazoprevir 100 mg | 80.3 |
| Grazoprevir 200 mg | 86.8 |
| Grazoprevir 400 mg | 87.5 |
| Grazoprevir 800 mg | 75.9 |
| Grazoprevir 400 mg/100 mg | 79.1 |
| Grazoprevir 800 mg/100 mg | 83.3 |
| Boceprevir 800 mg | 54.5 |
cEVR was defined as hepatitis C virus RNA levels to be < lower limit of quantitation ie, 25 IU/mL TND at Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory. (NCT02032901)
Timeframe: Week 12
| Intervention | Percentage of participants (Number) |
|---|---|
| Daclatasvir + Sofosbuvir in Treatment-naive Participants | 98.0 |
| Daclatasvir + Sofosbuvir in Treatment-experienced Participants | 100.0 |
EOTR were defined as hepatitis C virus RNA levels to be < lower limit of quantitation ie, 25 IU/mL TND at end of treatment. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory. (NCT02032901)
Timeframe: Up to the end of treatment (up to 24 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Daclatasvir + Sofosbuvir in Treatment-naive Participants | 99.0 |
| Daclatasvir + Sofosbuvir in Treatment-experienced Participants | 100.0 |
RVR was defined as hepatitis C virus RNA levels to be < lower limit of quantitation ie, 25 IU/mL TND at Week 4. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory. (NCT02032901)
Timeframe: Week 4
| Intervention | Percentage of participants (Number) |
|---|---|
| Daclatasvir + Sofosbuvir in Treatment-naive Participants | 63.4 |
| Daclatasvir + Sofosbuvir in Treatment-experienced Participants | 72.5 |
SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation ie., 25 IU/mL, target detected or target not detected at follow-up Week 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory. (NCT02032901)
Timeframe: Week 12 (Follow-up period)
| Intervention | percentage of participants (Number) |
|---|---|
| Daclatasvir + Sofosbuvir in Treatment-experienced Participants | 86.3 |
SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation ie., 25 IU/mL, TD or TND at follow-up Week 12. HCV RNA levels were measured by the Roche Cobas® TaqMan® HCV Test version 2.0 from the central laboratory. (NCT02032901)
Timeframe: Week 12 (Follow-up period)
| Intervention | Percentage of participants (Number) |
|---|---|
| Daclatasvir + Sofosbuvir in Treatment-naive Participants | 90.1 |
AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. (NCT02032901)
Timeframe: From Day 1 first dose to last dose plus 7 days
| Intervention | Participants (Number) | |
|---|---|---|
| SAEs | Discontinuations Due to AEs | |
| Daclatasvir + Sofosbuvir in Treatment-experienced Participants | 0 | 0 |
| Daclatasvir + Sofosbuvir in Treatment-naive Participants | 1 | 0 |
Percentage of participants who achieved HCV RNA
Timeframe: Week 1, 2, 6, 8 (treatment period)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 6 | Week 8 | |
| Daclatasvir + Sofosbuvir in Treatment-experienced Participants | 2.0 | 29.4 | 90.2 | 98.0 |
| Daclatasvir + Sofosbuvir in Treatment-naive Participants | 11.9 | 34.7 | 86.1 | 95.0 |
Percentage of participants who achieved HCV RNA
Timeframe: Week 1, 2, 4, 6, 8, 12, End of treatment (treatment period), Week 4 (follow-up period), Week 24 (follow-up period)
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | End of treatment | Follow-up Week 4 | Follow-up Week 24 | |
| Daclatasvir + Sofosbuvir in Treatment-experienced Participants | 23.5 | 68.6 | 98.0 | 98.0 | 100.0 | 100.0 | 100.0 | 86.3 | 82.4 |
| Daclatasvir + Sofosbuvir in Treatment-naive Participants | 39.6 | 77.2 | 94.1 | 100.0 | 100.0 | 98.0 | 99.0 | 91.1 | 89.1 |
Participants categorized into 2 genotypes (CC and non-CC) based on SNPs in the IL28B gene were assessed for SVR12, defined as response in which hepatitis C virus (HCV) RNA levels below lower limit of quantitation (LLOQ) below target detected or target not detected at follow-up Week 12 (LLOQ: 25 IU/mL). HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory. (NCT02032901)
Timeframe: Week 12 (Follow-up period)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Genotype: CC (n=40, 20) | Genotype: Non-CC (n=61, 31) | |
| Daclatasvir + Sofosbuvir in Treatment-experienced Participants | 95.0 | 80.6 |
| Daclatasvir + Sofosbuvir in Treatment-naive Participants | 90.0 | 90.2 |
SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation ie. 25 IU/mL, target detected or target not detected at follow-up Week 12. Cirrhosis was considered a negative predictor of SVR in participants treated with an interferon formulation or ribavirin. Presence or absence of cirrhosis was determined at baseline and follow-up Week 12 in the participants to evaluate the post-treatment relapse. (NCT02032901)
Timeframe: Baseline, Week 12 (Follow-up period)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| With cirrhosis (n= 19, 13) | Without cirrhosis (n= 75, 34) | |
| Daclatasvir + Sofosbuvir in Treatment-experienced Participants | 69.2 | 94.1 |
| Daclatasvir + Sofosbuvir in Treatment-naive Participants | 57.9 | 97.3 |
On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after < LLOQ during treatment, confirmed increase of > 1 log (subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks of treatment. (NCT02207088)
Timeframe: Up to 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 0 |
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants completing treatment and with HCV RNA < LLOQ at the end of treatment. (NCT02207088)
Timeframe: Within 12 weeks after the last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 1.5 |
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 94.1 |
SVR12 was defined as HCV RNA
Timeframe: At follow-up Week 12
| Intervention | Percentage of participants (Number) |
|---|---|
| Treatment-naive: Daclatasvir + Sofosbuvir 12 Weeks | 96.4 |
SVR12 was defined as HCV RNA
Timeframe: At follow-up Week 12
| Intervention | Percentage of participants (Number) |
|---|---|
| Treatment-experienced: Daclatasvir + Sofosbuvir 12 Weeks | 97.7 |
SVR12 was defined as HCV RNA
Timeframe: At follow-up Week 12
| Intervention | Percentage of participants (Number) |
|---|---|
| Treatment-naive: Daclatasvir + Sofosbuvir 8 Weeks | 75.6 |
SVR12 was defined as HCV RNA levels
Timeframe: At follow-up Week 12
| Intervention | Percentage of participants (Number) |
|---|---|
| Treatment-naive: Daclatasvir + Sofosbuvir 12 Weeks | 97.0 |
| Treatment-naive: Daclatasvir + Sofosbuvir 8 Weeks | 76.0 |
| Treatment-experienced: Daclatasvir + Sofosbuvir 12 Weeks | 98.1 |
AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may or may not have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. AEs were categorized as Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. (NCT02032888)
Timeframe: AEs: Day 1 to 7 days after last dose of study treatment (8 weeks or 12 weeks). SAEs: Day 1 to 30 days after last dose of study treatment (8 weeks or 12 weeks)
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| AEs | SAEs | AEs requiring dose interruption or discontinuation | Treatment-related AEs | Treatment-related Grade 3 to 4 AEs | Grade 3 to 4 AEs | Death | |
| Treatment-experienced: Daclatasvir + Sofosbuvir 12 Weeks | 37 | 3 | 0 | 17 | 0 | 4 | 0 |
| Treatment-naive: Daclatasvir + Sofosbuvir 12 Weeks | 75 | 1 | 0 | 39 | 0 | 3 | 0 |
| Treatment-naive: Daclatasvir + Sofosbuvir 8 Weeks | 29 | 0 | 0 | 13 | 1 | 2 | 0 |
AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may or may not have a causal relationship with treatment. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or drug dependency/abuse; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization. AEs were categorized as Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. (NCT02032888)
Timeframe: AEs: Day 1 of follow-up period (Week 9 or Week 13) to 7 days after end of 24 weeks follow-up period. SAEs: Day 1 of follow-up period (Week 9 or Week 13) to 30 days after end of 24 weeks follow-up period.
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| AEs | SAEs | AEs Grade 3 to 4 | SAEs Grade 3 to 4 | Death | |
| Treatment-experienced: Daclatasvir + Sofosbuvir 12 Weeks | 5 | 0 | 0 | 0 | 0 |
| Treatment-naive: Daclatasvir + Sofosbuvir 12 Weeks | 11 | 3 | 3 | 2 | 1 |
| Treatment-naive: Daclatasvir + Sofosbuvir 8 Weeks | 5 | 1 | 1 | 1 | 1 |
Grade 3-4 abnormalities on laboratory test results were defined as: International normalized ratio as 2.1-3.0*upper limit of normal (ULN) for grade 3 and >3.0*ULN for grade 4. Leukocytes as 1.0*10^9-1.5*10^9/L for grade 3 and <1.0*10^9/L for grade 4. Aspartate aminotransferase as 5.1-10.0*ULN for grade 3 and >10.0*ULN for grade 4. Bilirubin (total) as 2.6-5.0*ULN for grade 3 and >5.0*ULN for grade 4. Lipase (total) as 3.1-5.0*ULN for grade 3 and >5.0*ULN for grade 4. Alanine aminotransferase as 5.1-10.0*ULN for grade 3 and >10.0*ULN for grade 4. (NCT02032888)
Timeframe: From screening up to week 24 of post treatment follow--up
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| International normalized ratio | Leukocytes | Aspartate aminotransferase | Bilirubin (total) | Lipase (total) | Alanine aminotransferase | |
| Treatment-experienced: Daclatasvir + Sofosbuvir 12 Weeks | 1 | 1 | 1 | 2 | 1 | 1 |
| Treatment-naive: Daclatasvir + Sofosbuvir 12 Weeks | 1 | 0 | 0 | 5 | 5 | 0 |
| Treatment-naive: Daclatasvir + Sofosbuvir 8 Weeks | 0 | 0 | 1 | 1 | 1 | 1 |
Participants with HCV RNA levels
Timeframe: At Weeks 1, 2, 4, 6, 8, and 12 and at End of Treatment
| Intervention | Percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | End of treatment | |
| Treatment-experienced: Daclatasvir + Sofosbuvir 12 Weeks | 5.8 | 23.1 | 63.5 | 94.2 | 100.0 | 98.1 | 100.0 |
| Treatment-naive: Daclatasvir + Sofosbuvir 12 Weeks | 9.9 | 33.7 | 70.3 | 89.1 | 98.0 | 96.0 | 99.0 |
| Treatment-naive: Daclatasvir + Sofosbuvir 8 Weeks | 6.0 | 34.0 | 78.0 | 90.0 | 96.0 | NA | 100.0 |
Participants with hepatitis C virus CV) levels to be
Timeframe: Week 1, 2, 4, 6, 8, 12, End of treatment, and follow-up Week 4 and 24
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | End of treatment | Follow-up Week 4 | Follow-up Week 24 | |
| Treatment-experienced: Daclatasvir + Sofosbuvir 12 Weeks | 34.6 | 71.2 | 92.3 | 98.1 | 100.0 | 98.1 | 100.0 | 96.2 | 92.3 |
| Treatment-naive: Daclatasvir + Sofosbuvir 12 Weeks | 34.7 | 77.2 | 93.1 | 99.0 | 98.0 | 96.0 | 99.0 | 98.0 | 92.1 |
| Treatment-naive: Daclatasvir + Sofosbuvir 8 Weeks | 44.0 | 78.0 | 98.0 | 98.0 | 96.0 | NA | 100.0 | 82.0 | 72.0 |
SVR is defined as hepatitis C virus RNA
Timeframe: At Follow-up Week 12
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| CC Genotype (n=28,13,13) | Non-CC Genotype (n=73,37, 39) | |
| Treatment-experienced: Daclatasvir + Sofosbuvir 12 Weeks | 100.0 | 97.4 |
| Treatment-naive: Daclatasvir + Sofosbuvir 12 Weeks | 100.0 | 95.9 |
| Treatment-naive: Daclatasvir + Sofosbuvir 8 Weeks | 69.2 | 78.4 |
(NCT02202980)
Timeframe: Up to 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1) | 7.1 |
| LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1) | 0 |
| LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2) | 0 |
| LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1) | 0 |
| LDV/SOF 12 Weeks GT3 (Cohort 3 Group 2) | 0 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 4) | 0 |
| SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1) | 0 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2) | 0 |
| SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3) | 0 |
| SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4) | 0 |
| SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5) | 0 |
| SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6) | 0 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7) | 0 |
| SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8) | 0 |
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment. (NCT02202980)
Timeframe: Posttreatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1) | 92.9 |
| LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1) | 96.2 |
| LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2) | 74.1 |
| LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1) | 100.0 |
| LDV/SOF 12 Weeks GT3 (Cohort 3 Group 2) | 76.9 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 4) | 93.3 |
| SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1) | 26.7 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2) | 86.7 |
| SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3) | 83.3 |
| SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4) | 100.0 |
| SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5) | 100.0 |
| SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6) | 89.3 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7) | 66.7 |
| SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8) | 100.0 |
"Virologic failure was defined as:~On-treatment virologic failure:~Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while on treatment), or~Rebound (confirmed > 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or~Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)~Virologic relapse:~Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA < LLOQ at last on-treatment visit." (NCT02202980)
Timeframe: Up to Posttreatment Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1) | 7.1 |
| LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1) | 0 |
| LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2) | 22.2 |
| LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1) | 0 |
| LDV/SOF 12 Weeks GT3 (Cohort 3 Group 2) | 23.1 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 4) | 6.7 |
| SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1) | 73.3 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2) | 13.3 |
| SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3) | 11.1 |
| SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4) | 0 |
| SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5) | 0 |
| SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6) | 10.7 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7) | 30.0 |
| SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8) | 0 |
(NCT02202980)
Timeframe: Weeks 1, 2, 4, 6, 8, 12, 16, 20, and 24 (depending on treatment duration; Week 6 data was not collected for Cohorts 1-3)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Week 1 | Week 2 | Week 4 | |
| SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1) | 26.7 | 53.3 | 100.0 |
(NCT02202980)
Timeframe: Weeks 1, 2, 4, 6, 8, 12, 16, 20, and 24 (depending on treatment duration; Week 6 data was not collected for Cohorts 1-3)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 4) | 26.7 | 66.7 | 100.0 | 100.0 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2) | 26.7 | 66.7 | 100.0 | 100.0 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7) | 13.3 | 43.3 | 93.3 | 96.7 |
| SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3) | 16.7 | 88.9 | 100.0 | 100.0 |
(NCT02202980)
Timeframe: Weeks 1, 2, 4, 6, 8, 12, 16, 20, and 24 (depending on treatment duration; Week 6 data was not collected for Cohorts 1-3)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | |
| LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2) | 7.4 | 40.7 | 92.6 | 96.3 |
(NCT02202980)
Timeframe: Weeks 1, 2, 4, 6, 8, 12, 16, 20, and 24 (depending on treatment duration; Week 6 data was not collected for Cohorts 1-3)
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 6 | Week 8 | |
| SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4) | 5.9 | 41.2 | 76.5 | 100.0 | 100.0 |
| SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6) | 7.1 | 60.7 | 85.7 | 96.4 | 100.0 |
| SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5) | 5.3 | 42.1 | 84.2 | 94.7 | 100.0 |
| SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8) | 0 | 25.0 | 100.0 | 100.0 | 100.0 |
(NCT02202980)
Timeframe: Weeks 1, 2, 4, 6, 8, 12, 16, 20, and 24 (depending on treatment duration; Week 6 data was not collected for Cohorts 1-3)
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | |
| LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1) | 9.4 | 53.1 | 87.5 | 100.0 | 100.0 |
| LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1) | 28.0 | 60.0 | 92.0 | 100.0 | 100.0 |
| LDV/SOF 12 Weeks GT3 (Cohort 3 Group 2) | 7.7 | 7.7 | 84.6 | 100.0 | 100.0 |
(NCT02202980)
Timeframe: Weeks 1, 2, 4, 6, 8, 12, 16, 20, and 24 (depending on treatment duration; Week 6 data was not collected for Cohorts 1-3)
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 4 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
| LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1) | 7.1 | 64.3 | 100.0 | 100.0 | 100.0 | 92.9 | 92.9 | 100.0 |
SVR4 and SVR 24 were defined as HCV RNA < LLOQ at 4 and 24 weeks after stopping study treatment, respectively. (NCT02202980)
Timeframe: Posttreatment Weeks 4 and 24
| Intervention | percentage of participants (Number) | |
|---|---|---|
| SVR4 | SVR24 | |
| LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1) | 100.0 | 100.0 |
| LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1) | 96.2 | 96.2 |
| LDV/SOF 12 Weeks GT3 (Cohort 3 Group 2) | 76.9 | 76.9 |
| LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2) | 81.5 | 74.1 |
| LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1) | 92.9 | 92.9 |
| SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1) | 73.3 | 20.0 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 4) | 100.0 | 93.3 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2) | 86.7 | 86.7 |
| SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7) | 86.7 | 66.7 |
| SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3) | 88.9 | 83.3 |
| SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4) | 100.0 | 100.0 |
| SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6) | 92.9 | 89.3 |
| SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5) | 100.0 | 100.0 |
| SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8) | 100.0 | 100.0 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. (NCT02133131)
Timeframe: Up to Week 12
| Intervention | Number of participants (Number) |
|---|---|
| GT1: NC Grazoprevir/Elbasvir + SOF 4 Weeks | 0 |
| GT1: NC Grazoprevir/Elbasvir + SOF 6 Weeks | 0 |
| GT1: C Grazoprevir/Elbasvir + SOF 6 Weeks | 0 |
| GT1: C Grazoprevir/Elbasvir + SOF 8 Weeks | 1 |
| GT3: NC Grazoprevir/Elbasvir + SOF 8 Weeks | 0 |
| GT3: NC Grazoprevir/Elbasvir + SOF 12 Weeks | 0 |
| GT3: C Grazoprevir/Elbasvir + SOF 12 Weeks | 0 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. (NCT02133131)
Timeframe: Up to Week 14
| Intervention | Number of participants (Number) |
|---|---|
| GT1: NC Grazoprevir/Elbasvir + SOF 4 Weeks | 5 |
| GT1: NC Grazoprevir/Elbasvir + SOF 6 Weeks | 7 |
| GT1: C Grazoprevir/Elbasvir + SOF 6 Weeks | 7 |
| GT1: C Grazoprevir/Elbasvir + SOF 8 Weeks | 4 |
| GT3: NC Grazoprevir/Elbasvir + SOF 8 Weeks | 4 |
| GT3: NC Grazoprevir/Elbasvir + SOF 12 Weeks | 3 |
| GT3: C Grazoprevir/Elbasvir + SOF 12 Weeks | 3 |
The percentage of participants achieving SVR12, defined as HCV ribonucleic acid (RNA) <15 IU/mL 12 weeks after completing all study therapy, was determined for each arm. Plasma levels of HCV RNA were measured using the Roche COBAS© AmpliPrep/COBAS© TaqMan© HCV Test v. 2.0. (NCT02133131)
Timeframe: Up to 24 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| GT1: NC Grazoprevir/Elbasvir + SOF 4 Weeks | 33.3 |
| GT1: NC Grazoprevir/Elbasvir + SOF 6 Weeks | 89.3 |
| GT1: C Grazoprevir/Elbasvir + SOF 6 Weeks | 80.0 |
| GT1: C Grazoprevir/Elbasvir + SOF 8 Weeks | 89.5 |
| GT3: NC Grazoprevir/Elbasvir + SOF 8 Weeks | 93.3 |
| GT3: NC Grazoprevir/Elbasvir + SOF 12 Weeks | 100.0 |
| GT3: C Grazoprevir/Elbasvir + SOF 12 Weeks | 90.9 |
All treated participants were monitored for change in Absolute CD4 T Lymphocyte count from Baseline to the end of the treatment period. The mean change in each arm for all evaluable participants is reported in Cells/µL. (NCT01866930)
Timeframe: Day 1 to end of treatment; up to week 24 or week 48
| Intervention | Cells/uL (Mean) |
|---|---|
| Cohort A: HCV GT-2 or GT-3 | -42.4 |
| Cohort B: HCV GT-1 or GT-4 | -104.9 |
All treated participants were monitored for change in Platelet Count from Baseline to the end of the treatment period. The mean change in each arm for all evaluable participants (units of measurement = x10^9 cells/L). (NCT01866930)
Timeframe: Day 1 to end of treatment; up to week 24 or week 48
| Intervention | 10^9 cells/L (Mean) |
|---|---|
| Cohort A: HCV GT-2 or GT-3 | 32.7 |
| Cohort B: HCV GT-1 or GT-4 | 33.3 |
All treated participants were monitored for change in Total Lymphocyte Count from Baseline to the end of the treatment period. The mean change in each arm for all evaluable participants is reported in Cells/µL. (NCT01866930)
Timeframe: Day 1 to end of treatment; up to week 24 or week 48
| Intervention | Cells/µL (Mean) |
|---|---|
| Cohort A: HCV GT-2 or GT-3 | -0.38 |
| Cohort B: HCV GT-1 or GT-4 | -0.50 |
All treated participants were monitored for percent change in CD4 T Lymphocyte count from Baseline to the end of the treatment period. The mean percent change in each arm is presented for all evaluable participants. (NCT01866930)
Timeframe: Day 1 to end of treatment; up to week 24 or week 48
| Intervention | Percent change (Mean) |
|---|---|
| Cohort A: HCV GT-2 or GT-3 | -4.0 |
| Cohort B: HCV GT-1 or GT-4 | -13.4 |
All treated participants were monitored for percent change in Platelet Count from Baseline to the end of the treatment period. The mean percent change in each arm is presented for all evaluable participants. (NCT01866930)
Timeframe: Day 1 to end of treatment; up to week 24 or week 48
| Intervention | Percent change (Mean) |
|---|---|
| Cohort A: HCV GT-2 or GT-3 | 16.9 |
| Cohort B: HCV GT-1 or GT-4 | 20.1 |
All treated participants were monitored for percent change in Total Lymphocyte Count from Baseline to the end of the treatment period. The mean percent change in each arm is presented for all evaluable participants. (NCT01866930)
Timeframe: Day 1 to end of treatment; up to week 24 or week 48
| Intervention | Percent change (Mean) |
|---|---|
| Cohort A: HCV GT-2 or GT-3 | -15.33 |
| Cohort B: HCV GT-1 or GT-4 | -22.95 |
SVR12 was defined as HCV RNA less than lower limit of quantification (< LLOQ) (25 IU/mL; target detected or not detected) at follow-up week 12. (NCT01866930)
Timeframe: Follow-up week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A: HCV GT-2 or GT-3 | 88 |
| Cohort B: HCV GT-1 or GT-4 | 149 |
All treated participants were monitored for treatment emergent cytopenic abnormalities (anemia as defined by hemoglobin (Hb) < 10 g/dL, and/or neutropenia as defined by absolute neutrophil count (ANC) < 750 mm3 and/or thrombocytopenia as defined by platelets < 50,000/mm3) during the treatment period (Weeks 1, 2, 4, 6, 8, 12, 20, and 24, and at Weeks 28, 32, 36, 40, 44, and 48 for subjects requiring those visits). (NCT01866930)
Timeframe: After Day 1 to end of treatment; up to Weeks 24 or 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A: HCV GT-2 or GT-3 | 4 |
| Cohort B: HCV GT-1 or GT-4 | 15 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that. at any dose, results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. (NCT01866930)
Timeframe: After Day 1 to end of treatment; up to Weeks 24 or 48
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Deaths | SAEs | Lambda Dose Reduction | Discontinuation due to AEs | |
| Cohort A: HCV GT-2 or GT-3 | 0 | 6 | 4 | 4 |
| Cohort B: HCV GT-1 or GT-4 | 3 | 12 | 19 | 13 |
All treated participants were monitored for IFN-associated Flu-like and Musculoskeletal symptoms. Flu-like symptoms were defined as pyrexia, chills, or pain. Musculoskeletal symptoms were defined as arthralgia, myalgia, or back pain. Subjects were monitored throughout the treatment period during the treatment period (After day 1 up to week 24, or After day 1 up to week 48 for subjects requiring those visits). (NCT01866930)
Timeframe: After Day 1 to end of treatment; up to Weeks 24 or 48
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Musculoskeletal symptoms | Flu-like symptoms | |
| Cohort A: HCV GT-2 or GT-3 | 6 | 6 |
| Cohort B: HCV GT-1 or GT-4 | 21 | 19 |
RVR is defined as HCV RNA < LLOQ target not detected at Week 4 and eRVR defined as HCV RNA < LLOQ target not detected at Weeks 4 and 12 (NCT01866930)
Timeframe: Treatment weeks 4 and 12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| RVR | eRVR | |
| Cohort A: HCV GT-2 or GT-3 | 82 | 80 |
| Cohort B: HCV GT-1 or GT-4 | 149 | 138 |
Grade 3/4 treatment-emergent lab abnormalities that occurred in >=5% of subjects in either cohort are reported. The analysis included all treated subjects up to the end of the treatment period (Day 1 to week 24, or Day 1 to week 48 for subjects requiring those visits). Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling. AST = Aspartate aminotransferase, ALT = Alanine aminotransferase. (NCT01866930)
Timeframe: After Day 1 to end of treatment; up to Weeks 24 or 48
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Total Bilirubin | AST | ALT | |
| Cohort A: HCV GT-2 or GT-3 | 26 | 10 | 2 |
| Cohort B: HCV GT-1 or GT-4 | 63 | 13 | 10 |
54 reviews available for carbamates and Hepatitis C
| Article | Year |
|---|---|
Overview of hepatitis C infection, molecular biology, and new treatment.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; H | 2020 |
Hepatitis C-Associated Osteosclerosis: Improvement After Treatment with Sofosbuvir, Daclatasvir, and Ibandronate: Case Report and Literature Review.
Topics: Carbamates; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ibandronic Acid; Imidazoles; Mal | 2021 |
Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report.
Topics: Aged; Antiviral Agents; Carbamates; Cryoglobulinemia; Female; Glomerulonephritis, Membranoproliferat | 2017 |
Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; | 2017 |
Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.
Topics: Anilides; Antiviral Agents; Carbamates; Comorbidity; Cyclopropanes; Drug Therapy, Combination; Genot | 2017 |
Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.
Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug | 2017 |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hep | 2018 |
Cutaneous eruptions by new therapies against hepatitis C virus infection. Not as common as we presumed.
Topics: 2-Naphthylamine; Adrenal Cortex Hormones; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dru | 2018 |
Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations.
Topics: Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Therapy, Combination; Fluorenes; Gen | 2018 |
Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C.
Topics: Administration, Oral; Antiviral Agents; Benzazepines; Carbamates; Drug Combinations; Genotype; Hepac | 2018 |
Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; | 2018 |
Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, | 2019 |
Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs.
Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Economics, Medical; France; Hepatitis C; Humans | 2019 |
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepatitis C; Heterocyclic Compou | 2019 |
Treatment of hepatitis C virus genotype 3-infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; | 2014 |
Treating HCV in HIV 2013: on the cusp of change.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, C | 2014 |
HCV direct-acting antiviral agents: the best interferon-free combinations.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; | 2014 |
Hepatitis C virus NS5A inhibitors and drug resistance mutations.
Topics: Animals; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; He | 2014 |
MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.
Topics: Amides; Animals; Carbamates; Clinical Trials as Topic; Cyclopropanes; Hepatitis C; Humans; Protease | 2014 |
Daclatasvir for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Tri | 2014 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Top | 2014 |
Efficacy of daclatasvir in hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combin | 2014 |
Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Evaluation, Preclini | 2014 |
Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials | 2014 |
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Het | 2015 |
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heteroc | 2015 |
Organic carbamates in drug design and medicinal chemistry.
Topics: Amyloid Precursor Protein Secretases; Antiviral Agents; Carbamates; Chemistry Techniques, Synthetic; | 2015 |
A 4-drug combination (Viekira Pak) for hepatitis C.
Topics: 2-Naphthylamine; Anilides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; | 2015 |
Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dr | 2015 |
Advances in hepatitis C therapies.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatit | 2015 |
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Hepatit | 2016 |
Daclatasvir (Daklinza) for HCV genotype 3 infection.
Topics: Animals; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Genotype | 2015 |
Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Headache; Hepacivirus; Hepatitis | 2016 |
The safety of daclatasvir for the treatment of hepatitis C.
Topics: Administration, Oral; Animals; Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Hum | 2015 |
Technivie for HCV genotype 4 infection.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepaciv | 2015 |
New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
Topics: Amides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C; Hepatitis C, | 2017 |
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.
Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Cyclopropanes; Drugs, Investigation | 2016 |
Elbasvir/grazoprevir (Zepatier) for hepatitis C.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Com | 2016 |
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].
Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepaciviru | 2016 |
Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combinatio | 2016 |
[Latest Treatment of Viral Hepatitis--Overcoming Hepatitis C and Reactivation of Hepatitis B].
Topics: Anilides; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; DNA, Viral | 2016 |
Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatit | 2016 |
Grazoprevir/elbasvir fixed-dose combination for hepatitis C.
Topics: Amides; Animals; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Hepaci | 2016 |
Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
Topics: Adult; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Administration Schedule; Drug Co | 2017 |
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic | 2016 |
Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Imidazoles; | 2017 |
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; | 2017 |
Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepati | 2017 |
HCV management in resource-constrained countries.
Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patien | 2017 |
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
Topics: 2-Naphthylamine; Anilides; Anti-Retroviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Inte | 2017 |
The NS5A replication complex inhibitors: difference makers?
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Discovery; Hepatitis C; Humans; Imidazo | 2011 |
Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Discovery; Genome, Viral; Hepacivirus; | 2011 |
Hepatitis C viral kinetics: the past, present, and future.
Topics: Antiviral Agents; Carbamates; Deoxycytidine; Hepacivirus; Hepatitis C; Humans; Imidazoles; Models, B | 2013 |
HCV NS5A inhibitors in development.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazole | 2013 |
57 trials available for carbamates and Hepatitis C
| Article | Year |
|---|---|
Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
Topics: Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Comb | 2022 |
Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Diabetes Mellitus, Type 2; Female; Genotype; Glycat | 2020 |
Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; F | 2020 |
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Topics: Adult; Aged; Amides; Antiviral Agents; Asia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2020 |
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.
Topics: Administration, Oral; Antiviral Agents; Bayes Theorem; Carbamates; Drug Monitoring; Drug Therapy, Co | 2020 |
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluore | 2020 |
Comparing direct acting antivirals for hepatitis C using observational data - Why and how?
Topics: Antiviral Agents; Bayes Theorem; Benzimidazoles; Carbamates; Comparative Effectiveness Research; Dru | 2020 |
Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; | 2021 |
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Anti-Retroviral Agents; Body Mass Index; Carbama | 2017 |
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Female; Hepatitis C; Heterocyclic Compounds, | 2017 |
Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study.
Topics: Antiviral Agents; Carbamates; Case-Control Studies; Cohort Studies; Coinfection; Drug Combinations; | 2017 |
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combin | 2017 |
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; | 2017 |
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; | 2017 |
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; | 2017 |
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; | 2017 |
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Femal | 2018 |
Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; | 2018 |
Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2018 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; F | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; | 2018 |
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Australia; Carbamates; Cyclopropanes; Drug Admin | 2018 |
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Bacterial; Female; Genotype; Hepac | 2018 |
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Bacterial; Female; Genotype; Hepac | 2018 |
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Bacterial; Female; Genotype; Hepac | 2018 |
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Bacterial; Female; Genotype; Hepac | 2018 |
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Drug Therapy, Combinati | 2018 |
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Female; Genotype; H | 2019 |
Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis | 2019 |
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
Topics: Adult; Amides; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzofurans; Carbamates; Chr | 2019 |
Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.
Topics: Acute Disease; Administration, Oral; Adult; Amides; Antiviral Agents; Belgium; Benzofurans; Carbamat | 2019 |
Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients.
Topics: Adult; Aged; Amino Acid Substitution; Benzazepines; Carbamates; Drug Combinations; Female; Hepacivir | 2019 |
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Topics: Adult; Amides; Antiviral Agents; Atazanavir Sulfate; Benzofurans; Carbamates; Cyclopropanes; Darunav | 2019 |
Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Gra | 2019 |
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Carbamates; Female; Graft Rejection; Graft Survival; Hea | 2019 |
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Carbamates; Female; Graft Rejection; Graft Survival; Hea | 2019 |
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Carbamates; Female; Graft Rejection; Graft Survival; Hea | 2019 |
Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Carbamates; Female; Graft Rejection; Graft Survival; Hea | 2019 |
Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
Topics: Aged; Brazil; Carbamates; Drug Resistance, Viral; Female; Genetic Variation; Genotype; Hepacivirus; | 2019 |
An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Female; Hepatitis C; Hepatitis C Antibodies; | 2019 |
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; | 2019 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; | 2013 |
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Double-Bli | 2014 |
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Dru | 2014 |
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.
Topics: Amides; Carbamates; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepatitis C; Humans; Interferon | 2014 |
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; | 2015 |
Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Area Under Curve; Carbamates; Cyclop | 2015 |
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Topics: Antiviral Agents; Belgium; Carbamates; Cholestasis; Drug Therapy, Combination; Drug-Related Side Eff | 2015 |
Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
Topics: Adult; Aged; Antiviral Agents; Asian People; Carbamates; Cohort Studies; Drug Therapy, Combination; | 2016 |
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combina | 2016 |
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropan | 2016 |
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Hum | 2016 |
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dose-Response Relation | 2016 |
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combi | 2016 |
Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyc | 2016 |
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Topics: Aged; Antiviral Agents; Belgium; Carbamates; Compassionate Use Trials; Female; France; Genotype; Hep | 2016 |
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Topics: Adult; Aged; Amides; Benzofurans; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Rel | 2017 |
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Topics: Adult; Aged; Amides; Benzofurans; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Rel | 2017 |
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Topics: Adult; Aged; Amides; Benzofurans; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Rel | 2017 |
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Topics: Adult; Aged; Amides; Benzofurans; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Rel | 2017 |
Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects.
Topics: Adult; Animals; Antiviral Agents; Carbamates; Dogs; Female; Healthy Volunteers; Hepacivirus; Hepatit | 2017 |
Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.
Topics: Adult; Aged; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Genot | 2017 |
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Topics: Adolescent; Adult; Animals; Antiviral Agents; Carbamates; Cell Line; Chlorocebus aethiops; Drug Resi | 2010 |
Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Co | 2011 |
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.
Topics: Carbamates; Double-Blind Method; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Phenotype; | 2011 |
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Diarrhea; Drug Therapy, Combination; Female; Genotype; He | 2012 |
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Double-Blind Method; Hepacivirus; Hepatitis C; H | 2003 |
227 other studies available for carbamates and Hepatitis C
| Article | Year |
|---|---|
Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, | 2021 |
Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Fl | 2021 |
Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; F | 2022 |
RP-HPLC method development and validation for quantification of daclatasvir dihydrochloride and its application to pharmaceutical dosage form.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; H | 2021 |
Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; | 2022 |
Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interacti | 2022 |
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Child; Cyclopropanes; Genoty | 2022 |
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.
Topics: Antiviral Agents; Carbamates; Case-Control Studies; COVID-19 Drug Treatment; Disease Progression; Ge | 2022 |
hsa-miR-17-5p: A Possible Predictor of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin Therapy Efficacy in Hepatitis C Infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; H | 2022 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Dru | 2022 |
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Child; Cyclopropanes; Drug Therapy, | 2022 |
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis | 2022 |
Elbasvir/grazoprevir for the treatment of hepatitis C virus infection in people with opioid use disorder.
Topics: Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; | 2022 |
Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chroni | 2022 |
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combi | 2022 |
Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Female; | 2019 |
Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; H | 2020 |
Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Dru | 2019 |
Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.
Topics: Aged; Animals; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; ATP Binding Cassette Transport | 2019 |
Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Topics: Adult; Aged; Antiviral Agents; Bangladesh; Carbamates; Drug Therapy, Combination; Female; Follow-Up | 2019 |
Successful sofosbuvir lead-in monotherapy for the treatment of hepatitis C virus (HCV) infection in a pregnant woman living with HIV.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carbamates; Female; Hepatitis C; Her | 2019 |
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compou | 2020 |
Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; | 2020 |
Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Genot | 2020 |
The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Li | 2020 |
A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Hepatitis | 2020 |
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; F | 2020 |
Living Donor Liver Transplantation From Hepatitis C-Infected Donor to Hepatitis C-Infected Recipient.
Topics: Adult; Antiviral Agents; Carbamates; Child; Fatty Liver; Female; Hepacivirus; Hepatectomy; Hepatitis | 2020 |
Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Dr | 2020 |
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Combinations; Female | 2020 |
Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue | 2020 |
Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotyp | 2021 |
High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
Topics: Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; | 2020 |
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatit | 2020 |
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; | 2020 |
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; | 2020 |
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Fatal Outcome; Hepacivirus; Hepatitis | 2020 |
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; G | 2021 |
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis | 2021 |
Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
Topics: Aged; Antiviral Agents; Carbamates; Case-Control Studies; Drug Resistance, Viral; Drug Therapy, Comb | 2020 |
Epclusa Approved For Children With Hepatitis C.
Topics: Antiviral Agents; Carbamates; Child; Drug Approval; Drug Combinations; Hepatitis C; Heterocyclic Com | 2020 |
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatit | 2020 |
SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain.
Topics: Antiviral Agents; Benzimidazoles; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Dru | 2020 |
Ukrainian health authorities adopt hepatitis C project.
Topics: Antiviral Agents; Carbamates; Delivery of Health Care; Drug Therapy, Combination; Drugs, Generic; He | 2020 |
Acute hepatitis C infection with secondary liver injury successfully treated with sofosbuvir/velpatasvir combination.
Topics: Acute Disease; Adult; Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepatitis C; Hetero | 2020 |
Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion.
Topics: Animals; Antiviral Agents; Carbamates; Disease Models, Animal; Dogs; Drug Therapy, Combination; Geno | 2020 |
Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo.
Topics: Antiviral Agents; Carbamates; Female; Hepatitis C; Humans; Imidazoles; Maternal-Fetal Exchange; Plac | 2020 |
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis | 2021 |
Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Drug Resistance, Viral; Genome, Viral; Genotype; Hep | 2020 |
Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotyp | 2020 |
Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir.
Topics: Balloon Occlusion; Carbamates; Female; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Heterocycli | 2020 |
Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Hetero | 2021 |
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropa | 2022 |
Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation.
Topics: Antiviral Agents; Carbamates; Child; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 o | 2021 |
Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; | 2021 |
A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
Topics: Antiviral Agents; Brazil; Carbamates; Cell Line, Tumor; Cohort Studies; Drug Resistance, Viral; Drug | 2021 |
Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection.
Topics: Antiviral Agents; Carbamates; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Pyrro | 2021 |
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
Topics: Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus | 2020 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients.
Topics: Adult; Antiviral Agents; Biomarkers; Blood Chemical Analysis; Carbamates; Drug Therapy, Combination; | 2021 |
Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.
Topics: Amides; Analgesics, Opioid; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, | 2021 |
Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Co | 2021 |
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
Topics: Adult; Antiviral Agents; Australia; Canada; Carbamates; Drug Combinations; Female; Germany; Hepatiti | 2021 |
Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds | 2021 |
Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 | 2021 |
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic | 2021 |
Frailty Status Predicts New Long-term Care Insurance Certification in Hepatitis C Patients Receiving Antiviral Therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Eligibility Determination; Female; Frailty; H | 2021 |
Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cost of Illness; Disability Evaluation; Drugs | 2021 |
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluore | 2018 |
Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients.
Topics: Acute Disease; Adult; Antiviral Agents; Biomarkers; Carbamates; Creatinine; Drug Therapy, Combinatio | 2017 |
Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patients.
Topics: Antiviral Agents; Carbamates; Coinfection; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; | 2017 |
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; H | 2017 |
Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, C | 2017 |
Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
Topics: Carbamates; Cell Line; Cell Survival; Coculture Techniques; Down-Regulation; Hepacivirus; Hepatitis | 2017 |
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cyclopr | 2017 |
Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepati | 2018 |
Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Vira | 2017 |
Mixed Essential Cryoglobulinemia.
Topics: Antiviral Agents; Carbamates; Cryoglobulinemia; Exanthema; Hepatitis C; Heterocyclic Compounds, 4 or | 2017 |
Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Female; Hepatitis C; Humans; Imidazole | 2017 |
Belgian experience with direct acting antivirals in people who inject drugs.
Topics: Adult; Aged; Antiviral Agents; Belgium; Carbamates; Cohort Studies; Female; Hepacivirus; Hepatitis C | 2017 |
Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis.
Topics: Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; | 2017 |
Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Co | 2017 |
Preclinical and clinical properties of elbasvir (ERELSA
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Eva | 2017 |
Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil.
Topics: 2-Naphthylamine; Aged; Anilides; Antibiotics, Antineoplastic; Antiviral Agents; Carbamates; Cyclopro | 2017 |
Daclatasvir-Sofosbuvir for treatment of hepatitis C virus in patients with inherited bleeding disorders.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genetic Diseases, Inborn; He | 2017 |
Hepatobiliary and Pancreatic: Rare vascular tumor following treatment for hepatitis C with direct-acting antivirals.
Topics: Aged, 80 and over; Antiviral Agents; Carbamates; Fatal Outcome; Female; Hemangioendothelioma, Epithe | 2017 |
Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience.
Topics: Adult; Aged; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studie | 2017 |
Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.
Topics: Adult; Aged; Aged, 80 and over; Amides; Anti-Retroviral Agents; Antiviral Agents; Benzofurans; Carba | 2017 |
Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; D | 2017 |
Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combinat | 2017 |
Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.
Topics: Animals; Antiviral Agents; Biological Availability; Carbamates; Cell Line, Tumor; Cells, Cultured; D | 2017 |
Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, C | 2018 |
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination | 2018 |
New Oral HCV Drug.
Topics: Administration, Oral; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Contraindications, Drug; | 2017 |
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study.
Topics: Adult; Alleles; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; Carbamat | 2017 |
The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Topics: Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Carbamates; Cell Line; Cyclosporine; Evero | 2018 |
A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepati | 2018 |
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hep | 2018 |
New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Equ | 2018 |
Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow- | 2018 |
UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Coinfection; Hepatitis C; HIV In | 2018 |
Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Case-Control Studies; Cyclopropanes; Cytochrome P-450 | 2018 |
Comparison between core-shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Hepat | 2018 |
Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatiti | 2019 |
Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatiti | 2019 |
Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatiti | 2019 |
Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatiti | 2019 |
Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all?
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; R | 2018 |
Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Dogs; Drug Design; Enzyme Inhibitors; Genotype; Hep | 2018 |
High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Viral; Drug | 2018 |
A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection.
Topics: Acute Disease; Adult; Carbamates; China; Drug Therapy, Combination; Early Diagnosis; Early Medical I | 2018 |
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepati | 2018 |
Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Gene E | 2018 |
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Fem | 2018 |
Case report: Identification of recombinant HCV genotype 1b-2b by viral sequencing in two patients with treatment failure, who responded to re-treatment with sofosbuvir and daclatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotyping Techniques; Hepac | 2018 |
Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; F | 2018 |
Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Topics: Adult; Antiviral Agents; Carbamates; Computer Simulation; Cost-Benefit Analysis; Drug Combinations; | 2018 |
Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits.
Topics: Animals; Antiviral Agents; Biological Availability; Carbamates; Chromatography, High Pressure Liquid | 2018 |
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era?
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Rib | 2018 |
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Rib | 2018 |
Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
Topics: Animals; Antiviral Agents; Benzazepines; Biomarkers; Carbamates; Drug Combinations; Drug Resistance, | 2018 |
GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line, Tumor; Dogs; Drug Combinations; Drug Stability; Dr | 2018 |
Treating hepatitis C infection in patients with advanced CKD in the real world: time to refocus on what our real treatment goals should be.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotyp | 2018 |
Hepatitis C virus infection: 'beyond the liver'.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Dermatomyositis; Diagnosis, | 2018 |
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Com | 2019 |
Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Gen | 2018 |
Study on fluorescence properties of HCV antiviral (velpatasvir) and its fluorimetric determination in presence of sofosbuvir; application to stability study and human plasma.
Topics: Antiviral Agents; Carbamates; Drug Stability; Fluorescence; Fluorometry; Hepacivirus; Hepatitis C; H | 2018 |
A Stability-Indicating UPLC Method for the Determination of Potential Impurities and Its Mass by a New QDa Mass Detector in Daclatasvir Drug Used to Treat Hepatitis C Infection.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stabili | 2019 |
Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.
Topics: Aged; Antiviral Agents; Carbamates; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; F | 2018 |
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatit | 2018 |
Visualisation and analysis of hepatitis C virus non-structural proteins using super-resolution microscopy.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Im | 2018 |
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Topics: 2-Naphthylamine; Anemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Darbepoetin alfa; Fe | 2019 |
The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepatitis C; Hepat | 2018 |
Using telehealth to improve access to hepatitis C treatment in the direct-acting antiviral therapy era.
Topics: Adult; Aged; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Delivery of Health Care; Femal | 2020 |
NS5A Promotes Constitutive Degradation of IP3R3 to Counteract Apoptosis Induced by Hepatitis C Virus.
Topics: Animals; Apoptosis; Carbamates; Cell Line; F-Box Proteins; Hepacivirus; Hepatitis C; Humans; Imidazo | 2018 |
Successful Treatment of Fibrosing Cholestatic Hepatitis With Daclatasvir and Asunaprevir After Liver Transplantation: A Case Report.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; I | 2018 |
Reply to: "Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL recommendations on treatment of Hepatitis C 2018": EASL Recommendations on Treatment of Hepatitis C 2018: Precision on the tr
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liv | 2019 |
Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liv | 2019 |
Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluore | 2019 |
Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Cre | 2019 |
Effective drugs on the road to HCV elimination and a therapeutic gap to close.
Topics: Asia; Carbamates; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans | 2019 |
Sofosbuvir and Daclatsvir in Treatment of Hepatitis C Virus-related Membranoproliferative Glomerulonephritis With Cryoglobulinemia in a Patient With Hepatitis C Genotype 4.
Topics: Antiviral Agents; Carbamates; Cryoglobulinemia; Drug Therapy, Combination; Female; Glomerulonephriti | 2018 |
Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
Topics: Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver | 2019 |
Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.
Topics: Adult; Aged; Alanine Transaminase; Algorithms; Benzazepines; Carbamates; Clinical Trials, Phase II a | 2019 |
Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Topics: Aged; Animals; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cell Line; Chimera; Drug R | 2019 |
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genoty | 2019 |
Evaluation of brain volume alterations in HCV-infected patients after interferon-free therapy: A pilot study.
Topics: Adult; Aged; Anilides; Antiviral Agents; Attention; Brain; Carbamates; Cyclopropanes; Drug Therapy, | 2019 |
Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepat | 2019 |
Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Cells, Cultured; Drug Resistance, Viral; Drug Therapy, Combination; He | 2019 |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis | 2019 |
Hepatitis C Virus Genotype 8 Infection-Successful Treatment With Sofosbuvir/Velpatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compou | 2019 |
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients.
Topics: Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbam | 2019 |
SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbamates; Drug Interactions; Female; Hepatitis C; Hete | 2019 |
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials, Phase III as Topic; | 2019 |
Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation.
Topics: Acute Disease; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C; Humans; I | 2019 |
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug | 2019 |
Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis.
Topics: Aged; Antitubercular Agents; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; C | 2019 |
Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; H | 2019 |
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Topics: Aged; Anemia; Antiviral Agents; Carbamates; Cyclosporine; Drug Interactions; Drug Therapy, Combinati | 2019 |
Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; | 2019 |
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Ind | 2014 |
A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity.
Topics: Carbamates; Cell Line; Drug Resistance, Viral; Gene Expression Profiling; Genetic Fitness; Hepacivir | 2014 |
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
Topics: Antibodies, Neutralizing; Antiviral Agents; Carbamates; Cell Communication; Cells, Cultured; Drug Re | 2014 |
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.
Topics: Anilides; Antiviral Agents; Carbamates; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; | 2015 |
Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
Topics: Antiviral Agents; Carbamates; Cell Line; Hepacivirus; Hepatitis C; Humans; Imidazoles; Minor Histoco | 2015 |
Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dr | 2015 |
A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Fluorescent Antibody Technique; Genome, Viral; Hepac | 2015 |
HIV-hepatitis C co-infection.
Topics: Antiviral Agents; Carbamates; Coinfection; Hepatitis C; HIV Infections; Humans; Imidazoles; Pyrrolid | 2015 |
[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA].
Topics: Anti-HIV Agents; Carbamates; Drug Combinations; Gastroenterology; Germany; Hepatitis C; Imidazoles; | 2015 |
Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis | 2015 |
A 4-drug combination (Viekira Pak) for hepatitis C.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhib | 2015 |
Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
Topics: Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Hepati | 2015 |
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.
Topics: Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Gene Expression Regulation, Viral; Geno | 2016 |
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imid | 2016 |
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; China; Drug Resistance, Viral; Female; Fl | 2015 |
Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, C | 2016 |
Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
Topics: Allosteric Regulation; Animals; Antiviral Agents; Biphenyl Compounds; Carbamates; Cell Line; Drug Re | 2015 |
Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.
Topics: Animals; Antiviral Agents; Carbamates; Chimera; Drug Therapy, Combination; Hepacivirus; Hepatitis C; | 2016 |
Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug | 2016 |
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Atazanavir Sulfate; Carbamates; Coinfection; Cyclopropa | 2016 |
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropa | 2016 |
12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivir | 2016 |
Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients.
Topics: 2-Naphthylamine; Anilides; Carbamates; Coinfection; Cyclopropanes; Darunavir; Hepatitis C; HIV Infec | 2016 |
Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocy | 2016 |
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Female | 2016 |
Successful treatment of hepatitis C virus infection combining daclatasvir and simeprevir in a heart transplant recipient with decompensated cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Heart Transplantation; Hepatitis C; Humans; | 2016 |
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cycl | 2016 |
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female | 2016 |
Breast Hypertrophy Induced by Ombitasvir/Paritaprevir/Ritonavir and Ribavirina.
Topics: Anilides; Antiviral Agents; Breast Diseases; Carbamates; Cyclopropanes; Drug Therapy, Combination; F | 2016 |
Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Genotype | 2016 |
Falling up stairs.
Topics: 2-Naphthylamine; Accidental Falls; Anilides; Antiviral Agents; Bronchodilator Agents; Carbamates; Cu | 2016 |
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, P | 2017 |
New Drug Treats All Genotypes of Chronic HCV.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis | 2016 |
Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity.
Topics: Alanine; Antiviral Agents; Azepines; Carbamates; Cell Line; Cell Survival; Cells, Cultured; Drug Syn | 2016 |
First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2016 |
[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C; Hum | 2016 |
Wales approves new hepatitis C drug while England deliberates.
Topics: Antiviral Agents; Carbamates; Drug Approval; Drug Combinations; England; Hepatitis C; Heterocyclic C | 2016 |
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; H | 2016 |
A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry.
Topics: Antiviral Agents; Carbamates; Computational Biology; Drug Resistance, Viral; Genotype; Hepacivirus; | 2016 |
Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
Topics: Alleles; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy | 2017 |
Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Carbamates; Disease Progression; Drug Therapy, Combin | 2017 |
Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.
Topics: Animals; Anti-Retroviral Agents; Carbamates; Drug Resistance, Viral; Evolution, Molecular; Hepacivir | 2017 |
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combinat | 2017 |
Validated stability-indicating HPLC-DAD method for determination of the recently approved hepatitis C antiviral agent daclatasvir.
Topics: Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Hepatitis C; Imi | 2017 |
Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; | 2017 |
Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.
Topics: Amides; Amino Acid Substitution; Carbamates; Cell Line, Tumor; Cyclopropanes; Hepacivirus; Hepatitis | 2017 |
Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure.
Topics: Acute Disease; Administration, Oral; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genoty | 2017 |
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
Topics: Aged; Antiviral Agents; B-Lymphocyte Subsets; Biomarkers; Carbamates; Case-Control Studies; Cryoglob | 2017 |
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Co | 2017 |
Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis.
Topics: Antiviral Agents; B-Lymphocytes; Carbamates; CD4-Positive T-Lymphocytes; Cryoglobulinemia; Cryoglobu | 2017 |
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Dru | 2017 |
Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
Topics: Amino Acid Sequence; Antiviral Agents; Carbamates; Carrier Proteins; Drug Resistance, Viral; Global | 2008 |
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Topics: Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Viral; Female; Genetic Testing; Hepac | 2008 |
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Carbamates; Chromatography, High Pressure Liquid; Elas | 2009 |
Ribavirin analogs.
Topics: Anemia, Hemolytic; Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Humans; IMP Dehydrogenase | 2009 |
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
Topics: Antiviral Agents; Blood Proteins; Carbamates; Cell Line; Comparative Effectiveness Research; Dialysi | 2011 |
[BMS-790 052 - an oral antiviral hepatitis C antiviral in the pipeline].
Topics: Antiviral Agents; Carbamates; Germany; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pyrrolidines; R | 2011 |
The end of the beginning for hepatitis C treatment.
Topics: Antiviral Agents; Carbamates; Enzyme Inhibitors; Female; Hepacivirus; Hepatitis C; Humans; Imidazole | 2012 |
A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine.
Topics: Carbamates; Chromatography, Liquid; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liquid-Liquid Extr | 2012 |
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Vir | 2012 |
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.
Topics: Alkaline Phosphatase; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cholestasis; Drug Therapy | 2012 |
Virology: fresh assault on hepatitis C.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Design; Hepacivirus; Hepatitis C; Human | 2003 |
[Review of recent research on hepatitis C therapy for 54th annual meeting of the American association for the study of liver diseases].
Topics: Carbamates; Hepatitis C; Humans; Interferon-alpha; Interferons; Macrocyclic Compounds; Oligonucleoti | 2004 |
Hepatitis C drug being developed.
Topics: Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Macrocyclic Compounds; Quinoli | 2004 |
The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Topics: Carbamates; Drug Design; Hepacivirus; Hepatitis C; Humans; In Vitro Techniques; Macrocyclic Compound | 2004 |
Hepatitis C: it's a long way to new therapy, it's a long way to go...
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Macrocyclic | 2004 |
Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application.
Topics: Analysis of Variance; Animals; Antiviral Agents; Base Sequence; Carbamates; Disease Models, Animal; | 2006 |
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
Topics: Adult; Anti-HIV Agents; Carbamates; Furans; Hepatitis C; HIV Infections; Humans; Immunosuppressive A | 2006 |
Novel robust hepatitis C virus mouse efficacy model.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Pr | 2006 |
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Topics: Administration, Oral; Animals; Antiviral Agents; Carbamates; Drug Evaluation, Preclinical; Heart Dis | 2007 |